text
stringlengths 65
123k
| url
stringlengths 25
420
| crawl_date
timestamp[us, tz=UTC]date 2022-04-01 01:00:57
2022-09-19 04:34:04
|
|---|---|---|
OCC® Achieves Year-over-Year Increases in Net Sales and Gross Profit in the Third Quarter and First Nine Months of Fiscal Year 2022
ROANOKE, Va. , Sept. 12, 2022 /PRNewswire/ -- Optical Cable Corporation (Nasdaq GM: OCC) ("OCC®" or the "Company") today announced financial results for its third quarter ended July 31, 2022.
Consolidated net sales for the third quarter of fiscal year 2022 increased 11.2% to $17.4 million, compared to net sales of $15.6 million for the same period last year. The Company experienced an increase in net sales in its specialty markets, including the wireless carrier market, in the third quarter of fiscal 2022, compared to the same period last year. The increase was partially offset by a decrease in net sales in the enterprise market.
During the third quarter of fiscal year 2022, the Company continued to see product demand, sales and production volume increase compared to the same period last year. Its sales order backlog/forward load exceeded $15.0 million at the end of the third quarter of fiscal year 2022—remaining approximately three-to-five times higher than typical levels—as product demand continues to be robust.
Production volumes continued to be tempered during the third quarter of fiscal year 2022 by supply chain and labor constraints, hindering further net sales increases. The Company experienced improvement in production labor recruitment during the third quarter of fiscal year 2022, from which the Company expects to benefit in the future. The training of new production employees impacts production volumes (and labor costs) until those employees are fully trained and operating at capacity.
Gross profit increased 17.6% to $4.8 million in the third quarter of fiscal year 2022, compared to gross profit of $4.1 million for the same period last year.
Gross profit margin, or gross profit as a percentage of net sales, was 27.7% in the third quarter of fiscal year 2022 compared to 26.2% in the third quarter of fiscal year 2021.
Gross profit margins during the third quarter of fiscal year 2022 were impacted by increases in production labor and material costs, partially offset by necessary prospective price increases on new sales orders for many of the Company's products.
SG&A expenses increased to $5.0 million during the third quarter of fiscal year 2022, compared to $4.5 million for the third quarter of fiscal year 2021. The increase in SG&A expenses was primarily the result of net increases in employee and contracted sales personnel related costs.
For the third quarter of fiscal year 2022, OCC recorded a net loss of $372,000, or $0.05 per basic and diluted share, compared to net income of $5.4 million, or $0.71 per basic and diluted share, for the third quarter of fiscal year 2021, with gain on the extinguishment of the Company's paycheck protection program loan and employee retention tax credit positively impacting results in the third quarter of fiscal year 2021.
Consolidated net sales for the first nine months of fiscal year 2022 increased 13.3% to $49.0 million, compared to net sales of $43.3 million for the first nine months of fiscal year 2021. The Company achieved increases in net sales in both its enterprise and specialty markets, including the wireless carrier market, in the first nine months of fiscal year 2022, compared to the same period last year.
OCC reported gross profit of $13.9 million in the first nine months of fiscal year 2022, an increase of 23.8% compared to gross profit of $11.2 million in the first nine months of fiscal year 2021.
The Company's gross profit margins tend to be higher when it achieves higher net sales levels due to its operating leverage, as certain fixed manufacturing costs are spread over higher sales. This operating leverage positively impacted the gross profit margin during the first nine months of fiscal year 2022, particularly during the first quarter of fiscal year 2022. This positive impact during the first quarter of fiscal year 2022 was partially offset during the second and third quarters by the impact of increasing costs of raw materials, created by rapidly occurring inflation, for sales orders accepted prior to raw material cost increases.
SG&A expenses increased 10.0% to $14.8 million during the first nine months of fiscal year 2022 from $13.4 million for the first nine months of fiscal year 2021. The increase in SG&A expenses during the first nine months of fiscal year 2022 compared to the first nine months of fiscal year 2021 was primarily the result of increases in employee and contracted sales personnel related costs.
OCC recorded a net loss of $1.5 million, or $0.20 per basic and diluted share, for the first nine months of fiscal year 2022, compared to net income of $6.6 million, or $0.88 per basic and diluted share, for the first nine months of fiscal year 2021, with gain on the extinguishment of the Company's paycheck protection program loan and employee retention tax credits positively impacting results during the first nine months of fiscal year 2021.
Neil Wilkin, President and Chief Executive Officer of OCC, said, "Our third quarter results reflect the OCC team's success executing in a dynamic market that continues to demonstrate robust demand for our diversified product offering. During the quarter, we made progress in scaling up our production team to increase our production capacity, and these efforts will continue so we can meet expected strong product demand and capture additional growth opportunities. In addition, the OCC team continued to successfully execute strategies designed to mitigate the impact of supply chain constraints and inflationary pressures."
Mr. Wilkin added, "As a result of our growth strategies, demand for our suite of mission-critical cabling and connectivity products and solutions continues to be strong, and our large sales order backlog bodes well for the remainder of the fiscal year and into next year. We continue to focus on executing our growth strategies, increasing production capacity and operating efficiently as we serve our customers and end-users and drive enhanced value for shareholders."
As previously announced, OCC will host a conference call today, September 12, 2022, at 10:00 a.m. Eastern Time. Individuals wishing to participate in the conference call should call (800) 225-9448 in the U.S. or (203) 518-9856 internationally, Conference ID: OCCQ322. For interested individuals unable to join the call, a replay will be available through Monday, September 19, 2022 by dialing (800) 839-5637 or (402) 220-2562. The call will also be broadcast live over the internet and can be accessed by visiting the investor relations section of the Company's website at www.occfiber.com.
Optical Cable Corporation ("OCC®") is a leading manufacturer of a broad range of fiber optic and copper data communication cabling and connectivity solutions primarily for the enterprise market and various harsh environment and specialty markets (collectively, the non-carrier markets) and also the wireless carrier market, offering integrated suites of high-quality products which operate as a system solution or seamlessly integrate with other providers' offerings.
OCC® is internationally recognized for pioneering innovative fiber optic and copper communications technologies, including fiber optic cable designs for the most demanding environments and applications, copper connectivity designs to meet the highest data communication industry standards, as well as a broad product offering built on the evolution of these fundamental technologies.
OCC uses its expertise to deliver cabling and connectivity products and integrated solutions that are best suited to the performance requirements of each end-user's application. And OCC's solutions offerings cover a broad range of applications—from commercial, enterprise network, datacenter, residential and campus installations to customized products for specialty applications and harsh environments, including military, industrial, mining, petrochemical and broadcast applications, as well as for the wireless carrier market.
Founded in 1983, OCC is headquartered in Roanoke, Virginia with offices, manufacturing and warehouse facilities located in Roanoke, Virginia, near Asheville, North Carolina and near Dallas, Texas. OCC's facilities are ISO 9001:2015 registered and its Roanoke and Dallas facilities are MIL-STD-790G certified.
Optical Cable Corporation™, OCC®, Procyon®, Superior Modular Products™, SMP Data Communications™, Applied Optical Systems™, and associated logos are trademarks of Optical Cable Corporation.
Further information about OCC® is available at www.occfiber.com.
This news release by Optical Cable Corporation and its subsidiaries (collectively, the "Company" or "OCC") may contain certain forward-looking information within the meaning of the federal securities laws. The forward-looking information may include, among other information, (i) statements concerning our outlook for the future, (ii) statements of belief, anticipation or expectation, (iii) future plans, strategies or anticipated events, and (iv) similar information and statements concerning matters that are not historical facts. Such forward-looking information is subject to known and unknown variables, uncertainties, contingencies and risks that may cause actual events or results to differ materially from our expectations, and such known and unknown variables, uncertainties, contingencies and risks may also adversely affect Optical Cable Corporation and its subsidiaries, the Company's future results of operations and future financial condition, and/or the future equity value of the Company. A partial list of such variables, uncertainties, contingencies and risks that could cause or contribute to such differences from our expectations or that could otherwise adversely affect Optical Cable Corporation and its subsidiaries is set forth in Optical Cable Corporation's quarterly and annual reports filed with the Securities and Exchange Commission ("SEC") under the heading "Forward-Looking Information." OCC's quarterly and annual reports are available to the public on the SEC's website at http://www.sec.gov. In providing forward-looking information, the Company expressly disclaims any obligation to update this information, whether as a result of new information, future events or otherwise except as required by applicable laws and regulations.
(Financial Tables Follow)
View original content to download multimedia:
SOURCE Optical Cable Corporation
|
https://www.whsv.com/prnewswire/2022/09/12/optical-cable-corporation-reports-third-quarter-2022-financial-results/
| 2022-09-12T12:45:38Z
|
TORONTO, Sept. 12, 2022 /PRNewswire/ - Orvana Minerals Corp. (TSX: ORV) (the "Company" or "Orvana") ") is pleased to announce that it will be attending the Precious Metals Summit in Colorado.
Ms. Nuria Menéndez, Chief Financial Officer and Mr. Raúl Álvarez, Director of Exploration and Technical Services, will be attending the Precious Metals Summit held at Beaver Creek, Colorado during September 13-16, 2022. Ms. Menéndez will be presenting on Wednesday September 14, 2022 at 10.00 (MT).
The Company Presentation is available on Orvana's website at: https://www.orvana.com/English/investors/presentations/default.aspx
ABOUT ORVANA – Orvana is a gold-copper-silver company. Orvana's assets consist of the producing Orovalle Operation in northern Spain, the Don Mario property in Bolivia, currently in care and maintenance, and the Taguas property located in Argentina. Additional information is available at Orvana's website (www.orvana.com).
Cautionary Statements – Forward-Looking Information
Certain statements in this presentation constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws ("forward-looking statements"). Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, potentials, future events or performance (often, but not always, using words or phrases such as "believes", "expects", "plans", "estimates" or "intends" or stating that certain actions, events or results "may", "could", "would", "might", "will", "are projected to" or "confident of" be taken or achieved) are not statements of historical fact, but are forward-looking statements.
The forward-looking statements herein relate to, among other things, Orvana's ability to achieve improvement in free cash flow; the ability to maintain expected mining rates and expected throughput rates at El Valle Plant; the potential to extend the mine life of El Valle and Don Mario beyond their current life-of-mine estimates including specifically, but not limited to, in the case of Don Mario, the processing of the mineral stockpiles and the reprocessing of the tailings material, and sufficient funding to proceed with the processing; Orvana's ability to optimize its assets to deliver shareholder value; the Company's ability to optimize productivity at Don Mario and El Valle; estimates of future production (including without limitation, production guidance), operating costs and capital expenditures; mineral resource and reserve estimates; statements and information regarding future feasibility studies and their results; future transactions; future metal prices; the ability to achieve additional growth and geographic diversification; and future financial performance, including the ability to increase cash flow and profits; future financing requirements; mine development plans; and the possibility of the conversion of inferred mineral resources to mineral reserves.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies, which includes, without limitation, as particularly set out in the notes accompanying the Company's most recently filed financial statements. The estimates and assumptions of the Company contained or incorporated by reference in this information, which may prove to be incorrect, include, but are not limited to the various assumptions set forth herein and in Orvana's most recently filed Management's Discussion & Analysis and Annual Information Form in respect of the Company's most recently completed fiscal year (the "Company Disclosures") or as otherwise expressly incorporated herein by reference as well as: there being no significant disruptions affecting operations, whether due to labour disruptions, supply disruptions, power disruptions, damage to equipment or otherwise; permitting, development, operations, expansion and acquisitions at El Valle and Don Mario being consistent with the Company's current expectations; political developments in any jurisdiction in which the Company operates being consistent with its current expectations; certain price assumptions for gold, copper and silver; prices for key supplies being approximately consistent with current levels; production and cost of sales forecasts meeting expectations; the accuracy of the Company's current mineral reserve and mineral resource estimates; labour and materials costs increasing on a basis consistent with Orvana's current expectations; and the availability of necessary funds to execute the Company's plan. Without limiting the generality of the foregoing, this news release also contains certain "forward-looking statements" within the meaning of applicable securities legislation, including, without limitation, references to the results of the Company's exploration activities, including but not limited to, drilling results and analyses, mineral resource estimation, conceptual mine plan and operations, internal rate of return, sensitivities, taxes, net present value, potential recoveries, design parameters, operating costs, capital costs, production data and economic potential; the timing and costs for production decisions; permitting timelines and requirements; exploration and planned exploration programs;; and the Company's general objectives and strategies.
A variety of inherent risks, uncertainties and factors, many of which are beyond the Company's control, affect the operations, performance and results of the Company and its business, and could cause actual events or results to differ materially from estimated or anticipated events or results expressed or implied by forward looking statements. Some of these risks, uncertainties and factors include: the potential impact of the COVID-19 on the Company's business and operations, including: our ability to continue operations; our ability to manage challenges presented by COVID-19; the accounting treatment of COVID-19 related matters; Orvana's ability to prevent and/or mitigate the impact of COVID-19 and other infectious diseases at or near our mines; the general economic, political and social impacts of the continuing conflict between Russia and Ukraine, our ability to support the sustainability of our business including through the development of crisis management plans, increasing stock levels for key supplies, monitoring of guidance from the medical community, and engagement with local communities and authorities; fluctuations in the price of gold, silver and copper; the need to recalculate estimates of resources based on actual production experience; the failure to achieve production estimates; variations in the grade of ore mined; variations in the cost of operations; the availability of qualified personnel; the Company's ability to obtain and maintain all necessary regulatory approvals and licenses; the Company's ability to use cyanide in its mining operations; risks generally associated with mineral exploration and development, including the Company's ability to continue to operate the El Valle and/or ability to resume long-term operations at the Carlés Mine; the Company's ability to successfully implement a sulphidization circuit and ancillary facilities to process the current oxides stockpiles at Don Mario; the Company's ability to successfully carry out development plans at Taguas; sufficient funding to carry out development plans at Taguas and to process the oxides stockpiles at Don Mario; the Company's ability to acquire and develop mineral properties and to successfully integrate such acquisitions; the Company's ability to execute on its strategy; the Company's ability to obtain financing when required on terms that are acceptable to the Company; challenges to the Company's interests in its property and mineral rights; current, pending and proposed legislative or regulatory developments or changes in political, social or economic conditions in the countries in which the Company operates; general economic conditions worldwide; the challenges presented by COVID-19; fluctuating operational costs such as, but not limited to, power supply costs; current and future environmental matters; and the risks identified in the Company's disclosures. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements and reference should also be made to the Company's Disclosures for a description of additional risk factors.
Any forward-looking statements made herein with respect to the anticipated development and exploration of the Company's mineral projects are intended to provide an overview of management's expectations with respect to certain future activities of the Company and may not be appropriate for other purposes. Forward-looking statements are based on management's current plans, estimates, projections, beliefs and opinions and, except as required by law, the Company does not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change. Readers are cautioned not to put undue reliance on forward-looking statements. The forward-looking statements made in this information are intended to provide an overview of management's expectations with respect to certain future operating activities of the Company and may not be appropriate for other purposes.
View original content:
SOURCE Orvana Minerals Corp.
|
https://www.whsv.com/prnewswire/2022/09/12/orvana-announces-participation-precious-metals-summit-conference/
| 2022-09-12T12:45:44Z
|
Company has bolstered its resource bench with key experts to better support its brand partners in the home service industry
CHICAGO, Sept. 12, 2022 /PRNewswire/ -- Today, P1 Service Group, an industry-leading business growth partner that provides world-class resources to its home service partner companies across the country, announced the hiring of five new team members. The new additions to P1's experienced leadership team demonstrate the company's exceptional growth rate and early success since its founding in 2021.
"Adding these seasoned subject-matter experts with long-standing industry relationships to our team elevates our ability to deliver our 'people first' approach to a growing number of first-class home service companies around the nation," said Jeff Belk, CEO of P1 Service Group. "Our new team members help P1 stand out as the most experienced business growth partner in the home service industry. Their integrity and commitment to excellence perfectly complement our values and will support our partners in creating unique growth avenues."
The new team members include:
- Steve McConnell, Chief Financial Officer. McConnell, who has more than 20 years of experience supporting the profitable growth of multiple private-equity- backed companies, will assist P1 and its partner companies in developing functional programs for the accounting and human resources departments.
- Lisa White, Vice President of Partner Relations. White has spent more than 22 years in the trades, including 21 years with the Nexstar Network. She has a decades-long relationship with both Belk and P1 President Justin Carrol, and now joins P1 to lead business development, guide partner companies in operations, and help contractors navigate the changing dynamics of the home services industry.
- Dan Friesen, Vice President of Training. Friesen started in the trades in 1993 and spent 17 years at Nexstar, where he trained more than 50,000 people. Friesen, who joined P1 after knowing Belk, Carrol, and White for nearly 20 years, supports partners by managing and advising on the continuous training of their team members.
- Michelle Fadeley, Vice President of Marketing. Fadeley has more than 20 years of comprehensive experience leading marketing strategies and initiatives for companies ranging in size from start-ups to those with established national footprints. Recruited for her breadth of experience in growth marketing, Fadeley helps P1's partner brands grow by delivering personalized recommendations on marketing best practices and lead generation.
- Donata Hammonds, Vice President of Recruiting. Hammonds previously spent seven years running a successful recruiting business that worked with home service companies, including working with Carrol for more than two years, before coming to P1. At P1, Hammonds collaborates with partner companies to optimize recruiting strategies and ensure a reliable pipeline of strong talent.
"This group's expertise will help P1 achieve long-term growth and success," Carrol said. "We're delighted to have each of them on the P1 team and to assist our growing partner network."
For more information about P1 Service Group, please visit www.p1servicegroup.com. P1 Service Group is financially backed by River Sea Network and The Edgewater Funds.
Founded in 2021, P1 Service Group is an industry-leading growth partner to home service companies across the country. P1 supports its residential HVAC, plumbing, and electrical partner companies with a 'people first' approach, providing resources in the areas of recruiting, marketing, finance, training, leadership, acquisitions, business strategy, call center management, equipment pricing and procurement, and more. P1 partners with home service companies in the range of $10 to $100 million in annual revenue that share in the belief of its mission. P1 believes growth and profits come as a result of satisfied and supported team members through a positive, thriving culture. For more information, please visit www.p1servicegroup.com.
River Sea Network, founded in 2020, is a private investment management firm located in New York City. Although it pursues other strategies, River Sea is currently investing committed capital in the residential heating & air conditioning industry. Following a transaction, River Sea provides capital investment, strategic advice, business consultation and human resources to help companies achieve their full potential. For more information, please visit www.riverseanetwork.com.
The Edgewater Funds is a Chicago-based private equity firm with over $2.8 billion of capital commitments raised since 2001. Through Edgewater Growth Capital Partners, they partner with management to help accelerate growth in their businesses. They are a flexible partner and can execute control and non-control investments. Please contact info@edgewaterfunds.com for any questions or information.
MEDIA CONTACT:
Heather Ripley
Ripley PR
865-977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE P1 Service Group
|
https://www.whsv.com/prnewswire/2022/09/12/p1-service-group-showcases-first-year-growth-with-addition-five-team-members/
| 2022-09-12T12:45:51Z
|
OSHKOSH, Wis., Sept. 12, 2022 /PRNewswire/ -- Pacur, LLC, a market leading supplier of specialty plastic packaging materials for the medical device industry, today announced that Jason Eckel has been named Senior Vice President of Sales & Marketing for Pacur. Jason comes to Pacur with 20 years of global senior leadership experience in the specialty materials, polymer and packaging industries. Pacur is a portfolio company of middle market private equity firm Gryphon Investors.
"Jason brings a wealth of knowledge and experience that will help guide Pacur's commercial activities as we serve our customers in growing markets," said John Carlson, CEO of Pacur. "We welcome him to the team, and look forward to leveraging his relationships to secure new opportunities."
Most recently, Mr. Eckel was the Vice President of Sales, Healthcare at Transcendia, Inc. where he was responsible for setting strategic direction and leading the global healthcare business to profitable growth. Prior to joining Transcendia, Mr. Eckel held various senior executive roles at Accenture, where he consulted on customer experience and commercial excellence. Previously he had full P&L responsibility with Avient Corporation (formerly PolyOne) as North America General Manager for its Specialty Engineered Materials business, and also served as its Global Marketing Director. Mr. Eckel began his career with Dow Chemical's North America Packaging business unit holding various commercial roles, including marketing, where he created and launched the HEALTH+TM brand, a unique portfolio of medical-grade polymers for medical device and pharmaceutical packaging applications.
About Pacur
Founded in 1979 and based in Oshkosh, Wisconsin, Pacur (www.pacur.com) is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices. Pacur offers eco-friendly packaging solutions and utilizes materials which provide exceptional clarity and high temperature and chemical resistance, are ETO and gamma sterilizable, and have received FDA approval for use in medical and food packaging.
About Gryphon Investors
Based in San Francisco, Gryphon Investors (www.gryphoninvestors.com) is a leading private equity firm focused on profitably growing and competitively enhancing middle-market companies in partnership with experienced management. As of December 31, 2021, the firm has over $9 billion of assets under management. Gryphon targets making equity investments of $50 million to $300 million in portfolio companies with enterprise values ranging from approximately $100 million to $600 million. Gryphon prioritizes investment opportunities where it can form strong partnerships with owners and executives to build leading companies, utilizing Gryphon's capital, specialized professional resources, and operational expertise.
Contact
Lambert
Jennifer Hurson
845-507-0571
jhurson@lambert.com
View original content:
SOURCE Pacur
|
https://www.whsv.com/prnewswire/2022/09/12/pacur-names-jason-eckel-senior-vice-president-sales-amp-marketing/
| 2022-09-12T12:45:58Z
|
New Investor Time BioVentures Leads Round, With Risk & Return (R²) and Existing Backers
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Phantom Neuro, the first-of-its-kind neurotech startup that delivers a low power, high accuracy system for lifelike control of robotic orthopedic technologies, today announced a $6 million funding round led by new investor Time BioVentures. The round included participation from another new investor, Risk & Return (R²), an innovative venture fund focused on "capitalism for good". Support from returning investors LionBird Ventures, Draper Associates & Breakout Ventures now brings the company's total funding to $9.5M. With the financing, co-founder of Time BioVentures, D.A. Wallach, will join the company's board. The company also announced the addition of two key hires: Aurel Bouvier, PhD, Vice President of Implantable Systems and Erik Lloyd, Senior Neuroengineer.
Launched just six months ago, Phantom Neuro aims to dramatically enhance the lives of amputees and other patients with function deficits. The company's solution combines low-risk implantable sensors, AI, and enabling software to offer unparalleled control of orthopedic technologies, such as prosthetic limbs and exoskeletons.
"The field of advanced robotics has enormous potential to augment patients' daily lives, and yet we lack practical and effective commercially available devices to control these systems outside of the lab. Phantom Neuro is filling this void by creating an elegant link between biology and prosthetics that has the potential to revolutionize the standard of care for patients," says D.A. Wallach, General Partner of Time BioVentures. "Connor Glass, Phantom Neuro's founder, brings to this challenge formidable talents as a physician, inventor, and company builder. We believe he and his growing team have what it takes to deliver real solutions to patients with urgency and creativity."
Today over two million Americans live with limb loss, a number that is expected to nearly double by 2050. Over 185,000 amputations are conducted in the U.S. yearly due to trauma, increasing age, diabetes, and vascular disease; estimates of hospital charges to amputation patients in the United States total $10 billion annually. Illuminating new prosthetic technologies exist, yet modern device abandonment rates are still as high as 50%+ due to difficulty in operation, weight, and inconvenience. Phantom Neuro's answer to these obstacles is superior control of existing and next-generation orthopedic technologies. With improved patient outcomes through superior control, the incentives align for enhanced innovation in the robotic orthopedic space. Unique to Phantom's tech is also its promise of scalability - the platform has the safety and simplicity required to grow into a platform for lifelike control of virtually any wirelessly compatible device.
"We're privileged today to announce our second round of funding. I believe our rapid progress demonstrates the importance of our mission and the strength of our team. I'm thrilled to have the support of like-minded investors such as Time BioVentures and Risk & Return helping us hit our targets and work towards human trials," remarked Dr. Connor Glass, Founder and CEO of Phantom Neuro and primary inventor of Phantom's technology. "With their and returning investors' steadfast backing and advice, not to mention our growing team of experienced engineers, we're excited to achieve our next milestones."
The startup has been on an exhilarating trajectory since launch, fulfilling strategic steps leading them closer to human trials. Most recently the company announced a partnership with Blackrock Neurotech and the appointment of Dr. Geoffrey Ling, the current CEO of On Demand Pharmaceuticals and previously the Founding Director of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office, to the board.
About Phantom Neuro
Phantom is a neurotechnology company, spun out of a lab at the Johns Hopkins University School of Medicine, that is enabling lifelike control of robotic orthopedic technologies like prosthetic limbs and exoskeletons. You can find out more at www.phantomneuro.com
About Time BioVentures
Time BioVentures is a life sciences and healthcare investment firm based in Southern California. www.TimeBioVentures.com
CONTACT
Shannon Wilsey, Public Relations | Phantom Neuro
info@phantomneuro.com
View original content to download multimedia:
SOURCE Phantom Neuro Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/phantom-neuro-raises-6m-expanded-seed-funding-company-growth-development-advanced-platform-patient-capability-restoration/
| 2022-09-12T12:46:04Z
|
Deal marks fourth investment from Pharos Fund IV, focused on value-based care
DALLAS and NASHVILLE, Tenn., Sept. 12, 2022 /PRNewswire/ -- Pharos Capital Group, LLC ("Pharos"), a middle-market private equity firm based in Dallas and Nashville, announced today it has made a significant investment in Renal Care 360° (or the "Company"), a comprehensive nephrology practice and chronic care management company founded by accomplished renal care entrepreneur Joe Cashia. Renal Care 360° partners with health systems, physician groups and local communities to provide enhanced community healthcare management services with a primary focus on patients in underserved, rural communities.
Pharos's investment, along with additional equity investment from the Company's founding shareholders, will be used to support continued growth of the Company's RC360° Connected Care Program, geographic expansion through acquisitions, and development of value-based care programs. Terms of the transaction were not disclosed.
Renal Care 360° has developed a unique model centered on early detection of unidentified chronic conditions using proprietary data analytics. Once medical conditions are identified, the Company offers early interventions through its affiliated physician practices with personalized education, real-time engagement, local and virtual clinic options, and dedicated care coordination to slow disease progression and improve outcomes for chronic kidney disease ("CKD"), end stage kidney disease ("ESKD"), and other co-morbidities. Renal Care 360° is also raising awareness and improving education of kidney disease in areas most impacted by inequities in access to care, enabling its health system and physician group partners to proactively engage and care for their patients.
Jim Phillips, a Partner at Pharos, said, "With the nationwide push to reform kidney care through deeper engagement of the population's most vulnerable CKD and ESKD patients, we have observed Renal Care 360°'s use of machine learning to early-identify and intervene with comprehensive, compassionate care to be a uniquely impactful model. Their specialized approach helps to slow disease progression, prevent unnecessary hospital admissions, enable physician and health system partners to continuously engage with their patients, and dramatically improve patient experiences and outcomes. We are thrilled to be partnering with a management team whose longstanding dedication to kidney care, physician practice management, home health, and population health is only rivaled by their passion to meaningfully improve and prolong the lives of many thousands of patients who may otherwise slip through the cracks."
Renal Care 360° founder Joe Cashia will continue to lead the Company as Chairman and CEO. Mr. Cashia is a 35-plus-year veteran of the healthcare industry with deep experience across the continuum of kidney care who has partnered with physicians and hospitals across the country and has created, acquired, and managed more than 1,000 healthcare centers. Previously serving as CEO of National Renal Alliance, Vivere Health, and Ascend Health Care Services and in various Board roles, Mr. Cashia has extensive experience in scaling complex healthcare service organizations with a deep appreciation for the importance of partnering with physician leaders and clinicians to drive value-based care initiatives and improve patient outcomes.
Mr. Cashia noted, "We are pleased to bring in such an experienced, healthcare-focused partner to help Renal Care 360° rapidly expand its care model to touch the lives of as many patients as possible. Pharos's dedication to bridging inequities in care, demonstrated by their proven track record guiding value-based healthcare organizations, will be invaluable as we grow our clinic footprint, scale chronic care management infrastructure to meet the overwhelming market need, and work with health systems and payors to align incentives around optimization of patient outcomes to generate transformational cost savings to the system."
This marks the fourth investment from Pharos's latest flagship fund, Pharos Capital Partners IV, L.P., investing alongside its parallel fund, Pharos Capital Partners IV-A, L.P., a licensed Rural Business Investment Company. The funds will continue Pharos's mission of lowering costs, improving outcomes, and expanding access to care, particularly within underserved rural communities.
About Renal Care 360°
Renal Care 360º is a comprehensive nephrology practice and chronic care management company partnering with health systems, physician groups and local communities to provide enhanced community healthcare management services. Renal Care 360°'s Connected Care Program partners with PCPs, nephrologists, and other physician groups to augment existing services by providing patients with a customized care coordination and education program based on the patient's health needs. In addition to contracted chronic care management services, Renal Care 360° intends to acquire nephrology practices that share a passion to transform kidney care through early detection and deep patient engagement with comprehensive care management.
For business development opportunities with Renal Care 360°, please contact Molly Braun at 985-264-4074 or mbraun@renalcare360.com.
About Pharos Capital Group
Based in Dallas and Nashville, Pharos Capital Group (www.pharosfunds.com) is a physician-founded investment firm focused on growing healthcare companies that aim to lower the total cost of care, improve patient outcomes and reduce healthcare inequalities in underserved markets, especially within urban and rural communities. Since inception, Pharos has invested in 58 companies and has over $1.2 billion of private equity assets under management as of June 30, 2022. Pharos typically invests $25-$50 million in rapidly growing middle market companies seeking later stage funding for internal growth, acquisitions, leveraged buyouts, management buyouts, or recapitalizations across healthcare sectors.
For business development opportunities with Pharos Capital Group, please contact Adam Persiani at 214-740-7003 or apersiani@pharosfunds.com.
Contact
Jennifer Hurson
845-507-0571
jhurson@lambert.com
View original content:
SOURCE Pharos Capital Group
|
https://www.whsv.com/prnewswire/2022/09/12/pharos-capital-invests-renal-care-360-capitalizes-new-chronic-kidney-care-management-platform/
| 2022-09-12T12:46:11Z
|
MARLBOROUGH, Mass., Sept. 12, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that six abstracts have been accepted for poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 10 – 12, 2022.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
"We are pleased to announce the acceptance of six posters for presentation at the annual SITC meeting. These posters will highlight in vitro as well as, in vivo tumor efficacy, and clinical work with our INTASYL compounds targeting PD-1, CTLA-4, CTGF, TIGIT, and BRD4, as well as the manufacturing, in collaboration with our partner AgonOx, Inc., of clinical scale batches of TIL with and without PH-762, our PD-1 gene silencing INTASYL™ compound," said Dr Simon Fricker, Vice President of Research and Development at Phio Pharmaceuticals. "We have worked intensely over the past year to advance our programs evaluating the potential of INTASYL treatment in immuno-oncology and adoptive cell therapy in vitro and in well-established animal models. The team is excited to share the results of these programs during these upcoming posters at SITC."
Details on the Company's poster presentations and related presentation schedules will be forthcoming.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor microenvironment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. PH-762, our lead clinical compound targeting PD-1, is being developed as a standalone drug therapy with local intratumoral administration to a tumor as well as a critical component of cellular immunotherapy, more specifically to improve tumor cell killing capability of adoptively transferred tumor infiltrating lymphocyte (TIL) therapy. For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, military conflict between Ukraine and Russia, inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:
SOURCE Phio Pharmaceuticals Corp.
|
https://www.whsv.com/prnewswire/2022/09/12/phio-pharmaceuticals-announces-acceptance-six-abstracts-37th-annual-meeting-society-immunotherapy-cancer-sitc/
| 2022-09-12T12:46:17Z
|
The Co-Pilot for Patients and Sites products create high-performance experiences to automate research protocol adherence
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- ProofPilot, the protocol automation platform for clinical trials, unveils new product offerings for life science companies at the DPharm 2022 Conference. Additionally, ProofPilot will participate in DPharm's Innovative Patient-Centric Sources & Solutions track and the Pharma Innovation; Reporting from the Trenches track. ProofPilot's Co-Pilot for Patients and Co-Pilot for Sites products are the company's key engagement offerings to ensure a sponsor's study is orchestrated flawlessly by digitally automating clinical workflows.
According to Tufts CSDD, the typical Phase III study suffers from 119 deviations on average, affecting about a third of the participants. "ProofPilot is building on its legacy of democratizing clinical trials by paying special attention to the highly complex orchestration required for conducting pharmaceutical trials," said Joseph Kim, Chief Strategy Officer of ProofPilot. "There are many hidden steps required to execute and participate in a protocol, and ProofPilot is the only company I have seen to automate the research protocol to remove that guesswork and simplify the complex to improve adherence in the flow of conduct. As research evolves to become more decentralized, automated orchestration like this becomes even more of a critical success factor for high-quality execution. There has always been a tie between protocol deviations and patient drop-out and our platform is uniquely positioned to eliminate both."
ProofPilot will share details of its two new life science products at DPharm 2022:
- Co-Pilot for Sites was designed to eliminate protocol deviations by connecting the dots amongst disparate tasks while filling in the holes in the protocol. Intelligently orchestrating all the relevant alerts, reminders, how-to's, and technology amongst staff needed at the point of care will eliminate site burden and improve protocol execution. Co-Pilot for Sites is delivered via a web-based application allowing site staff to seamlessly move from any device. The automated workflows lead to better quality data, lower costs and a more easily operable study.
- Co-Pilot for Patients was designed to engage and improve the clinical journey for study participants. Giving patients confidence and keeping them engaged via culturally appropriate and diverse personalized content in the form of trial guides, what to expect, and time-to-complete estimate alerts and notifications. The intelligent orchestration technology behind the platform is timed and triggered by the interaction of the participant with the site and their exact step in the clinical journey, resulting in an improvement in patient engagement and a decrease in patient dropout. Delivered in a web application, Co-Pilot for Patients allows participants to use any of their own devices.
In deploying ProofPilot's protocol automation platform, sponsors are able to monitor in real-time operational insights of a study's execution and get ahead of potential protocol deviations and patient dropout.
ProofPilot will also participate in two keynote presentations:
- Innovative Patient-Centric Sources & Solutions on Tuesday, September 13, at 11:35 a.m. EST
- The Last Mile of Digital Biomarker Research with Rich Carter, VP and Chief Digital Officer of Digital Health, on Tuesday, September 13, at 1:55 p.m. EST
ProofPilot recently announced a strategic partnership with Citeline Connect, the all-in-one clinical trial recruitment platform developed by Informa Pharma Intelligence. The collaboration combines ProofPilot's Patient and Site Staff Co-Pilot offerings with Citeline Connect's Patient Recruitment Collective to effectively deliver research solutions to improve enrollment, protocol adherence, and patient retention. Together, Citeline and ProofPilot will enable Pharma researchers to more competently recruit and engage a diverse set of patients according to ethnicity, age, background, and location.
About ProofPilot
ProofPilot supports clinical trials with the industry's first fully automated digital protocol platform. The platform orchestrates stakeholder tasks and optimizes clinical workflows, improving stakeholder experiences and data quality. The elimination of guesswork and research protocol deviations creates high-performance experiences for sites and patients. Founded in 2014, ProofPilot was one of the first global digital clinical trial solutions allowing virtual, hybrid, and in-person research offerings with its patient and site Co-Pilot packages. To learn more, visit https://www.proofpilot.com/.
Stay up-to-date on ProofPilot news at: https://www.linkedin.com/company/proofpilot
Media Contact
EvolveMKD
ProofPilot@EvolveMKD.com
View original content to download multimedia:
SOURCE ProofPilot
|
https://www.whsv.com/prnewswire/2022/09/12/proofpilot-unveil-new-life-sciences-products-dpharm-2022-conference/
| 2022-09-12T12:46:24Z
|
LEXINGTON, Ky., Sept. 12, 2022 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC) ("Ramaco Resources" or the "Company") today announced the appointment of four senior executives into newly created positions at the Company. Paul Horn will serve as Senior Vice President and Ramaco's Chief Mine Development Officer, Scott Kreutzer will join as Senior Vice President and Chief Administrative Officer, Tim Chatting will serve as Director of Financial Reporting, and Katie Monroe will serve as Director of Land Administration.
The hires are an integral part of Ramaco's ongoing growth and production expansion. Ramaco has recently announced plans to nearly triple its annual production of metallurgical coal from 2021 levels over the coming years and is also surveying its potential to mine its rare earth element reserves in Wyoming.
"We are building on our already strong bench to help us transition to the next level of growth for our company," said Randall Atkins, Ramaco Resources' Chairman and Chief Executive Officer. "In our first five years we basically grew from scratch to become a 2 million ton a year production operation. Over the next few years, we intend to triple that size to produce over 6.5 million tons annually. To effectively execute to reach these levels we are bringing onboard additional senior management in a variety of operational, financial and administrative disciplines to round out our very effective existing team."
Paul Horn brings with him almost 30 years of experience as one of the most senior mining executives in the Central Appalachian market. He served for over twenty years for the privately held Booth Energy Group with ten years as the President and Chief Operating Officer. In those roles he oversaw numerous large scale underground and surface mining complexes in both Kentucky and West Virginia. He began his career in operations at Alliance Coal and has also served as the past Chairman of the Kentucky Coal Association.
Horn's role at Ramaco will be to spearhead and oversee the development and expansion of all the Company's existing and new mining complexes.
"Paul is true proven mining professional with a deep knowledge of our business. We look forward to having him play a critical role as we execute on our growth plans to bring several new mine complexes and infrastructure production facilities on-line," said Chris Blanchard, Ramaco's Chief Operating Officer. "Speaking for myself and the rest of the operations team, we are excited to work with Paul and quickly integrate him into our growing operational and development efforts."
Scott Kreutzer comes to Ramaco with over 25 years of experience in operational, strategic, legal and land administration matters. He had served as an Executive Vice President and both Chief Operating Officer as well as Chief Strategy Officer at Contura Energy. He also previously served as Senior Vice President for Land Administration at both Contura and Alpha Natural Resources. He has also worked at Eagle Specialty Materials as General Counsel and TECO Coal as Head of Business Development.
In his role as Chief Administrative Officer he will provide senior oversight on Ramaco's administrative and related legal functions, as well as coordination between operations and marketing on strategy. He will also oversee development efforts and work with our new Director of Land Administration.
"We are in growth mode to become a substantial presence in the US metallurgical coal space, and Scott's multi-talented experience at a number of large coal groups will allow him to play a key role in the evolution of our administrative, operational, and marketing functions and strategy," said Jeremy Sussman, Ramaco's Chief Financial Officer. "On behalf of our entire senior management team, we are excited to welcome Scott to Ramaco."
Tim Chatting comes to Ramaco from Lexmark International in Lexington where he held high-level financial accounting and SEC reporting roles for over 25 years. Most recently he served as Senior Manager overseeing complex accounting processes and emerging topics, such as carbon offset programs. When Lexmark was publicly traded, Tim was the Senior Manager of SEC Reporting responsible for the preparation and review of SEC filings. Tim will oversee SEC related accounting matters at Ramaco.
Katie Monroe comes to Ramaco from the land and tax practice groups at Jackson Kelly in Charleston, West Virginia focusing on all aspects of land management and administration. Prior to that she led the Land Management division at Columbia Gas Transmission LLC overseeing a large team that administered the company's land rights. She has also served as a title specialist/title attorney for EQT Production Company.
About Ramaco Resources, Inc.
Ramaco Resources, Inc. is an operator and developer of high-quality, low-cost metallurgical coal in southern West Virginia, southwestern Virginia and southwestern Pennsylvania. Its executive offices are in Lexington, Kentucky, with operational offices in Charleston, West Virginia and Sheridan, Wyoming. The Company currently has three active mining complexes in Central Appalachia and one mine not yet in production near Sheridan, Wyoming. Contiguous to the Wyoming mine it operates a research and pilot facility related to the production of advanced carbon products and materials from coal. In connection with these activities, it holds a body of roughly 50 intellectual property patents, pending applications, exclusive licensing agreements and various trademarks. For more information about us, please visit our website at www.ramacoresources.com.
Point of Contact:
INVESTOR RELATIONS: info@ramacometc.com or 859-244-7455
View original content:
SOURCE Ramaco Resources, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/ramaco-resources-inc-announces-key-senior-executives-support-multi-year-production-growth-strategy/
| 2022-09-12T12:46:31Z
|
Phase 1b Multiple Ascending Dose (MAD) Study Initiated
RGLS8429 in healthy volunteers was well-tolerated with dose-proportional PK
Topline data from first cohort of patients with ADPKD anticipated in 1H 2023
SAN DIEGO, Sept. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. Additionally, the Company announced the initiation of its Phase 1b MAD clinical trial of RGLS8429.
Summary of Results from Phase 1 SAD Study
The Phase 1 SAD study demonstrated that RGLS8429 has a favorable safety and PK profile. RGLS8429 was well-tolerated with no serious adverse events reported. Among the 32 subjects treated with RGLS8429 or placebo, there were nine adverse events all of which were mild, except one (sinus infection) which was graded moderate in severity. Preliminary results suggest plasma exposure is dose proportional across the four doses tested and compare favorably to the PK data from the first-generation compound, RGLS4326.
Phase 1b MAD Study Initiated
The phase 1b MAD study is a double-blind, placebo-controlled study in patients with ADPKD. The primary objectives of the MAD study are to assess safety, tolerability, and pharmacokinetics of RGLS8429 and to evaluate the efficacy of RGLS8429 treatment across three different dose levels, including changes in polycystins, cystic kidney volume (htTKV), and overall kidney function. The first planned dose level to be tested in patients with ADPKD is 1 mg/kg dosed every other week for three months. Topline data from the first cohort of patients is expected in 1H 2023.
More information about the MAD clinical trial is available at clinicaltrials.gov (NCT05521191).
"The safety and PK data generated in our Phase 1 SAD trial are highly encouraging and allow us the flexibility to use a range of dose levels as we explore the safety and efficacy of RGLS8429 in the Phase 1b MAD study," said Jay Hagan, President and Chief Executive Officer of Regulus Therapeutics. "We are excited about the initiation of the MAD study, and we look forward to presenting top line data from the first cohort of patients in the first half of 2023."
About ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60. Approximately 160,000 individuals are diagnosed with the disease in the United States alone, with an estimated global prevalence of 4 to 7 million.
About RGLS8429
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including the expected timing for initiating clinical studies, the expected timing for reporting topline data, and the timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:
SOURCE Regulus Therapeutics Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/regulus-therapeutics-announces-positive-topline-safety-pharmacokinetic-pk-data-phase-1-single-ascending-dose-sad-clinical-trial-rgls8429-treatment-autosomal-dominant-polycystic-kidney-disease-adpkd/
| 2022-09-12T12:46:37Z
|
STERLING, Va., Sept. 12, 2022 /PRNewswire/ -- ADG-REI Technology Ventures, a collaboration between REI Systems of Sterling, VA, and ADG Tech Consulting of Herndon, VA, today announced that it has been awarded a joint venture (JV) contract by the U.S. Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) worth $110M. Under a three-year contract, ADG-REI Technology Ventures will provide Agile DevSecOps services for mission-critical immigration systems.
The contract is part of the USCIS Outcome-Based Delivery and Development Operations (DevOps) Services (ODOS) III program. ADG-REI Technology Ventures provides leading-edge DevSecOps and User Experience Design (UXD) services to frequently deploy cost-effective and high-quality code supporting the USCIS mission—overseeing lawful immigration to the United States. The team will leverage an open-source technology stack, microservices architecture, and human-centered design practices in an Agile environment to deliver new business functionalities daily. The JV's technical experts will be responsible for developing high-quality business functionality to work within customer-centric architectures and processes.
"For nearly 20 years, REI Systems has partnered with the Department of Homeland Security to honor its mission of safeguarding the American people. We have a proven track record delivering innovative software solutions that cross many of the markets we serve," said Samidha Manu, Vice President of Federal Civilian Services. "Expanding our Agile DevSecOps presence within DHS further demonstrates our past successes and ability to deliver fully tested rapidly operational capabilities into our customers' hands."
REI Systems provides reliable, effective, and innovative technology solutions that advance federal, state, local, and nonprofit missions. Our technologists and consultants are passionate about solving complex challenges that impact millions of lives. We take a Mindful Modernization® approach in delivering our application modernization, grants management systems, government data analytics, and advisory services. Mindful Modernization is the REI Way of delivering mission impact by aligning our government customers' strategic objectives to measurable outcomes through people, processes, and technology. For more information, visit REIsystems.com.
ADG Tech Consulting is an IT and software development consulting provider with 12 years of international and domestic professional experience. ADG provides 24 hours, seven days a week support. Its consultants specialize in leading-edge technology to efficiently meet our clients' existing and ever-changing needs. For more information, visit adgtech.net.
Media & Public Relations
Marketing@reisystems.com
View original content to download multimedia:
SOURCE REI Systems
|
https://www.whsv.com/prnewswire/2022/09/12/rei-systems-awarded-contract-provide-devsecops-citizenship-immigration-services-joint-venture-with-adg-tech-consulting/
| 2022-09-12T12:46:44Z
|
AMSTERDAM, Sept. 12, 2022 /PRNewswire/ -- Repeats Group B.V. ("Repeats"), a pan-European plastics recycling platform focused on the production of high-quality recycled low-density polyethylene ("LDPE") from post-industrial and commercial films, announced today that it has made an investment in Polimero Srl ("Polimero" or the "Company"), a producer of recycled LDPE located in northern Italy, close to Venice. The financial terms of the transaction were not disclosed. Repeats is a portfolio company of Ara Partners ("Ara"), a global private equity firm focused on industrial decarbonization.
Repeats' investment in Polimero marks its expansion into Italy, an important step in building a pan-European plastics recycling platform. It follows Repeats' recent two investments in Spain and the Netherlands, with expansion into other European countries planned for later this year.
Polimero uses a mechanical process to convert plastic waste into resin suitable for commercial and industrial applications. As part of Repeats, Polimero plans to continue expanding its production to meet the growing demand for recycled LDPE in Europe.
Polimero is led by Simonetta Tiberto, who has been with the company since 2010 and will continue to lead the Italian operations and execution of its growth plan.
"Polimero has a great reputation in the industry as an important player in the LDPE recycling environment in northern Italy," said Greg Rung, CEO of Repeats. "We see significant opportunity for Polimero to further penetrate the Italian market by providing its clients with higher quality recycled resin. We are delighted that Simonetta and her team are joining Repeats and look forward to building on their success to date."
"We share Repeats' and Ara's ambition to build one of the largest LDPE recyclers in Europe," said Simonetta Tiberto, CEO of Polimero. "We are excited to have Repeats' support as we continue to expand our business and geographic reach. All our efforts are aimed at creating a circular ecosystem and best serving customers who increasingly require high-quality recycled plastics."
"We are excited for Repeats to enter the Italian market and partner with Simonetta," said Tuan Tran, Partner at Ara Partners. "The Repeats platform is well positioned for rapid growth and plans to become the largest independent producer of recycled LDPE resins in Europe. We are pleased to support Repeats in its ongoing efforts to decarbonize the European plastics market."
Based in the Netherlands, Repeats - Recycled PE AT Scale - is a pan-European plastics recycling platform converting polyethylene ("PE") plastic waste into resin suitable for a variety of commercial and industrial flexible plastic applications. Repeats also has operations in Spain and the Netherlands. For more information on Repeats, please visit www.repeats-group.com.
Founded in 2010 and based in Rovigo, Polimero produces recycled LDPE pellets from both post-commercial and post-industrial plastic waste, which can be used in packaging applications. For more information about Polimero, please visit Home - Polimero Srl.
Ara Partners is a private equity firm focused on industrial decarbonization investments. Ara Partners invests in the industrial and manufacturing, chemicals and materials, energy efficiency and green fuels, and food and agriculture sectors, seeking to create companies with significant decarbonization impact. It operates from offices in Boston, Massachusetts, Houston, Texas and Dublin, Ireland. Ara Partners closed its second fund with approximately $1.1 billion in capital commitments in September 2021. For more information about Ara Partners, please visit www.arapartners.com.
Contacts
Mark Semer / Alex Jeffrey
Gasthalter & Co. LP.
arapartners@gasthalter.com
(212) 257-4170
View original content:
SOURCE Ara Partners
|
https://www.whsv.com/prnewswire/2022/09/12/repeats-group-invests-polimero-srl-continuing-build-one-leading-ldpe-plastic-recyclers-europe/
| 2022-09-12T12:46:51Z
|
LOS ANGELES, Sept. 12, 2022 /PRNewswire/ -- Rexford Industrial Realty, Inc. (the "Company" or "Rexford Industrial") (NYSE: REXR), a real estate investment trust focused on creating value by investing in and operating industrial properties located in Southern California infill markets, today announced that the Company will present at the Bank of America Securities 2022 Global Real Estate Conference on September 14, 2022, at 2:10pm ET. A live webcast will be available on the Company's investor relations website with a replay available until December 14, 2022.
In advance of the Company's participation in upcoming investor meetings, the Company has posted an updated investor presentation which includes quarter-to-date operating results, transactions and capital markets activities. The presentation is available on the Company's investor relations website at www.ir.rexfordindustrial.com.
Rexford Industrial creates value by investing in, operating and redeveloping industrial properties throughout infill Southern California, the world's fourth largest industrial market and consistently the highest-demand, lowest supply market in the nation. The Company's highly differentiated strategy enables internal and external growth opportunities through its proprietary value creation and asset management capabilities. Rexford Industrial's high-quality, irreplaceable portfolio comprises 344 properties with approximately 41.6 million rentable square feet occupied by a stable and diverse tenant base. Structured as a real estate investment trust (REIT) listed on the New York Stock Exchange under the ticker "REXR," Rexford Industrial is an S&P MidCap 400 Index member. For more information, please visit www.rexfordindustrial.com.
This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," or "potential" or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect the Company's good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the Company's future results to differ materially from any forward-looking statements, see the reports and other filings by the Company with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's most recent Form 10-Q. The Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.
Contact:
Aric Chang
Senior Vice President, Investor Relations and Capital Markets
310.734.6952
achang@rexfordindustrial.com
View original content:
SOURCE Rexford Industrial
|
https://www.whsv.com/prnewswire/2022/09/12/rexford-industrial-present-bank-america-securities-2022-global-real-estate-conference-provides-updated-investor-presentation/
| 2022-09-12T12:46:59Z
|
Three-day online event attracted 14,600+ bidders from 46 countries to compete for 8,300+ items
EDMONTON, AB, Sept. 12, 2022 /PRNewswire/ - Ritchie Bros. latest Edmonton, AB auction included 8,300+ equipment items selling for CA$76+ million (US$58+ million) in gross transaction value, which is a 29% increase over the same event last year.
The three-day online event on September 7 – 9, 2022, attracted more than 14,600 bidders from 46 countries. Approximately 94 percent of the equipment in the unreserved auction was sold to Canadian buyers, including 59 percent sold to Albertans. The remaining six percent of the equipment was sold to international buyers from as far away as Colombia, India, and Ireland.
"We had a lot of happy consignors, with equipment and trucks bringing strong demand and pricing through all three days of the auction," said Andrew Lutic, Regional Sales Manager, Ritchie Bros. "Leading up to the event our Edmonton site was busy with buyers inspecting items to add to their fleet for upcoming projects. For those that were unable to get the equipment they need for the winter season, we have a ton of upcoming buying opportunities including our next big Edmonton auction in late October."
More than 1,100 consignors sold equipment in the Edmonton auction, including a major realignment for Ninkovich Gravel Ltd.
"When you work with Ritchie, you get a company that's thoughtful, considerate, and always looking out for your best interests," said Dave Ninkovich of Ninkovich Gravel Ltd. "They provided direction on how to increase the value of my assets at auction and it worked, as we surpassed my original expectations and hit the price I was hoping for."
- 2017 Komatsu D155AXI-8 dozer – CA$400,000 (US$304,040)
- 2014 Kenworth C500 National NBT45TM 45-ton straight boom truck - CA$357,500 (US$271,736)
- 2015 Caterpillar 740BEJ ejector articulated dump truck – CA$325,000 (US$247,033)
- 2014 Caterpillar 349FL hydraulic excavator – CA$265,000 (US$201,427)
- 2013 Peterbilt 367 2012 vacuum industrial on 8x6 hydro vac truck – CA$260,000 (US$197,626)
- Gross Transaction Value: CA$76+ million (US$58+ million)
- Items Sold: 8,300+
- Bidders: 14,600+
- Consignors: 1,100+
Established in 1958, Ritchie Bros. (NYSE and TSX: RBA) is a global asset management and disposition company, offering customers end-to-end solutions for buying and selling used heavy equipment, trucks and other assets. Operating in a number of sectors, including construction, transportation, agriculture, energy, mining, and forestry, the company's selling channels include: Ritchie Bros. Auctioneers, the world's largest industrial auctioneer offering live auction events with online bidding; IronPlanet, an online marketplace with weekly featured auctions and providing the exclusive IronClad Assurance® equipment condition certification; Marketplace-E, a controlled marketplace offering multiple price and timing options; Ritchie List, a self-serve listing service for North America; Mascus, a leading European online equipment listing service; Ritchie Bros. Private Treaty, offering privately negotiated sales; and sector-specific solutions GovPlanet, TruckPlanet, and Ritchie Bros. Energy. The Company's suite of solutions also includes Ritchie Bros. Asset Solutions and Rouse Services LLC, which together provides a complete end-to-end asset management, data-driven intelligence and performance benchmarking system; SmartEquip, an innovative technology platform that supports customers' management of the equipment lifecycle and integrates parts procurement with both OEMs and dealers; plus equipment financing and leasing through Ritchie Bros. Financial Services. For more information about Ritchie Bros., visit RitchieBros.com.
Photos and video for embedding in media stories are available at rbauction.com/media.
View original content:
SOURCE Ritchie Bros.
|
https://www.whsv.com/prnewswire/2022/09/12/ritchie-bros-sells-ca76-million-equipment-september-edmonton-auction/
| 2022-09-12T12:47:06Z
|
RLDatix Catalix will deliver analytics and insights to inform and improve operational efficiencies across healthcare organizations
CHICAGO, Sept. 12, 2022 /PRNewswire/ -- RLDatix, the leading global provider of healthcare operations technology and services, announced today the launch of RLDatix Catalix, a new enterprise platform for improving core operational processes across healthcare organizations. Catalix will provide the automation, intelligence and longitudinal data integration that is essential for better outcomes while leveraging the benefits of Amazon Web Services (AWS) for market leading data protection, privacy and security.
The COVID-19 pandemic has accelerated the unprecedented financial and care delivery challenges that the healthcare industry is facing. Staff shortages, burnout and the ongoing care backlog are stretching healthcare organizations like never before, leading to a renewed effort to manage costs and improve operational processes. The World Health Organization states that 45 million adverse events occur every year - accounting for 15% of total hospital expenditures in developed countries - and Open Access Government estimates that over 40 million health workers will be needed to cover ongoing global shortages.
Powered by AWS, Catalix is an enterprise platform that will leverage millions of data points across the RLDatix product portfolio including workforce management, safety, risk, and compliance. Customers will be provided with insights that help improve safety and quality through proactive mitigation and more efficient allocation of staff across their organizations.
"RLDatix is passionate about partnering with organizations to deliver safer care," said Jeff Surges, CEO, RLDatix. "Our comprehensive solutions portfolio is utilized across thousands of care systems and connecting all that data at the enterprise level will unlock new insights that improve outcomes. Catalix will help organizations reduce operational complexity and costs while simplifying the adoption of innovative new solutions that help make healthcare safer."
"We are excited to offer an analytics platform that has the potential to positively impact so many people," said Barbara Staruk, Chief Product Officer, RLDatix. "Our customers have the most comprehensive sets of healthcare operations data in the world, and RLDatix Catalix will help them unlock its limitless potential."
Catalix is available immediately with North American RLDatix Risk clients being the first to have the opportunity to join. RLDatix Peer Support, launched at ASHRM, is fully Catalix ready.
RLDatix is on a mission to change healthcare. We help organizations become safer by providing governance, risk, compliance (GRC) and workforce management technology that drives overall improvement and better outcomes. Our solutions help customers to proactively identify risk, enhance operational efficiency and compliance, and manage their people in the fairest and most effective way to meet care demand. With more than 6,000 customers in over 20 countries, RLDatix is making healthcare safer for patients and workforces around the world. RLDatix is controlled by Five Arrows, TA Associates and Nordic Capital as major shareholders. For more information, visit www.rldatix.com.
For more information:
Mike Etzinger
Chief Marketing Officer – North America
RLDatix
metzinger@rldatix.com
View original content to download multimedia:
SOURCE RLDatix
|
https://www.whsv.com/prnewswire/2022/09/12/rldatix-announces-catalix-an-enterprise-platform-connect-safety-risk-compliance-workforce-data-drive-better-outcomes-safer-healthcare/
| 2022-09-12T12:47:12Z
|
New tool will help organizations engage with health workers in need of support following a traumatic event
CHICAGO, Sept. 12, 2022 /PRNewswire/ -- RLDatix, the leading global provider of healthcare operations technology and services that drive safer care, announced today the launch of RLDatix Peer Support, a new application to help healthcare organizations provide timely emotional first aid to members of their care team - both clinical and non-clinical - in need of support. Fully RLDatix Catalix ready, Peer Support will help combat burnout by identifying, early on, health workers who need support after experiencing a specific traumatic event or who are struggling with cumulative trauma related to work and non work-related stressors.
According to the National Academy of Medicine, burnout reached crisis levels among the US health workforce even before COVID-19, with 35-54% of nurses and physicians reporting symptoms. The National Institutes of Health states that burnout not only affects health worker wellbeing but could also impact the quality of care delivered. The effects of burnout are only further compounded by historically low staffing levels, with the American Hospital Association projecting the overall shortage of nurses to reach 1.1 million by the end of the year. By identifying distressed caregivers sooner, RLDatix Peer Support will help reduce burnout related costs - which the American Medical Association estimates to be nearly $5 billion annually - while also helping to mitigate its human toll.
"When a traumatic healthcare event occurs, it is not only the patient and family that are impacted, but the caregiver as well," said Jeff Surges, CEO, RLDatix. "Health worker wellbeing is critical to providing safer care, and RLDatix Peer Support will empower caregivers to speak up when they or their colleagues need help."
"Patient safety is reliant on the psychological safety of our caregivers," said Aimee Samuels, Patient Safety Officer, Samaritan Health Services. "Without a comprehensive and systematic approach to peer support after medical harm, our employees are left to suffer alone in shame and fear. A visible and accessible platform to proactively connect peers – without barriers – affirms our commitment to the psychological wellbeing of our caregivers and creates an environment where we are safer together."
"Healthcare organizations have an obligation to ensure the safest possible environment for their staff,"
said Tim McDonald, Chief Patient Safety and Risk Officer, RLDatix. "That is why it is crucial to have a system in place that prioritizes outreach and provides a solution to help address issues around confidentiality, stigma, and access. RLDatix Peer Support will help organizations ensure that no clinical or non-clinical member of their team falls through the cracks and that they feel supported in their time of need."
Coupled with RLDatix's consulting, services and training offerings, healthcare organizations now have another vital tool when it comes to combatting burnout. For more information on RLDatix Peer Support, visit www.rldatix.com.
RLDatix is on a mission to change healthcare. We help organizations become safer by providing governance, risk, compliance (GRC) and workforce management technology that drives overall improvement and better outcomes. Our solutions help customers to proactively identify risk, enhance operational efficiency and compliance, and manage their people in the fairest and most effective way to meet care demand. With more than 6,000 customers in over 20 countries, RLDatix is making healthcare safer for patients and workforces around the world. RLDatix is controlled by Five Arrows, TA Associates and Nordic Capital as major shareholders. For more information, visit www.rldatix.com.
For more information:
Mike Etzinger
Chief Marketing Officer – North America
RLDatix
metzinger@rldatix.com
View original content to download multimedia:
SOURCE RLDatix
|
https://www.whsv.com/prnewswire/2022/09/12/rldatix-launches-peer-support-solution-help-provide-safer-care-combat-clinician-burnout/
| 2022-09-12T12:47:19Z
|
Freshpet donating $150,000 to winning animal shelters; campaign now open for public nominations
SECAUCUS, N.J., Sept. 12, 2022 /PRNewswire/ -- Freshpet (FRPT) is partnering with actress and animal rescue advocate Sarah Michelle Gellar to celebrate its fifth annual Fresh Start initiative. The program, which celebrates and rewards no-kill animal shelters, is open to the public through a submission process beginning today and running for two weeks. The Fresh Start program has distributed more than $400k to no-kill shelters across the country since it began in 2018.
Gellar, whose family has one rescue and two other dogs, will serve as a judge, helping select 16 shelters from across the country to receive funding, including one overall winner receiving $25,000, and five grand prize regional winners who will each receive $15,000. Other grants will be awarded, including 10 runners-up, two in each region, receiving $5,000 each. Submissions are open to the public Sept. 12-25 via ThankYouRescues.com. Following the submission period, winners will be announced the week of Oct. 17.
"We treat our pets like they're our kids; they're such a big part of our family," said Gellar. "We've always been big supporters of animal adoption, because there are so many deserving animals that need good homes. And right now, the need is stronger than ever, with many shelters overcrowded and in need of support," she added. "There are so many rescues doing incredible work across the country, so partnering with Freshpet to recognize and reward them is something I couldn't pass up."
According to Best Friends Animal Society1, of the approximately 4,000 animal shelters in the U.S., only 52% are no-kill shelters, many of which operate with volunteer staff and via donations. Dollars donated through Fresh Start assist shelters with a variety of needs, from healthcare for animals and adoption support to operating cost and equipment. All funding awarded from Freshpet can be utilized at the shelters' discretion.
"Fresh Start allows us to continue to unleash the power of giving to pets and people working to make their lives better," said Steve Elwell, Director of Digital at Freshpet. "There's an amazing network of animal shelters and organizations throughout the country that are championing the wellbeing of companion pets that can use our help, whether through volunteering or donations, and we're happy that we can extend the Fresh Start initiative to help reward them for their work."
Joining Gellar to judge this year's program are pet influencer Tatum Talks (hi.this.is.tatum), Freshpet's expert veterinarian Dr. Aziza Glass, as well as shelter partners, St. Hubert's and Pennsylvania SPCA. Freshpet has helped more than 160 animal shelters throughout the country as part of its work with no-kill shelters and anti-cruelty programs. Its advocacy efforts also include donations of more than 14 million meals.
For more information about Freshpet and the Fresh Start program, visit ThankYouRescues.com, and connect with Freshpet on Facebook, Twitter, and Instagram.
About Freshpet
Freshpet's mission is to improve the lives of dogs and cats through the power of fresh, real food. Freshpet recipes are blends of fresh meats, vegetables and fruits made sustainably at their Kitchens in Bethlehem, PA. Thoughtfully prepared, all food is made using natural ingredients, cooking in small batches at lower temperatures to preserve the natural goodness of the ingredients. Freshpet foods and treats are kept refrigerated from the moment they are made until they arrive at Freshpet fridges in your local market.
Freshpet is available in select mass, grocery (including online), natural food, club, and pet specialty retailers across the United States, Canada and Europe. From the care taken to source ingredients and make each recipe, to the moment it reaches your home, Freshpet's integrity, transparency and social responsibility are the way they like to run their business.
View original content to download multimedia:
SOURCE Freshpet
|
https://www.whsv.com/prnewswire/2022/09/12/sarah-michelle-gellar-teams-up-with-freshpet-reward-animal-shelters/
| 2022-09-12T12:47:25Z
|
BONN, Germany, Sept. 12, 2022 /PRNewswire/ -- Scanbot SDK GmbH welcomed Dag Jessel as Chief Financial Officer (CFO). With more than 10 years of experience working as a Private Equity CFO/ Managing Director for several small and medium-sized businesses, Dag has now joined the leadership team at the software company in Bonn, Germany. Scanbot SDK focuses on mobile data extraction and has been growing rapidly during the last few years. For the road ahead, the company can count on Dag's expertise in finance, operations, and leadership.
"I am very happy to welcome such an experienced colleague at Scanbot SDK. Dag Jessel has shown repeatedly that he can strategically and operationally move a company forward. This will help us to create even more value for our customers and stakeholders. I am sure that he will support us extensively in our rapid growth and bring further momentum to our business", says Christoph Wagner, CEO at Scanbot SDK.
Dag, who graduated in aerospace engineering and holds an MBA from INSEAD, previously served as Managing Director and CFO at nox NachtExpress, a European B2B logistics company focused on transporting time-critical goods overnight. Prior to this, he held leading positions at the aviation industry supplier E.I.S. Aircraft, the electronics industry service provider Gardien, and the Lufthansa group, working both in Germany and abroad. At Lufthansa, he worked in managerial positions in the areas of engineering, operations, and mergers and acquisitions, before becoming Director of Finance & HR for North Asia. Thanks to his analytical way of thinking and his experience in leading international teams, he flourished in all these roles.
"With Scanbot SDK, I'm entering the software-as-a-service (SaaS) industry for the first time. The company convinced me with its vision to help consumers and employees digitize real-world information and make capturing data as easy, accurate, and fast as possible. I am looking forward to the new challenges and I am convinced that together we can even further accelerate the growth of Scanbot SDK", says Dag Jessel.
Logo - https://mma.prnewswire.com/media/1896251/Scanbot_SDK_logo.jpg
Photo - https://mma.prnewswire.com/media/1893542/Scanbot_SDK_GmbH.jpg
Contact:
Niklas Kreck,
+49 (0)228 94800044
View original content to download multimedia:
SOURCE Scanbot SDK GmbH
|
https://www.whsv.com/prnewswire/2022/09/12/scanbot-sdk-joins-dag-jessel-new-cfo/
| 2022-09-12T12:47:32Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Shutterstock, Inc. (NYSE: SSTK) (the "Company"), a leading global creative platform for transformative brands and media companies, today announced that Sejal Amin is joining the Company's leadership team and Executive Committee as Chief Technology Officer (CTO), effective September 12, 2022.
With more than 20 years of global leadership, product and technology experience, Sejal will deliver a technology vision and strategy that transforms Shutterstock's technology platform to deliver a new and unparalleled experience to customers and contributors.
"I am thrilled to welcome Sejal to Shutterstock, as we continue our digital transformation to a full-service creative platform that democratizes creativity, pushes creative boundaries, and provides unparalleled experiences for our customers and contributors around the world," said Paul Hennessy, Chief Executive Officer at Shutterstock. "Sejal is a well-respected and revered leader with a proven track record of growth and innovation, and I am confident that she will be successful in leading Shutterstock's technology platform into its next disruptive phase."
"Shutterstock is a company that has transformed immensely from its inception almost 20 years ago, and I am honored to be the next Chief Technology Officer," said Sejal Amin. "The innovation the Company has achieved – from world class workflow applications to industry-leading proprietary technology – is tremendous, and I look forward to expanding upon the Company's vision, harnessing the potential of Shutterstock's diversified offering as we celebrate a new era for Shutterstock."
Recently, she was Chief Product and Technology Officer for Khoros, a Vista Portfolio company where she was integrating a distributed Product and Technology organization while defining a Product and Operational strategy to execute on the company's vision and growth goals. Just prior to that, she was CTO for the Thomson Reuters Tax and Accounting Tax Professionals Business. She has a wide range of technology leadership experience across several business units at Thomson Reuters managing global product development teams and portfolios of growing size and complexity for 15+ years.
With Sejal's appointment to CTO, Shutterstock now has three women on the Executive Committee, and two women leading the product development strategy, including Chief Product Officer, Meghan Schoen.
About Shutterstock, Inc.
Shutterstock, Inc. (NYSE: SSTK), is a leading global creative platform for transformative brands and media companies. Directly and through its group subsidiaries, Shutterstock's comprehensive collection includes high-quality licensed photographs, vectors, illustrations, 3D models, videos and music. Working with its growing community of over 2 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 415 million images and more than 26 million video clips available.
Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The Company also owns Splash News, the world's leading entertainment news agency for newsrooms and media companies worldwide, Pond5, the world's largest video marketplace, TurboSquid, the world's largest 3D content marketplace; PicMonkey, a leading online graphic design and image editing platform; Offset, a high-end image collection; Shutterstock Studios, an end-to-end custom creative shop; PremiumBeat, a curated royalty-free music library; Shutterstock Editorial, a premier source of editorial images and videos for the world's media; Amper Music, an AI-driven music platform; and Bigstock, a value-oriented stock media offering.
For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook.
View original content to download multimedia:
SOURCE Shutterstock, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/shutterstock-appoints-sejal-amin-chief-technology-officer/
| 2022-09-12T12:47:38Z
|
– Brad Paisley, Dierks Bentley with Hot Country Knights, Tracy Lawrence, Kelleigh Bannen, Ashley Campbell, Melinda Doolittle, Lindsay Ell, Charles Esten, Chrissy Metz and special guests will perform classics from the '90s to raise funds to fight Alzheimer's and all other dementia –
NASHVILLE, Tenn., Sept. 12, 2022 /PRNewswire/ -- Kimberly Williams-Paisley, Ashley Williams and Jay Williams will host the fifth annual star-studded 'Dance Party to End ALZ' in Nashville at the Wildhorse Saloon on Sunday, November 13. Apple Music's Beats 1 "Today's Country" radio host Kelleigh Bannen will serve as emcee for the event as well as perform.
This year's lineup includes Brad Paisley, Dierks Bentley with Hot Country Knights, Tracy Lawrence, Kelleigh Bannen, Ashley Campbell, Melinda Doolittle, Lindsay Ell, Charles Esten, Chrissy Metz, and special guests. Nashville's very own will take the stage to perform their favorite songs from the 1990's to raise awareness and funds in the fight to end Alzheimer's and all other dementia.
"For the past five years, Dance Party to End ALZ has been bringing people together to dress up, dance and experience great live music as some of the biggest names in country music sing cover songs from the '80s and '90s," said Kimberly Williams-Paisley. "Most importantly, though, my siblings Ashley, Jay and I throw this event to help drive awareness and funds for a cause that affects millions of American families, including our own. To date, we've raised more than $1.3 million for the Alzheimer's Association, helping fund research that is going to one day help lead us to a cure for this devastating disease."
General admission tickets and VIP table packages are available now. To purchase tickets or become a sponsor, visit alz.org/danceparty.
Funds raised through the Dance Party to End ALZ will directly support the Alzheimer's Association's research grant program.
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. For more information, visit alz.org or call the 24/7 Helpline at 800.272.3900.
View original content to download multimedia:
SOURCE Alzheimer’s Association
|
https://www.whsv.com/prnewswire/2022/09/12/siblings-kimberly-williams-paisley-ashley-williams-jay-williams-host-fifth-annual-dance-party-end-alz-benefiting-alzheimers-association/
| 2022-09-12T12:47:45Z
|
INDIANAPOLIS, Sept. 12, 2022 /PRNewswire/ -- Simon® is pleased to welcome Hermès to its Atlanta portfolio at Phipps Plaza with the announcement of the signing of a lease for a new 7,000 sq. foot boutique, planned to open the end of the second quarter of 2024.
"Hermès is synonymous with artisanal craftmanship and rich heritage," said Vicki Hanor, Senior Vice President of Luxury Leasing, Simon. "The addition of Hermès at Phipps Plaza is another exciting step in the luxury evolution our consumers expect in Atlanta."
About Simon
Simon is a real estate investment trust engaged in the ownership of premier shopping, dining, entertainment and mixed- use destinations and an S&P 100 company (Simon Property Group, NYSE: SPG). Our properties across North America, Europe and Asia provide community gathering places for millions of people every day and generate billions in annual sales.
About Hermès
Since 1837, Hermès has remained faithful to its artisan model and its humanist values. The freedom to create, the constant search for beautiful materials, the transmission of savoir-faire of excellence, and the aesthetic of functionality all forge the singularity of Hermès, a house of objects created to last. An independent, family owned company, Hermès is dedicated to keeping the majority of its production in France through its 51 workshops and production sites and to developing its network of 306 stores in 45 countries. The group employs more than 16,600 people worldwide, including nearly 10,400 in France, among whom more than 5,600 are craftsmen*. Axel Dumas, a sixth-generation family member, has been Hermès CEO since 2013.
Founded in 2008, the Fondation d'entreprise Hermès supports projects in the areas of artistic creation, training and the transmission of savoir-faire, biodiversity, and the preservation of the environment.
* As of 31st December 2020
View original content to download multimedia:
SOURCE Simon
|
https://www.whsv.com/prnewswire/2022/09/12/simon-herms-announce-lease-signing-atlanta/
| 2022-09-12T12:47:51Z
|
- Company will leverage the recently completed capital raise to unlock the next phase of growth and expansion with large, global enterprise merchants and strategic partners.
- New and existing institutional investors participated in the placement.
- Splitit's management team and board of directors also participated as a strong show of confidence in the company's direction.
- Proceeds to be used to enhance the company's ability to scale its Installments-as-a-Service platform, the first-of-its-kind, white-label installments service.
ATLANTA, Sept. 12, 2022 /PRNewswire/ -- Splitit (ASX: SPT, OTCQX: SPTTY) recently announced it had completed a A$10.5 million private placement with institutional investors. The company will leverage this capital to unlock the next phase of growth and expansion with large, global enterprise merchants and strategic partners.
The capital raising brought in several new large institutional investors along with current institutional investors participating. The raise also included participation from Splitit's management team and board of directors, adding A$712,500 as a strong show of confidence in the company's direction.
"We are very pleased with the market's response to our strategy, as we break away from the crowded BNPL space with our Installments-as-a-Service platform," said Splitit CEO Nandan Sheth. "This new investment enables us to scale our service into new underserved verticals such as education, business services and digital-native retailers. Our new model not only simplifies checkout for the consumer but also provides a consistent and simplified merchant-branded experience for our merchant partners."
The new capital allows Splitit to accelerate its product roadmap so platform partners can embed our service directly into their technology stack while supporting a next-generation one-click installment checkout, further simplifying the shopper experience.
Launched in May 2022, Splitit's white-label Installments-as-a-Service platform eliminates unnecessary consumer friction and improves lackluster conversion numbers inherent with legacy buy now, pay later options. Splitit's merchant-branded experience embeds into the merchant's checkout flow to allow merchants to focus on delivering a more cohesive shopping experience.
Splitit's flexible platform helps merchants deliver a faster and simpler payment experience that generates incremental sales, AOV, and brand satisfaction. A single global API makes Splitit's Installment-as-a-Service the easiest pay-later option to adopt, integrate and operate while delivering an uncluttered, simplified experience.
To learn more about Splitit's Installments-as-a-Service platform, visit: www.splitit.com
Splitit powers the next generation of Buy Now, Pay Later (BNPL) through its merchant-branded Installments-as-a-Service platform. Splitit is solving the challenges businesses face with legacy BNPL while unlocking BNPL at the point of sale for card networks, issuers and acquirers all through a single network API. Splitit's Installments-as-a-Service platform mitigates issues with legacy BNPL like the declining conversion funnel, clutter at the checkout and a lack of control of the merchant's customer experience while putting the power back in the hands of merchants to nurture and retain customers, drive conversion and increase average order value. Splitit's white-label BNPL is the easiest installment option for merchants to adopt, integrate and operate while delivering an uncluttered, simplified experience embedded into their existing purchase flow. Headquartered in Atlanta, Splitit has an R&D center in Israel and offices in London and Australia. Splitit is listed on the Australian Securities Exchange (ASX) under ticker code SPT and also trades on the US OTCQX under ticker SPTTY (ADRs) and STTTF (ordinary shares).
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933.
Contact Information
View original content to download multimedia:
SOURCE Splitit USA, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/splitit-completed-105-million-capital-raise-unlock-next-phase-white-label-installment-as-a-service-growth-plan/
| 2022-09-12T12:47:58Z
|
New Album "Mission Peace" Dropped Friday August 26, 2022
ASPEN, Colo., Sept. 12, 2022 /PRNewswire/ -- It is Midterms Season! Staunch Moderates' Midterms Strategy is: 1) the recent dropping of our sophomore R & B hip hop album, "Mission Peace," available NOW on all major music streaming platforms, including Spotify, Apple Music, Amazon Music, Pandora, and SoundCloud, along with an additional 54 outlets globally; 2) the completion of our 90 Minutes Documentary Film and beginning of its marketing and distribution, and finally 3) the continued distribution of our BIGFOOTS FOOTBALL six-episode music video series, which started August 1st up to the kickoff of the NFL football season September 8th, a la HBO's Ballers distribution style, on Staunch Moderates News' YouTube Channel.
Staunch Moderates own Biggie Smalls, Casanova Ace, a former WWE wrestling star and current rapper is featured on our album, Mission Peace," along with special guest artists Jefferey Skunk Baxter of the Doobie Brothers & founding member of Steely Dan, plus CJ Vanston (Tears for Fears, Dali Lama, Joe Cocker, Ringo Star), E.P. Gregory T. Simmons. Our new band name that all members seem to dig is, "DJ Staunch & the Bigfoots."
When asked, "Who are our inspirations?" we like to say: Frank Sinatra, The Rat Pack, Ramsey Lewis, The Jacksons, Quincy Jones, Steelie Dan, and the Doobie Brothers. We hope you hear them in our tunes!
The complete track listing for Mission Peace is as follows:
Track Title Time
Love 6:05
Bali Girl 5:35
Bigfoots Football 4:23
Olympics & Peace 3:14
Bill Maher 2:48
SMN Remix 3:05
Elon Musk 6:12
DC Aliens 3:21
Peace 2:47
Genres of music within our music are: R&B, jazz, hip hop, rock n roll, classical, gospel, Olympics and Hawaiian.
2021 "The First Realm" Album: (Soundcloud link here)
2022 "Mission Peace" Album: (Soundcloud link here)
Many ask, "what's the rationale behind our Bigfoot Mascot, "Staunch?" Think of it, the "Bigfoot-print" of our country, say at least an 80 percentile all Moderates, the silent majority! Also, we Staunch Moderates are in the paradigm shifting business: from the most terrifying folklore character to the coolest beings on the planet, not human but Bigfoot. Well this is a paradigm shifting analogy to what we are really trying to do to change our socio-political Divide, from anger, aggression, and hate to love, moderation and peace through our music and various different forms of entertainment. It's a tall order, but we are trying!
We currently have over 38 million views and streams of our tracks and other content on our Old MTV-like, Staunch Moderates News YouTube Channel. That's roughly 10% of the U.S. population.
A Staunch Moderates quote we feel worth to remember: "Set our differences aside, find common middle ground, reach across the aisle, tell a joke, evaluate, negotiate, compromise and decide the most equitable solutions humanly possible, like in the 1787 drafting of our Constitution and many other democratic constitutions around the world like it. Checks and balances rather than winner take all!!!"
The pitch: Hey, have you heard of the Staunch Moderates? They're this hip, cool, trending Intellectual Movement of 2022 about addressing the Divide & to strive for National & World Peace, basically an intellectual movement about peace. They've got Bigfoots! They've got Bigfoots Football. They've got Bigfoots Baseball. They've got Staunch Moderates News! Last year they made a 14 track hip hop album, "The First Realm." Just now, they just dropped their second album, "Mission Peace." Listen in & join the Movement. You too can take part in addressing the Divide and striving for National and World Peace. The unthinkable has become the thinkable, because of the platform the Staunch Moderates are bringing to you, again a way that you can address the Divide and strive for National and World Peace. Tune in, tell your friends and dig the music. Peace!
Staunch Moderates are an Intellectual Movement that addresses our country's current intellectual and political divide and strives for both national and world peace. Formed in December of 2019, the Movement hit the ground running, campaigning for their messages throughout the 2020 Election Year. They actively campaigned at sixteen different state Primaries by hosting 35 vital societal issue forums and conducted polls and produced several interviews with different political celebrities during the conventions and debates. With Casanova Ace rapping, the team even hosted a live Election Day Show with a panel of ten of their closest political celebrity friends, including former Congressman Barry Goldwater, former bodybuilding champion Lou Ferrigno, Olympian Maggie Connor and former White House press office Edward P. Lozzi, among others. For fans, constituents and the curious, check it all out at StaunchModerates.org or any of their social media channels.
Website: http://www.staunchmoderates.org/ www.StaunchModerates.org
Facebook: Facebook.com/staunchmoderates
Instagram: staunch_moderates
Twitter: @SModerates
YouTube: Staunch Moderates News
Vimeo: https://vimeo.com/staunchmoderates
View original content:
SOURCE Staunch Moderates
|
https://www.whsv.com/prnewswire/2022/09/12/staunch-moderates-intellectual-movements-midterm-strategy-rapper-casanova-ace-dj-staunch-release-sophomore-album-mission-peace-doubling-down-movements-intellectual-political-philosophy-moderation-over-extremism/
| 2022-09-12T12:48:05Z
|
NORTHBROOK, Ill., Sept. 12, 2022 /PRNewswire/ -- Stepan Company (NYSE: SCL), announced today that it has entered into an agreement to acquire the surfactant business and associated assets of PerformanX Specialty Chemicals, LLC. The acquisition will include intellectual property, commercial relationships, and inventory. The definitive agreement is subject to normal closing conditions and the transaction is expected to close in the third quarter of 2022.
"PerformanX is a strong strategic fit within Stepan's Surfactants business and provides attractive market diversification opportunities for our alkoxylation product line," said Scott R. Behrens, President and Chief Executive Officer of Stepan Company. "The acquisition of PerformanX's business should increase annual revenue by approximately $20 million and be accretive to Stepan's EBITDA margin. We look forward to welcoming PerformanX's customers to Stepan by continuing to provide the same high level of quality and service to which they have been accustomed."
In 2021 Stepan Company announced plans to build and operate a new alkoxylation plant at its existing Pasadena, Texas facility. Alkoxylates are a core surfactant technology critical to the agricultural, oilfield, construction, pulp and paper, lubricant and household end use markets. Stepan's $245 million investment is expected to provide flexible capacity of 75,000 metric tons per year, capable of both ethoxylation and propoxylation, and positions the Company to serve the growing global demand of our Surfactant and Polymer businesses. The new alkoxylation capacity in Pasadena, Texas is expected to come online in early 2024.
Corporate Profile
Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection products and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.
Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia.
The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com.
More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com. Contact: Luis E. Rojo 847-446-7500
Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.
There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to the impact of the COVID-19 pandemic; accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.
These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content:
SOURCE Stepan Company
|
https://www.whsv.com/prnewswire/2022/09/12/stepan-company-executes-agreement-acquire-us-surfactants-producer/
| 2022-09-12T12:48:11Z
|
Baird equity research analyst Ben Kallo initiated coverage with a price target of $8
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Swvl Holdings Corp ("Swvl" or the "Company") (NASDAQ: SWVL), a global provider of transformative tech-enabled mass transit solutions, today announced that Baird has initiated coverage on the Company with "Outperform" Rating and price target substantially higher than Swvl's current trading price.
Copies of the full analyst report can be obtained directly from Baird.
Mostafa Kandil, Swvl Founder and CEO, said, "We are grateful to see institutional research analysts take notice of what we believe to be another record-breaking quarter in Q2 where we grew revenues 3.4x year on year while improving profitability in line with our expectation to turn cash flow positive in 2023 and we achieved multiple strategic milestones including organic SaaS launches in Kuwait and Brazil and completed our acquisitions of Urbvan, Volt Lines and door2door."
Youssef Salem, Swvl CFO, said, "With a well-capitalized balance sheet after raising $29m in early Q3, a clear roadmap to cashflow generation next year, the completion of several recent acquisitions, integrated and significant revenue and cost synergies being realized, continued month-on-month organic growth, lock-up agreements extended by 31 shareholders and executives and now additional equity research initiation, we believe that we are at an inflection point in our shareholder value maximization journey. We look forward to additional research coverage initiation soon."
All reports on Swvl prepared by analysts represent the views of such analysts and are not necessarily those of Swvl. Swvl is not responsible for the content, accuracy or timelines provided by analysts. Swvl does not expressly or by implication warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, assumption, data, forecast, price target, estimate or projection contained in the reports or industry notes provided by analysts, and the dissemination of such reports or industry notes does not necessarily constitute or imply the Company's endorsement or recommendation.
About Swvl
Swvl is a global provider of transformative tech-enabled mass transit solutions, offering intercity, intracity, B2B and B2G transportation across > 20 countries. The Company's platform provides complimentary semi-private alternatives to public transportation for individuals who cannot access or afford private options. Every day, Swvl's parallel mass transit systems are empowering individuals to go where they want, when they want – making mobility safer, more efficient, accessible, and environmentally friendly. Customers can book their rides on an easy-to-use proprietary app with varied payment options and 24 / 7 access to high-quality private buses and vans.
Swvl was co-founded by Mostafa Kandil, who began his career at Rocket Internet, where he launched the car sales platform Carmudi in the Philippines, which became the largest car classifieds company in the country in just six months. He then served as Rocket Internet's Head of Operations. In 2016, Kandil joined Careem, a ride-sharing company and the first unicorn in the Middle East. He supported the platform's expansion into multiple new markets.
For additional information about Swvl, please visit www.swvl.com.
Forward-Looking Statements
Certain statements made herein are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events and other statements that are not historical facts.
These statements are based on the current expectations of Swvl's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Swvl. These statements are subject to a number of risks and uncertainties regarding Swvl's business, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions and other effects of the COVID-19 pandemic; the ability of Swvl to execute its growth strategy, manage growth profitably and retain its key employees; competition with other companies in the mobility industry; Swvl's limited operating history and lack of experience as a public company; recent implementation of certain policies and procedures to ensure compliance with applicable laws and regulations, including with respect to anti-bribery, anti-corruption, and cyber protection; the risk that Swvl is not able to execute its portfolio optimization plan; the risk that Swvl is unable to attract and retain consumers and qualified drivers and other high quality personnel; the risk that Swvl is unable to protect and enforce its intellectual property rights; the risk that Swvl is unable to determine rider demand to develop new offerings on its platform; the difficulty of obtaining required registrations, licenses, permits or approvals in jurisdictions in which Swvl currently operates or may in the future operate; the fact that Swvl currently operates in and intends to expand into jurisdictions that are, or have been, characterized by political instability, may have inadequate or limited regulatory and legal frameworks and may have limited, if any, treaties or other arrangements in place to protect foreign investment or involvement; the risk that Swvl's drivers could be classified as employees, workers or quasi-employees in the jurisdictions they operate; the fact that Swvl has operations in countries known to experience high levels of corruption and is subject to territorial anti-corruption laws in these jurisdictions; the ability of Swvl to maintain the listing of its securities on Nasdaq; Swvl's acquisitions may not be beneficial to Swvl as a result of the cost of integrating geographically disparate operations and the diversion of management's attention from its existing business, among other things; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission. The foregoing list of risk factors is not exhaustive. There may be additional risks that Swvl presently does not know or that Swvl currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Swvl's expectations, plans or forecasts of future events and views as of the date of this communication. Swvl anticipates that subsequent events and developments will cause Swvl's assessments and projections to change. However, while Swvl may elect to update these forward-looking statements in the future, Swvl specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Swvl's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor Contact
Youssef Salem
Swvl CFO
Investor.relations@swvl.com
View original content:
SOURCE Swvl Holdings Corp
|
https://www.whsv.com/prnewswire/2022/09/12/swvl-announces-initiation-equity-analyst-coverage-by-baird-with-outperform-rating/
| 2022-09-12T12:48:17Z
|
Additionally, retailer's Top Toys list, presented this year by FAO Schwarz, features 50 of the most anticipated holiday toys and games from must-have brands available at Target
- Exclusive FAO Schwarz toys will be available only at Target stores, Target.com and FAO store locations starting in October
- The assortment will feature more than 120 toys and a capsule collection celebrating the 160th anniversary of FAO Schwarz
- All Target store toy departments and Target.com will feature dedicated space for FAO Schwarz, with toy demonstrations planned throughout the holiday season
- Target's holiday Bullseye's Top Toys list will offer more exclusives and affordable gift options, with items starting at $14.99
MINNEAPOLIS, Sept. 12, 2022 /PRNewswire/ -- Target Corporation (NYSE: TGT) today announced an exclusive multiyear agreement with iconic toy brand FAO Schwarz to ignite even more magic and inspiration across Target's unrivaled toy assortment. Starting mid-October, FAO Schwarz toys will be available exclusively at Target stores, Target.com and FAO Schwarz stores. In addition, Target announced the 10th annual Bullseye's Top Toys list, presented by FAO Schwarz, which includes the most anticipated toys and games from a wide variety of brands available at Target. With a curated assortment of toys at a variety of affordable prices, more exclusive items and only-at-Target experiences with FAO Schwarz and Disney store at Target, Target is committed to offering guests a one-stop shop for all of their toy-buying needs this holiday season and beyond.
"One of the reasons families love shopping at Target is because of our incredible assortment of toys, and that selection is only getting better with our new exclusive agreement with the beloved FAO Schwarz brand," said Jill Sando, executive vice president and chief merchandising officer, Target. "From hot new items to time-tested favorites, we've curated our annual list of Bullseye's Top Toys to create an easy, fun and affordable way for guests to find just the right gift for every toy lover on their list. Simply put, there's only one place parents and gift givers need to shop for toys this holiday season — and that's Target."
Inside the Target and FAO Schwarz Exclusive Collection and In-Store Holiday Experience
Launching mid-October in all Target stores and on Target.com, the FAO Schwarz assortment will include more than 120 items across all toy categories, with a broad range of toys to inspire magical moments and nostalgic memories signature to FAO Schwarz. Products will range in price from $9.99-$149.99, including 50 toys under $20. The new lineup features the FAO Schwarz Style Runway 4-Sided Fashion Show Playset, FAO Schwarz Ride On Train, FAO Schwarz Makeup Vanity Mirror Set, legacy Dance on Piano Mat and over 50 new plush toys. To celebrate the 160th anniversary of FAO Schwarz, a capsule collection will feature several nostalgic FAO toys under $25, such as the Hot Wheels Collector Set, Funko Toy Soldier Pop, FAO 160th Anniversary Teddy Bear and UNO. Plus, guests will be able to enjoy even more FAO Schwarz toys with new exclusive product drops all season long.
All Target store toy departments will feature dedicated space for FAO Schwarz, including playful store displays to highlight must-have FAO toys. Select Target stores and Target.com will also feature toy demonstrations throughout the holiday season with Target's toy experts, inviting toy enthusiasts of any age to get creative and enjoy hands-on play within the Target aisles.
"We are incredibly thrilled to partner exclusively with Target after having forged such a successful relationship together over the past couple of years. There truly is no better way to kick off our 160th anniversary than to announce this partnership," said David Niggli, chief merchandising officer, FAO Schwarz. "FAO Schwarz has been celebrating the wonder of childhood and bringing awe and discovery to all children — and the child inside all of us — for 160 years, and now families everywhere across the U.S. can enjoy this experience at their local Target store."
Target Celebrates 10 Years of Bullseye's Top Toys List
Additionally, as kids, parents and gift givers alike begin to plan their holiday lists, Target is back with the Bullseye's Top Toys list, featuring 50 of the most sought-after holiday toys, including 23 toys and games available exclusively at Target stores and Target.com this season.
With Top Toys starting at $14.99, gift givers will find toys for every kid on their list from top brands like Disney, LOL Surprise, Mattel, FAO Schwarz and more. The list includes popular characters like PAW Patrol and Marvel's Black Panther: Wakanda Forever as well as dolls from HarperIman, an inclusive doll brand. Guests can view the full list and find more product information on Target.com. Plus, starting in October, guests can shop select Bullseye's Top Toys at a pop-up shop inside FAO Schwarz's iconic New York City flagship in Rockefeller Center.
Bullseye's Top Toys of 2022:
Inspire New Stories
- HarperIman Ashton doll – Exclusive
- Rainbow High Shadow High 4 pack – Exclusive
- Baby Alive Princess Ellie Grows Up! Doll
- Cry Babies First Emotions Dreamy / Cry Babies First Emotions Jassy
- Gabby's Purrfect Dollhouse
- Mermaze Mermaidz Winter Waves Color Change Mermaid Fashion Dolls
- What the Fluff
Inspire Imagination
- Bluey Ultimate Lights & Sounds Playhouse with Lucky – Exclusive
- Barbie Vacation House – Exclusive
- LEGO Black Panther: Wakanda Forever – Exclusive
- Cocomelon Transforming Fire Truck – Exclusive
- Melissa & Doug Fun at the Fair! Game Center Play Tent – Exclusive
- LEGO Harry Potter The Shrieking Shack & Whomping Willow – Exclusive
- LOL Surprise Sunshine Gurl & Moonlight B.B Mega Family Pack – Exclusive
- Magic Mixies Magical Crystal Ball – Exclusive
- Tonies Peppa Pig Toniebox Starter Set – Exclusive
- Animal Planet Deep Sea Shark Adventure Playset – Exclusive
- Imaginext Jurassic World: Dominion Mega Stomp & Rumble Giga Dinosaur
- MEGA Pokémon Motion Pikachu Mechanized Building Set – 1092pcs
- LOL Surprise O.M.G. Fashion Show Mega Runway Extreme Surprise Play Set
- World of EPI Black Panther: Wakanda Forever Dolls
- Got2Glow Baby Fairy Finder
- Play-Doh Kitchen Creations Ultimate Ice Cream Truck Playset
- Pixobitz Studio
- Spidey and his Amazing Friends Spider Crawl-R 2-in-1 Deluxe Headquarters Playset
- Star Wars L0-LA59 (Lola) Animatronic Edition
- LEGO Friends Olivia Space Academy
Inspire Dreams and Creativity
- OSMO Creative Starter Kit – Exclusive
- FAO Schwarz Makeup Vanity Mirror Set – Exclusive
- FAO Schwarz Style Runway 4-Sided Fashion Show Playset – Exclusive
- Our Generation Hair Salon Playset
- PAW Patrol Cat Pack Playset – Exclusive
- Fisher-Price DJ Bouncin' Beats Interactive Musical Learning Toy
- Kinetic Sand Swirl N' Surprise
- 5 Surprise Disney Store Mini Brands Toy Store Playset
- PAW Patrol Big Truck Pups Truck Stop Headquarters Transforming Playset
- Cool Maker Stitch 'N Style Fashion Studio Sewing Machine
- LEGO Succulents – Exclusive
Inspire Active Play
- FAO Schwarz Ride On Train – Exclusive
- Hot Wheels Mario Kart Rainbow Road Raceway Track Set
- Target Toy Shopping Cart – Exclusive
- Monster Jam Monster Garage Playset
- NERF Elite 2.0 Motoblitz CS 10 Blaster
- Pop It Pro
- Chuckle and Roar Mini Golf Play Set – Exclusive
Inspire Fun Family Moments
- Yahtzee Frenzy – Exclusive
- Hand to Hand Wombat
Inspire Future Gamers
- Jurassic World: Dominion Epic Battle Pack Figure Set – Exclusive
- Beyblade Burst QuadDrive Collision Nebula Battle Set – Exclusive
- Bakugan Genesis Collection Pack
- Legends of Akedo Powerstorm Triple Strike Tag Team Arena
Target Delivers a One-Stop Shopping Experience
Target's robust suite of toy offerings make for an easy and convenient one-stop shopping experience this holiday season. Target's free, fast and contactless Order Pickup and Drive Up services allow guests to get everything on their shopping list conveniently, with no designated pickup time or membership required. Guests can also receive personalized, same-day delivery through Shipt and get items delivered right to their doorstep by personal shoppers in as soon as an hour. And as always, Target RedCard holders can enjoy 5% off their purchases all season long, and guests can save throughout the holiday season by joining Target Circle, the retailer's free loyalty program.
For more information about Bullseye's Top Toys, visit A Bullseye View.
Miscellaneous
Statements in this release regarding expectations about the agreement between Target and FAO Schwarz are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties which could cause Target's actions to differ materially. The most important risks and uncertainties are described in Item 1A of Target's Form 10-K for the fiscal year ended January 29, 2022. Forward-looking statements speak only as of the date they are made, and Target does not undertake any obligation to update any forward-looking statement.
About Target
Minneapolis-based Target Corporation (NYSE: TGT) serves guests at nearly 2,000 stores and at Target.com, with the purpose of helping all families discover the joy of everyday life. Since 1946, Target has given 5% of its profit to communities, which today equals millions of dollars a week. Additional company information can be found by visiting the corporate website and press center and by following @TargetNews.
View original content to download multimedia:
SOURCE Target Corporation
|
https://www.whsv.com/prnewswire/2022/09/12/target-announces-exclusive-multiyear-agreement-with-fao-schwarz-ahead-holiday-season/
| 2022-09-12T12:48:24Z
|
COVID-19 Maintained Its Ranking in the Top Five Telehealth Diagnoses across the Nation, according to FAIR Health's Monthly Telehealth Regional Tracker
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- In June 2022, after two months of growth, national telehealth utilization fell 3.7 percent, from 5.4 percent of medical claim lines in May to 5.2 percent in June, according to FAIR Health's Monthly Telehealth Regional Tracker.1 Declines also occurred in the Northeast (4.8 percent) and South (2.4 percent), but there was an increase in telehealth utilization of 2.9 percent in the West and no change in the Midwest. The data represent the privately insured population, including Medicare Advantage and excluding Medicare Fee-for-Service and Medicaid.
Diagnoses
In June 2022, COVID-19 maintained the same ranking among the top five telehealth diagnoses that it held in May, both nationally and in every US census region. It ranked at number two nationally and in every region but the South, where it ranked at number three. This stability contrasted with the period from April to May, when COVID-19 climbed in the rankings nationally and in every region except the Northeast, where it remained stable.
Certain other diagnoses shifted in the rankings in June 2022. For example, from May to June, developmental disorders and joint/soft tissue diseases and issues traded places nationally, with the latter ending in fourth place and the former in fifth place. Similarly, skin infections and issues and urinary tract infections traded places in the South, with the latter ending in fourth place and the former in fifth place.
Specialties
From May to June 2022, in the West, psychologist fell from fourth to fifth place in the list of top five telehealth specialties, switching places with primary care nonphysician.
Procedure Codes
In June 2022, the rankings of the top five telehealth procedure codes did not change nationally or in any region when compared to the prior four months. The number one telehealth procedure code nationally and in every region remained CPT®2 90837, one-hour psychotherapy.
Costs
For June 2022, the Telehealth Cost Corner spotlighted the cost of CPT 90836, 45-minute psychotherapy with evaluation and management visit. Nationally, the median charge amount for this service when rendered via telehealth was $180.72, and the median allowed amount was $111.81.3
About the Monthly Telehealth Regional Tracker
Launched in May 2020 as a free service, the Monthly Telehealth Regional Tracker uses FAIR Health data to track how telehealth is evolving from month to month. An interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions. Each infographic shows month-to-month changes in telehealth's percentage of medical claim lines, as well as that month's top five telehealth procedure codes, diagnoses and specialties. Additionally, in the Telehealth Cost Corner, a specific telehealth procedure code is featured, with its median charge amount and median allowed amount.
FAIR Health President Robin Gelburd stated: "We welcome sharing these varying windows into telehealth utilization as it continues to evolve. This is one of the many ways we pursue our healthcare transparency mission."
For the Monthly Telehealth Regional Tracker, click here.
Follow us on Twitter @FAIRHealth
About FAIR Health
FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of private healthcare claims data, which includes over 38 billion claim records and is growing at a rate of over 2 billion claim records a year. FAIR Health licenses its privately billed data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D; FAIR Health includes among the private claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. FAIR Health also is named a top resource for patients in Dr. Marty Makary's book The Price We Pay: What Broke American Health Care—and How to Fix It and Dr. Elisabeth Rosenthal's book An American Sickness: How Healthcare Became Big Business and How You Can Take It Back. For more information on FAIR Health, visit fairhealth.org.
Contact:
Rachel Kent
Senior Director of Marketing
FAIR Health
646-396-0795
rkent@fairhealth.org
1 A claim line is an individual service or procedure listed on an insurance claim.
2 CPT © 2021 American Medical Association (AMA). All rights reserved.
3 A charge amount is the provider's undiscounted fee, which a patient may have to pay when the patient is uninsured, or when the patient chooses to go to a provider who does not belong to the patient's plan's network. An allowed amount is the total fee paid to the provider under an insurance plan. It includes the amount that the health plan pays and the part the patient pays under the plan's in-network cost-sharing provisions (e.g., copay or coinsurance if the patient has met the deductible).
View original content to download multimedia:
SOURCE FAIR Health
|
https://www.whsv.com/prnewswire/2022/09/12/telehealth-utilization-fell-nearly-four-percent-nationally-june-2022/
| 2022-09-12T12:48:31Z
|
The first multi-vendor MIPI A-PHY link between a Sony Semiconductor Solutions' transmitter and a Valens Semiconductor receiver resulted in seamless interoperability
HOD HASHARON, Israel, Sept. 11, 2022 /PRNewswire/ -- Valens Semiconductor (NYSE: VLN) today announced the successful completion of a joint interoperability testing session between a transmitter developed by Sony Semiconductor Solutions and a Valens Semiconductor receiver. Testing included high-speed data transmission, demonstrating key MIPI A-PHY communication features including error correction and retransmission mechanisms.
"As a pioneer in MIPI A-PHY technology, Valens Semiconductor's primary goal has been to expand and strengthen the MIPI A-PHY ecosystem and Sony Semiconductor Solutions, a leader in the sensor market, is a great partner to enable this growth," said Gideon Kedem, SVP and Head of Automotive at Valens Semiconductor. "MIPI A-PHY is the most robust and resilient automotive connectivity technology available, and the successful completion of the interoperability testing is a significant achievement for the ecosystem. The addition of more suppliers providing A-PHY compliant IC products continues the momentum towards widescale market adoption of this standard".
"Interoperability between multiple vendors' components is crucial for the success of any standard, and we are happy to reach this important milestone with MIPI A-PHY," said Kenji Onishi, General Manager, Automotive Business Department, Sony Semiconductor Solutions Corporation. "As market leaders, it is highly important for Sony Semiconductor Solutions to introduce cutting-edge technology into our image sensors, and MIPI A-PHY serializer integration will provide significant cost and performance benefits for our automotive customers."
About Valens Semiconductor
Valens Semiconductor pushes the boundaries of connectivity by enabling long-reach, high-speed video and data transmission for the Audio-Video and Automotive industries. Valens' HDBaseT® technology is the leading standard in the Audio-Video market with tens of millions of Valens' chipsets integrated into thousands of products in a wide range of applications. Valens' Automotive chipsets are deployed in systems manufactured by leading customers and are on the road in vehicles around the world. Valens is a key enabler of the evolution of ADAS and autonomous driving and its advanced technology is the basis for the new industry standard for high-speed in-vehicle connectivity. For more information, visit https://www.valens.com/.
Forward-Looking Statements
Valens may, in this communication, make certain statements that are not historical facts and relate to analysis or other information which are based on forecasts or future or results. Examples of such forward-looking statements include, but are not limited to, statements regarding future prospects, product development and business strategies. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements but are not the exclusive means for identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections and other forward-looking statements will not be achieved. You should understand that a number of factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in such forward-looking statements, including the risks set forth under "Risk Factors" in our Registration Statement on Form F-1 and our other SEC filings. Valens cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Valens does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Press Contacts:
Yoni Dayan
Head of Communications
Valens Semiconductor Ltd.
Yoni.dayan@valens.com
Investor Contacts:
Daphna Golden
Vice President Investor Relations
Valens Semiconductor Ltd.
investors@valens.com
Moriah Shilton
Financial Profiles, Inc.
ValensIR@finprofiles.com
Logo - https://mma.prnewswire.com/media/1517334/Valens_Logo.jpg
View original content:
SOURCE Valens Semiconductor
|
https://www.whsv.com/prnewswire/2022/09/12/valens-semiconductor-successfully-completes-mipi-a-phy-interoperability-testing/
| 2022-09-12T12:48:37Z
|
LONDON, Sept. 12, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, today announced that Chairman of the Board and Chief Executive Officer, James Foster is presenting at H.C. Wainwright's 24th Annual Global Investment Conference, held in New York, NY and that the pre-recorded and on-demand presentation is now available.
Session details are as follows:
Date: September 12-14, 2022 at Lotte New York Palace Hotel, New York, NY
Title: Virax BioLabs Company Presentation
Virax Participant: James Foster, Chairman and Chief Executive Officer
Presentation Link: https://journey.ct.events/view/5b9cade7-f8ea-41c8-b7c6-ff3e1f490fab
Virax management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting from Maxim Jacobs, CFA at Maxim.Jacobs@russopartnersllc.com
Founded in 2013, Virax Biolabs Group Limited is an innovative biotechnology group focused on the detection and diagnosis of viral diseases, with a particular interest in the field of immunology.
Virax Biolabs Group Limited is currently developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus. For more information, please visit www.viraxbiolabs.com.
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
View original content to download multimedia:
SOURCE Virax Biolabs
|
https://www.whsv.com/prnewswire/2022/09/12/virax-biolabs-presents-hc-wainwrights-24th-annual-global-investment-conference/
| 2022-09-12T12:48:43Z
|
FAIRFAX, Va., Sept. 12, 2022 /PRNewswire/ -- VMD Corp, a leading provider of Cybersecurity, Agile Engineering, and Critical Infrastructure Protection services to the U.S. Federal Government, today announced that it has won a task order with the Transportation Security Administration (TSA) for a period of one year with four-one-year option periods. The work, which involves supporting the agency's Office of Information Technology (IT), Technology Solutions Division (TSD), includes Security Engineering and Compliance (SEAC) support for TSA mission critical systems in which our services will help improve security operations of our nation's traveling public.
"We are extremely pleased to be adding another dimension to our work with TSA," VMD President Vivek Malhotra said. "Our partnership with TSA is one of the longest in our client portfolio and we enjoy performing mission-critical work alongside our TSA stakeholders. We're looking forward to bringing our cybersecurity teams and expertise to this work."
The TSA SEAC cybersecurity task order involves staffing employees with information security credentials and experience who will work closely with developers, infrastructure support, and operational teams, as well as with TSA Division Directors to share insights and implement best practices designed to secure mission critical systems. The work will be based on the latest cybersecurity guidance from the Federal government and industry while using leading toolsets that require expertise in cybersecurity assessments, continuous monitoring, engineering, vulnerability identification, risk analysis, incident and security event monitoring, privileged user management, and information assurance.
This win demonstrates VMD's long-standing commitment to support the TSA mission. Since 2012 the company has provided support to the TSA across all three of its practice areas: Cybersecurity, Agile Engineering, and Critical Infrastructure Protection.
CONTACT: Caryn Alagno
202-236-9073
View original content to download multimedia:
SOURCE VMD Corp
|
https://www.whsv.com/prnewswire/2022/09/12/vmd-wins-tsa-security-engineering-amp-compliance-seac-cybersecurity-task-order-expanding-tsa-portfolio/
| 2022-09-12T12:48:50Z
|
BIARRITZ, France, Sept. 12, 2022 /PRNewswire/ -- Founded by Christophe Buée and Pierre-Nicolas Lebas in 2013 in France, Winback designs, manufactures, and distributes cutting-edge medical devices based on non-invasive technologies.
Winback has always been inspired by therapists and it led it to become the world leader of Tecartherapy in rehabilitation and pain management by re-inventing the use of currents to combine them with established therapeutic approaches such as manual therapy, cryotherapy and compression.
Praised worldwide by physiotherapists, 10 000 devices are used every day to perform treatments. The bottom line for Winback's success is: innovation thanks to R&D teams in France and South Korea, consumer-centricity and a powerful global community of experts activating the online & offline Winback Academy.
In 2021, Winback has reached a turnover of over 30 million dollars across the globe with 7 offices operating in 55 countries. The success story does not end there since Winback is now expanding its expertise in the Beauty market with the acquisition of Bloomea:
Bloomea's genesis started in France in 1999 with its patented innovation "Modeling Bloomea" initially developed for scars management post cosmetic surgeries. Officially launched in 2015, Bloomea with its "La Fontaine" device obtained the Pierantoni prize and the French Cosmetic Award in Hong Kong.
With such a growth rate, Bloomea is today a start-up of 20 people with an international footprint, developing a holistic range of devices including radio frequency technologies & skincare products for premium institutes. Long term partner with Winback, Bloomea is now joining the Group to pursue its strong growth serving world's best beauty brands and salons.
Contact: Arnaud Dutilh, Global marketing director at Winback, arnaud@winback.com
View original content to download multimedia:
SOURCE WINBACK
|
https://www.whsv.com/prnewswire/2022/09/12/winback-world-leader-tecar-therapy-high-frequency-electrotherapy-physiotherapy-expands-its-expertise-beauty-market-with-acquisition-bloomea/
| 2022-09-12T12:48:56Z
|
As deceptive shipping practices get more sophisticated, law enforcement and intelligence agencies aim to enhance their Maritime Domain Awareness. Windward's advanced Maritime AI™ platform provides them with the much needed improved visibility at sea to protect borders and national interests
LONDON, Sept. 12, 2022 /PRNewswire/ -- Windward (LSE: WNWD), the leading Maritime AI™ company, announced today four new law enforcement and intelligence agency customers across the US, Europe, the Middle East, and Latin America. Windward's AI-powered platform will be used to increase the customers' Maritime Domain Awareness (MDA) to monitor their maritime borders efficiently and confidently and protect their citizens and national interests by minimizing illicit activities and monitoring developing threats.
Included in Windward's expansion in the public sector is a three-year contract with an EMEA government customer and a contract extension of up to five years with an existing US Federal Customer.
Law enforcement and intelligence agencies across the globe are increasingly facing a multitude of threats from the maritime domain which negatively impact the security, safety, economy, and environment of their states. These threats include Illegal, Unreported and Unregulated (IUU) fishing, terrorism, drug trafficking, oil dumping, human rights abuses, and more. With 90% of global trade transported by sea, the greater economic impact of maritime crime is significant. It is becoming increasingly important for authorities to enhance their visibility of any activity associated within their territorial waters with advanced technology.
Windward's platform will enable authorities to make smarter decisions based on real-time tracking, actionable insights, and automatic updates using predictive risk modeling powered by machine and deep learning. Windward's Maritime AI™ utilizes data sets including weather, AIS, satellite imagery, port, vessel, and ownership to provide a holistic view of the maritime domain. The platform analyzes numerous factors including vessel behaviors, ownership structures, company risks, and others, predicting in real-time which companies and vessels are likely to be high risk.
"The current geopolitical climate is filled with tension and as we enter a new era of constantly evolving risk, governments are looking to increase awareness of what happens at sea," said Ami Daniel, Co-founder and CEO of Windward. "Malicious actors are adapting to new regulations, using more sophisticated methods to avoid detection. To stay one step ahead and mitigate risk, authorities need to adapt as well and use best-in-class technology to get the full picture they need to keep their borders safe."
Windward's Maritime AI™ platform is powered by advanced machine learning and behavioral analytics models, empowering its clients across the government, finance, shipping, energy sectors, and beyond to optimize business practices and efficiently navigate all aspects of maritime risk in real-time.
About Windward
Windward (LSE:WNWD), a publicly traded company on the London Stock Exchange, is the leading Maritime AI™ company, enabling organizations to achieve business and operational readiness. Windward's AI-powered solution allows stakeholders including banks, commodity traders, insurers, and major energy and shipping companies to make real time, predictive intelligence-driven decisions, providing a 360° view of the maritime ecosystem and its broader impact on safety, security, finance, and business. For more information visit: https://windward.ai/.
Media Contact
David Hoffman
Headline Media
david@headline.media
+972-52-842-1955
View original content:
SOURCE Windward
|
https://www.whsv.com/prnewswire/2022/09/12/windward-expands-its-public-sector-customer-base-with-government-agencies-across-us-emea-latam-determined-crack-down-illicit-maritime-activity/
| 2022-09-12T12:49:02Z
|
NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT (SEE "OFFER AND DISTRIBUTION RESTRICTIONS" BELOW). PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES ARE REQUIRED BY THE OFFEROR, THE ISSUER, THE DEALER MANAGER AND SOLICITATION AGENT, AND THE TENDER AND TABULATION AGENT TO INFORM THEMSELVES ABOUT, AND TO OBSERVE, ANY SUCH RESTRICTIONS.
SANTIAGO, Chile, Sept. 12, 2022 /PRNewswire/ -- WOM S.A. (the "Offeror") today announces the extension of the Early Participation Deadline (as defined in the tender offer and consent solicitation memorandum dated August 26, 2022 (the "Tender Offer and Consent Solicitation Memorandum")) for its previously announced invitation to eligible holders of Kenbourne Invest S.A.'s (the "Issuer") outstanding 6 7/8% Senior Notes due 2024 (the "2024 Notes") and 4.7% Senior Notes due 2028 (the "2028 Notes" and together with the 2024 Notes, the "Notes") to tender for cash such Notes up to the Aggregate Maximum Tender Amount of the Notes validly tendered and purchased equal to US$270.0 million (such invitation, the "Tender Offers"), and together with the Tender Offers, its solicitation of consents to certain proposed amendments (the "Proposals", and together with the Tender Offers, the "Offers") to the relevant indentures governing the Notes.
The Offeror commenced the Offers on August 26, 2022. The new Early Participation Deadline, unless extended or earlier terminated by the Offeror, will be 5:00 p.m., September 16, 2022, for each series of Notes. All other terms and conditions of the Offers, as previously announced and described in the Tender Offer and Consent Solicitation Memorandum, remain unchanged.
The following table sets forth certain key events of the Offers, as extended. Further information may be found in the Tender Offer and Consent Solicitation Memorandum:
The Offers are being conducted pursuant to the Tender Offer and Consent Solicitation Memorandum, the announcement dated August 26, 2022, this announcement and the Offeror's other press releases used in the Offers. This announcement does not contain the full terms and conditions of the Offers, which are contained in the Tender Offer and Consent Solicitation Memorandum. Noteholders are advised to read carefully the Tender Offer and Consent Solicitation Memorandum for full details of, and information on, the procedures for participating in the Offers. Capitalized terms used in this announcement but not defined herein shall have the meanings given to them in the Tender Offer and Consent Solicitation Memorandum. A copy of the Tender Offer and Consent Solicitation Memorandum is available to eligible persons upon request from the Tender and Tabulation Agent.
J.P. Morgan Securities LLC is acting as Dealer Manager and Solicitation Agent for the Offers (the "Dealer Manager and Solicitation Agent") and D.F. King & Co., Inc. is acting as Tender and Tabulation Agent (the "Tender and Tabulation Agent").
Questions and requests for assistance in connection with the Offers may be directed to the Dealer Manager and Solicitation Agent.
THE DEALER MANAGER AND SOLICITATION AGENT
J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
United States of America
Attn: Latin America Debt Capital Markets
U.S. Toll Free: +1 (866) 846-2874
Collect: +1 (212) 834-7279
Questions and requests for assistance in connection with the delivery of Tender Instructions may be directed to the Tender and Tabulation Agent.
THE TENDER AND TABULATION AGENT
D.F. King & Co., Inc.
48 Wall Street, 22nd Floor
New York, New York 10005
Attn: Michael Horthman
By Facsimile (For Eligible Institutions Only): +1 (212) 709-3328
Attn: Michael Horthman
Banks and Brokers call: +1 (212) 269-5550 (collect)
All others call toll-free: +1 (866) 388-7535
E-mail: wom@dfking.com
DISCLAIMER This announcement must be read in conjunction with the Tender Offer and Consent Solicitation Memorandum. This announcement and the Tender Offer and Consent Solicitation Memorandum contain important information which should be read carefully before any decision is made with respect to the Offers. Before participating in the Offers, Noteholders are recommended to seek their own financial or legal advice from their stockbroker, bank manager, legal adviser, accountant or other independent financial or legal adviser. Noteholders whose Notes are held on their behalf by a broker, dealer, commercial bank, custodian, trust company or other nominee or intermediary or clearing system (including any Clearing System) must contact such entity if they wish to tender Notes in the relevant Tender Offer and/or participate in the relevant Proposal.
In accordance with normal practice, none of the Dealer Manager and Solicitation Agent, the Tender and Tabulation Agent, the Trustee, the Notes Agents, the Offeror nor any of their respective directors, officers, employees or affiliates express any view or opinion on the merits of, or makes any representation or recommendation whatsoever regarding this announcement, the Tender Offer and Consent Solicitation Memorandum, the Offers or makes any recommendation as to whether Noteholders should tender Notes in the Tender Offers or otherwise participate in the Offers.
None of the Dealer Manager and Solicitation Agent, the Tender and Tabulation Agent (or any of their respective directors, employees or affiliates) assumes any responsibility for the accuracy or completeness of the information concerning the Offeror, the Notes, or the Offers contained in this announcement or in the Tender Offer and Consent Solicitation Memorandum. None of the Dealer Manager and Solicitation Agent, the Tender and Tabulation Agent (or any of their respective directors, employees or affiliates) is acting for any Noteholder, or will be responsible to any Noteholder for providing any protections which would be afforded to its clients or for providing advice in relation to the Offers, and accordingly none of the Dealer Manager and Solicitation Agent, the Tender and Tabulation Agent (or any of their respective directors, employees or affiliates) assumes any responsibility for any failure by the Offeror to disclose information with regard to the Offeror or the Notes which is material in the context of the Offers and which is not otherwise publicly available.
OFFER AND DISTRIBUTION RESTRICTIONS
Neither this announcement nor the Tender Offer and Consent Solicitation Memorandum constitute an invitation to participate in the Offers to or from any person located or resident in any jurisdiction where it is unlawful to make such invitation or for there to be such participation under applicable securities or other laws. In certain jurisdictions, the distribution of the Tender Offer and Consent Solicitation Memorandum may be restricted by law. Persons into whose possession the Tender Offer and Consent Solicitation Memorandum comes are required by the Offeror, the Dealer Manager and Solicitation Agent and the Tender and Tabulation Agent to inform themselves about and to observe any such restrictions.
General
Neither this announcement nor the Tender Offer and Consent Solicitation Memorandum constitute an offer to purchase, or the solicitation of an offer to tender or sell, or to exercise any voting or consent rights with respect to any, Notes to or from, or by, any person located or resident in any jurisdiction where such offer or solicitation is unlawful, and tenders of Notes by Noteholders originating from any jurisdiction in which such offer or solicitation is unlawful will be rejected. The Offers are not being made, directly or indirectly, in any jurisdiction where to do so would impose any obligations on the Offeror in such jurisdiction, including any requirement to qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction, file any general consent to service of process in any such jurisdiction, subject itself to taxation in any such jurisdiction if it is not otherwise so subject, make any filing with any regulatory body in any such jurisdiction or otherwise have any document approved by, or submitted to, any regulating body in such jurisdiction, in each case in relation to the Offers and the Proposals. In those jurisdictions where the securities laws or other laws require the Offers to be made by a licensed broker or dealer and the Dealer Manager and Solicitation Agent or any of its affiliates is such a licensed broker or dealer in such jurisdiction, the Offers shall be deemed to be made on behalf of the Offeror by such Dealer Manager and Solicitation Agent or affiliate (as the case may be) in such jurisdiction and the Offers are not made in any such jurisdiction where either the Dealer Manager and Solicitation Agent or any of its affiliates is not licensed. Neither the delivery of the Tender Offer and Consent Solicitation Memorandum nor any purchase of Notes shall, under any circumstances, create any implication that there has been no change in the affairs of the Offeror since the date hereof, or that the information herein is correct as of any time subsequent to the date hereof.
Each Noteholder participating in the Offers will be deemed to give certain representations with respect to the jurisdictions referred to below, and generally, on submission of Notes for tender in the Tender Offers and submission of consent to the Proposals. Any tender of Notes for purchase pursuant to the Offers from a Noteholder that is unable to make these representations will be rejected. Each of the Offeror, the Dealer Manager and Solicitation Agent and the Tender and Tabulation Agent reserves the right, in its absolute discretion, to investigate, in relation to any tender of Notes for purchase pursuant to the Tender Offers, or submission of consent to the Proposals, whether any such representation given by a Noteholder is correct and, if such investigation is undertaken and as a result the Offeror determines (for any reason) that such representation is not correct, such tender will be rejected.
United Kingdom
The communication of this announcement, the Tender Offer and Consent Solicitation Memorandum and any other documents or materials relating to the Offers is not being made, and such documents and/or materials have not been approved, by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended (the "FSMA"). Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is only directed at and may be communicated to (i) persons who have professional experience in matters relating to investments, being investment professionals as defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order"); (ii) persons who fall within Article 43(2) of the Financial Promotion Order; or (iii) any other persons to whom these documents and/or materials may lawfully be provided. Any investment or investment activity to which the Tender Offer and Consent Solicitation Memorandum relates is available only to such persons or will be engaged in only with such persons and other persons should not rely on it.
European Economic Area (EEA)
Each person in a Relevant State who receives any communication with respect to the Offers contemplated in the Tender Offer and Consent Solicitation Memorandum will be deemed to have represented, warranted and agreed to and with the Dealer Manager and Solicitation Agent and the Offeror that it is a qualified investor within the meaning of Article 2(e) of the Prospectus Regulation.
Luxembourg
The terms and conditions relating to this announcement and the Tender Offer and Consent Solicitation Memorandum have not been approved by and will not be submitted for approval to the Luxembourg Financial Services Authority (Commission de Surveillance du Secteur Financier) for purposes of public offering in the Grand Duchy of Luxembourg ("Luxembourg"). Accordingly, the Offers may not be made to the public in Luxembourg, directly or indirectly, and none of the Tender Offer and Consent Solicitation Memorandum or any other prospectus, form of application, advertisement or other material may be distributed, or otherwise made available in or from, or published in, Luxembourg except in circumstances which do not constitute a public offer of securities to the public, subject to prospectus requirements, in accordance with the Luxembourg Act of July 10, 2005 on prospectuses for securities.
Chile
The terms and conditions relating to the Tender Offer and Consent Solicitation Memorandum have not been approved by and will not be submitted for approval to the Chilean Financial Market Commission (Comisión para el Mercado Financiero) for purposes of public offering in Chile. Therefore, the Offers may not be made to the general public in Chile, directly or indirectly, and none of the Tender Offer and Consent Solicitation Memorandum or any other prospectus, form of application, advertisement or other material may be distributed, or otherwise made available in or from, or published in, Chile except in circumstances which do not constitute a public offer of securities to the public according to General Rule No. 336 of the Financial Market Commission.
View original content:
SOURCE WOM S.A.
|
https://www.whsv.com/prnewswire/2022/09/12/wom-sa-announces-extension-early-participation-deadline-tender-offer-consent-solicitation-kenbourne-invest-sas-oustanding-us510000000-6-78-senior-notes-due-2024-us435000000-47-senior-notes-due-2028/
| 2022-09-12T12:49:08Z
|
Woolpert Africa combines the mapping, surveying and data services of Woolpert, Southern Mapping and AAM.
JOHANNESBURG, Sept. 12, 2022 /PRNewswire/ -- Woolpert has integrated the staff, resources and local experience of its two geospatial companies in Africa, Southern Mapping Company and AAM, to form Woolpert Africa. The team will provide geospatial data collection, processing and management to support common applications in Africa, including services in mining, power, infrastructure, agriculture and the environment.
Woolpert acquired Southern Mapping Company in 2019. Based in Johannesburg, Southern Mapping, a Woolpert Company, specializes in lidar, hyperspectral imagery and remote sensing technologies. AAM, a Woolpert Company, is a photogrammetric mapping, surveying and GIS firm headquartered in Australia. AAM joined Woolpert in 2021. It has offices in Johannesburg and Cape Town and staff across multiple African countries and the Gulf States.
"Individually, each of our companies have made a name for themselves across Africa by providing cutting-edge geospatial services to address a wide range of needs," Woolpert Senior Vice President Joseph Seppi said. "Together, we are an industry-leading company that lives and works across the continent and understands doing business in Africa. Together, we are the largest full-service geospatial firm in Africa."
These companies introduced the first lidar system in Africa and the first hyperspectral system based in South Africa. The Woolpert Africa team has mapped more than 2 million square kilometers of the continent and has worked in more than 45 African countries, completing more than 1,500 projects.
"This alignment of regional resources is in line with our strategic vision to expand technology and innovation to best serve our clients, while giving staff the opportunity to create and advance," Woolpert CEO Scott Cattran said. "We're very excited to announce the launch of Woolpert Africa."
About Woolpert
Woolpert is the premier architecture, engineering, geospatial (AEG) and strategic consulting firm, with a vision to become one of the best companies in the world. We innovate within and across markets to effectively serve public, private and government clients worldwide. Woolpert is an ENR Top 150 Global Design Firm, earned six straight Great Place to Work certifications and nurtures a culture of growth, inclusion, diversity and respect. Founded in 1911 in Dayton, Ohio, Woolpert has been America's fastest-growing AEG firm since 2015. The firm has 1,900 employees and 60 offices on four continents. woolpert.com.
Media contact: Jill Kelley; 937-531-1258, jill.kelley@woolpert.com
View original content to download multimedia:
SOURCE Woolpert
|
https://www.whsv.com/prnewswire/2022/09/12/woolpert-aligns-geospatial-companies-resources-form-woolpert-africa/
| 2022-09-12T12:49:15Z
|
Thriller Film, "ISSAC" Directed by Webber Films to Be First Joint Venture Release
ATLANTA, Sept. 12, 2022 /PRNewswire/ -- World One TV, has signed a First Look Deal with WeVidIt Media to provide projects hosted by the WeVidit App to present to the pitch platform to secure financing, it was announced today.
WeVidIt Media, Inc. and its wholly owned subsidiary WeVidIt, Inc., together "WeVidIt" is using an investment marketplace and pitch platform to address funding issues in the film and television industry. WeVidIt connects professional filmmakers to consumer movie lovers and enables those consumers to invest in films.
"I am extremely excited to announce our partnership with World One TV. Both brands are well-aligned in our mission for greater Diversity, Equity, and Inclusion (DEI) in the entertainment industry. WeVidIt Media is committed to helping World One TV's filmmakers and producers in their development and productions," stated Matt Sherwood, Ph.D., Chief Executive Officer, WeVidIt Media, Inc.
"The WeVidIt App democratizes the investment opportunity in the film and TV industry by allowing anyone to invest in movies and series' stock offerings. Investors can gain a 100% tax deduction (Section 181 of the U.S. tax code) and profit from the films' success. World One TV's First Look Deal with WeVidIt Media will enable economic inclusion for the average person who has not had access to invest in these shows, and also give World One TV's sourced producers a clear path to success," says Sean Reid, President, World One TV.
World One TV, based in Fayetteville, GA, is a black-owned global streaming platform headed by a team with over 70 years of experience. The company is dedicated to showcasing a wide collection of inclusive and curated film and television centered on black and international cinema.
ISSAC is psychological thriller that treads the lines of reality and fiction. Issac, a young reclusive mortician who inherited his stepfather's mortuary business meets a friendly waitress, Cassi. The two create an instant connection and after a night of terror, they pursue a revenge murder together. The film, starring Dove Cameron, mixes reality with surreal imagery, showing how one may operate while in isolation, due to the circumstances he has been given. Issac inevitably makes a choice and never questions the morality of his decisions. "I am excited for the opportunity to work with WeVidit & World One TV on releasing ISSAC to the world," said Director, Screenwriter and Producer, Josh Webber
World One TV is currently streaming on Roku, Google Play (Android) Samsung Galaxy Store and Amazon Fire Stick. Plans are also underway to develop a World One TV Apple app, scheduled to be launched the fourth quarter of 2022.
For additional information log onto:
www.worldonetv.com
www.wevidit.com
View original content to download multimedia:
SOURCE World One TV
|
https://www.whsv.com/prnewswire/2022/09/12/world-one-tv-signs-first-look-deal-with-wevidit-media/
| 2022-09-12T12:49:22Z
|
Crowds in Scotland gathered along the route to watch the coffin holding Queen Elizabeth II's body travel to Edinburgh, where it will be on public view before being flown to London on Tuesday.
Copyright 2022 NPR
Crowds in Scotland gathered along the route to watch the coffin holding Queen Elizabeth II's body travel to Edinburgh, where it will be on public view before being flown to London on Tuesday.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/britain-continues-to-mourn-the-death-of-queen-elizabeth-ii
| 2022-09-12T13:18:54Z
|
On Saturday and Sunday, Ukrainian forces reclaimed a wide swath of territory in the northeast in a swift-moving counteroffensive that appeared to catch the Russians by surprise.
Copyright 2022 NPR
On Saturday and Sunday, Ukrainian forces reclaimed a wide swath of territory in the northeast in a swift-moving counteroffensive that appeared to catch the Russians by surprise.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/how-much-did-russias-war-with-ukraine-change-in-a-single-weekend
| 2022-09-12T13:18:58Z
|
Seventy-eight-year-old Angelita Perez is a working senior who truly cares about the men and women of her generation as they walk through the sunset of their lives. She owns and still opts to be an active caregiver at Hillcrest Care, a small assisted living facility she founded in 2014 in El Dorado Hills, Calif.
What looks like a middle-class residence perched on the elevated suburban outskirts of El Dorado — which lies 30 miles to the east of California's capital of Sacramento — is actually a haven for six male seniors, five aged 85-97 and a 52-year-old Navy veteran under hospice care. With most assisted living facilities and nursing homes tending to at least 20 wards, Hillcrest Care is a much smaller operation.
But what it lacks in size, it makes up for in better care and homelier ambience — Perez says that, in such an intimate setting, seniors' needs are more easily monitored and served. Helping frail seniors perform even the most basic chores may be easier said than done, but Perez — who goes by "Lita" to friends and family and "Angel" to a grateful patient's family — mastered the work with a natural ease.
What has endeared her to her patients and their families is the commitment and familial warmth that comes into play in every aspect of caregiving for residents who are mostly in their late 80s and 90s.
"I make sure they feel so fresh and in fine spirits throughout the day," she stressed, "from the moment they wake up till bedtime."
She and her staff perform the work generously — with a human touch that lifts their patients' sense of self-worth — a gentle circling pat on the back, a loving swipe on the cheek, reassuring pressure on the palm and even a soft kiss on the forehead makes the seniors feel as though they never left home.
Everyone is freshened up and garbed in comfy casual wear before taking meals, oftentimes as a group, giving them a chance to engage in a little lively banter every day. Occasionally served are Asian dishes that always excite senior palates numbed by continental tastes.
An important rule of the house is to never engage in a verbal joust with the patients, some of whom are experiencing dementia or sheer memory regression. Perez underscores the importance of keeping the mood on the sunny side, even to the point of flattery. She finds the trick to dealing with patients' mental and emotional swings and quirks essential to enhancing their overall well-being.
She proudly recounts an incident in which a patient was rushed to the hospital in need of urgent care and, feeling overlooked while under observation, loudly complained, "Get me back (to the care home); I'm treated like a king there!"
In the two assisted living facilities she's started since 2012, Perez has attended to dozens of seniors. More than a few times after a resident's death, bereaved family have conveyed to Perez their gratitude for her help in ensuring their loved one could spend their twilight years in grace and dignity.
Perez is well-cut for the calling. Arriving in California in 1987 as a Filipino immigrant with only a high school diploma, she found a job in housekeeping at a hospital in Alameda. While doing her chores, she observed patient care, too, sometimes extending an extra hand when it was needed.
Eventually, she felt like she could offer more for others than making their beds and doing their laundry, so she negotiated with her supervisor to have time to take a course to become a Certified Nursing Aide. Her supervisor responded with a firm work-or-study option. A future supervisor, fortunately, was more sympathetic to her plan for a career change.
After earning her CNA certification, she worked in that capacity for the hospital for the next 19 years, experiencing the many varied aspects of patient care.
By 2012, she'd saved up enough to go out on her own, setting up an assisted living facility in Folsom, some 10 miles east of El Dorado, where Hillcrest Care started business two years later.
She opted to move to El Dorado but eventually shuttered the Folsom location.
Perez's concern for those under her charge is emblematic of a serious challenge facing America's health care industry: caring for the country's rapidly aging population.
Health-care statisticians forecast the United States' Baby Boomerswill have 75 million seniors in the next 20 years. There are currently 40 million Americans aged over 65, including 5.6 million aged over 85; the nation's population of those at least 85 years old is expected to double by 2036.
Currently, only 3% of seniors occupy some 78,000 units between the assisted living facilities and nursing homes in the U.S. An estimated one million units will be needed by 2040. California, where Perez is located, is home to some 5,600 units but is expected to need 127,000 in the next 20 years.
Beyond the physical structures, an equally urgent challenge is the number of trained caregivers, whose ranks were decimated by the COVID-19 pandemic.
All of that raises two pertinent questions: How many like Angelita Perez will the country's nursing educational institutions be able to train to meet the massive need for senior care in the coming years? And will the U.S. reopen its doors to Philippine-trained nurses?
There are anecdotal tales in hospitals worldwide of Filipina nurses being the preferred "marines" assigned to dispense convalescent care in wards for seniors, as well as those with special needs, primarily due to their extraordinary patience and natural social skills to relate with such patients, even under strenuous conditions. As with Perez's life experience, Filipina nurses' outlooks are often shaped by a culture that reveres its elders and an ability to survive with minimal resources.
Such traits, Perez believes, make her stand out as in the field of gerontological care. And at her age, she could be a patient herself, but she's defying expectations — petite and barely under five feet in height, she may look fragile; however, she is agile and sturdy for a woman of her age; she could assist bulkier patients doing strenuous maneuvers all by herself.
Where does that strength emanate?
Perez has the genes of a long life. Her father passed away at 93, far higher than the average Filipino's life expectancy, and her paternal grandfather lived to 104. At 93, her eldest sister in Virginia still regularly mows the lawn and drives long distances without any reliever; an aunt with fairly good cognitive functions just marked her 101st birthday.
Perez and her nine brothers and sisters were also raised in the rural Philippines, where they were steeped in the virtue of contentment.
"We grew up together happy with whatever we had, never craving for the extra stuff our peers were enjoying," she reflected after recalling the times when she and her four sisters would sleep together under a mosquito net on their home's bamboo floor in the living area while her brothers did likewise in a space in the kitchen.
Her father was a carpenter who was only able to get by after finishing an ordered furniture crafted to customized design. Her mother performed a full-time role attending to her family and home. And in observance of a cherished Filipino tradition, the entire family would gather at the end of every day in front of their waiting father and mother to do the "mano" — young Filipinos' gesture of holding their elders' hand and pressing it gently on their forehead. The duty was done without fail every day when the church bells tolled at dusk.
Perez believes that sort of childhood may have fortified her with the kind of physical and mental constitution needed to take on the rigors and routines of caregiving where younger care staff could easily give up.
Asked how long she'll be able to do the arduous tasks that come with the work, she snapped, "As long as I can!"
Copyright 2022 NPR. To see more, visit https://www.npr.org.
|
https://www.wyomingpublicmedia.org/2022-09-12/meet-the-78-year-old-bringing-authentically-filipino-care-to-sacramento-area-seniors
| 2022-09-12T13:18:59Z
|
Operations at Ukraine's Zaporizhzhia nuclear power plant were fully stopped on Sunday as a safety precaution. Russia and Ukraine are accusing each other of shelling the plant.
Copyright 2022 NPR
Operations at Ukraine's Zaporizhzhia nuclear power plant were fully stopped on Sunday as a safety precaution. Russia and Ukraine are accusing each other of shelling the plant.
Copyright 2022 NPR
|
https://www.wyomingpublicmedia.org/2022-09-12/the-last-reactor-at-europes-largest-nuclear-power-plant-has-stopped
| 2022-09-12T13:19:06Z
|
Book: Trump planned to refuse to leave White House after election loss
(CNN) - After losing the 2020 election, former President Donald Trump reportedly told aides he wouldn’t physically leave the White House in efforts to keep incoming President Joe Biden from taking over.
A new book by New York Times reporter Maggie Haberman details new revelations on the final days of Trump’s presidency.
In reporting provided to CNN from the book by Haberman, Trump repeatedly told aides following his election loss that he would refuse to leave the White House.
In Haberman’s book, “Confidence Man: The Making of Donald Trump and the Breaking of America,” she reports that Trump told one aide, “I’m just not going to leave.”
“We’re never leaving. How can you leave when you won an election?” the book claims Trump told another aide.
Trump’s insistence that he would not leave the White House has never been previously reported and shines a new light on the final days of his administration.
Haberman writes of the shift in Trump’s private comments on his election loss.
In the immediate aftermath of the 2020 presidential election, Trump seemed to recognize his loss.
He comforted one advisor, saying, “We did our best,” and reportedly told junior press aides that he thought “we had it.”
At some point, Trump’s mood shifted, and he was heard saying he wouldn’t leave.
He was even overheard asking Republican National Committee Chair Ronna McDaniel, “Why would I leave if they stole it from me?”
Haberman, who is also a CNN contributor, reported Trump quizzed nearly everyone around him on how to stay in power. Among those he reportedly asked was the valet who brought him a Diet Coke when Trump pressed a red button on his Oval Office desk.
Haberman said Trump’s son-in-law and advisor, Jared Kushner, was reluctant to confront him over the election loss.
Kushner encouraged a group of aides to go to the White House and brief Trump. When asked why he was not attending the briefing, Kushner likened it to a deathbed scene, saying, “The priest comes later.”
Haberman’s book comes out Oct. 4.
Copyright 2022 CNN Newsource. All rights reserved.
|
https://www.whsv.com/2022/09/12/book-trump-planned-refuse-leave-white-house-after-election-loss/
| 2022-09-12T13:27:20Z
|
Teacher shortages are real, but not for the reason you heard
BIRMINGHAM, Ala. (AP) — Everywhere, it seems, back-to-school has been shadowed by worries of a teacher shortage.
The U.S. education secretary has called for investment to keep teachers from quitting. A teachers union leader has described it as a five-alarm emergency. News coverage has warned of a crisis in teaching.
In reality, there is little evidence to suggest teacher turnover has increased nationwide or educators are leaving in droves.
Certainly, many schools have struggled to find enough educators. But the challenges are related more to hiring, especially for non-teaching staff positions. Schools flush with federal pandemic relief money are creating new positions and struggling to fill them at a time of low unemployment and stiff competition for workers of all kinds.
Since well before the COVID-19 pandemic, schools have had difficulty recruiting enough teachers in some regions, particularly in parts of the South. Fields like special education and bilingual education also have been critically short on teachers nationwide.
For some districts, shortages have meant children have fewer or less qualified instructors.
In rural Alabama’s Black Belt, there were no certified math teachers last year in Bullock County’s public middle school.
“It really impacts the children because they’re not learning what they need to learn,” said Christopher Blair, the county’s former superintendent. “When you have these uncertified, emergency or inexperienced teachers, students are in classrooms where they’re not going to get the level of rigor and classroom experiences.”
While the nation lacks vacancy data in several states, national pain points are obvious.
For starters, the pandemic kicked off the largest drop in education employment ever. According to the Bureau of Labor Statistics, the number of people employed in public schools dropped from almost 8.1 million in March 2020 to 7.3 million in May. Employment has grown back to 7.7 million since then, but that still leaves schools short around 360,000 positions.
“We’re still trying to dig out of that hole,” said Chad Aldeman, policy director at the Edunomics Lab at Georgetown University.
It’s unknown how many of those positions lost were teaching jobs, or other staff members like bus drivers — support positions that schools are having an especially hard time filling. A RAND survey of school leaders this year found that around three-fourths of school leaders say they are trying to hire more substitutes, 58% are trying to hire more bus drivers and 43% are trying to hire more tutors.
Still, the problems are not as tied to teachers quitting as many have suggested.
Teacher surveys have indicated many considered leaving their jobs. They’re under pressure to keep kids safe from guns, catch them up academically and deal with pandemic challenges with mental health and behavior.
National Education Association union leader Becky Pringle tweeted in April: “The educator shortage is a five-alarm crisis.” But a Brown University study found turnover largely unchanged among states that had data.
Quit rates in education rose slightly this year, but that’s true for the nation as a whole, and teachers remain far more likely to stay in their job than a typical worker.
Hiring has been so difficult largely because of an increase in the number of open positions. Many schools indicated plans to use federal relief money to create new jobs, in some cases looking to hire even more people than they had pre-pandemic. Some neighboring schools are competing for fewer applicants, as enrollment in teacher prep programs colleges has declined.
The Upper Darby School District in Pennsylvania has around 70 positions it is trying to fill, especially bus drivers, lunch aides and substitute teachers. But it cannot find enough applicants. The district has warned families it may have to cancel school or switch to remote learning on days when it lacks subs.
“It’s become a financial competition from district to district to do that, and that’s unfortunate for children in communities who deserve the same opportunities everywhere in the state,” Superintendent Daniel McGarry said.
The number of unfilled vacancies has led some states and school systems to ease credential requirements, in order to expand the pool of applicants. U.S. Education Secretary Miguel Cardona told reporters last week that creative approaches are needed to bring in more teachers, such as retired educators, but schools must not lower standards.
Schools in the South are more likely to struggle with teacher vacancies. A federal survey found an average of 3.4 teaching vacancies per school as of this summer; that number was lowest in the West, with 2.7 vacancies on average, and highest in the South, with 4.2 vacancies.
In Birmingham, the school district is struggling to fill around 50 teaching spots, including 15 in special education, despite $10,000 signing bonuses for special ed teachers. Jenikka Oglesby, a human resources officer for the district, says the problem owes in part to low salaries in the South that don’t always offset a lower cost of living.
The school system in Moss Point, a small town near the Gulf Coast of Mississippi, has increased wages to entice more applicants. But other districts nearby have done the same. Some teachers realized they could make $30,000 more by working 30 minutes away in Mobile, Alabama.
“I personally lost some really good teachers to Mobile County Schools,” said Tenesha Batiste, human resources director for the Moss Point district. And she also lost some not-so-great teachers, she added — people who broke their contracts and quit three days before the school year started.
“It’s the job that makes all others possible, yet they get paid once a month, and they can go to Chick-fil-A in some places and make more money,” Batiste said.
A bright spot for Moss Point this year is four student teachers from the University of Southern Mississippi. They will spend the school year working with children as part of a residency program for aspiring educators. The state has invested almost $10 million of federal relief money into residency programs, with the hope the residents will stay and become teachers in their assigned districts.
Michelle Dallas, a teacher resident in a Moss Point first-grade classroom, recently switched from a career in mental health and is confident she is meant to be a teacher.
“That’s why I’m here,” she said, “to fulfill my calling.”
___
This story is part of an Associated Press collaboration with AL.com, The Christian Science Monitor, The Dallas Morning News, The Fresno Bee in California, The Hechinger Report, The Seattle Times and The Post and Courier in Charleston, South Carolina.
___
Associated Press writers Brooke Schultz in Harrisburg, Pa., Collin Binkley in Washington, D.C., and Carolyn Thompson in Buffalo, N.Y. contributed to this report. Lurye reported from New Orleans. Schultz is a corps member for the Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.
___
The Associated Press education team receives support from the Carnegie Corporation of New York. The AP is solely responsible for all content.
___
For more back-to-school coverage, visit: https://apnews.com/hub/back-to-school
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/teacher-shortages-are-real-not-reason-you-heard/
| 2022-09-12T13:27:31Z
|
Along Fabrication Street, industrial buildings are adorned in vibrant artwork, which spills out into alleyways and nearby streets.
For more than 10 years, the Fabrication Yard has been open to artists of all levels, providing a free space to practice their craft.
Ed Martinez, known to many as “Eder,” is one of the earliest painters in the space. He’s from New York, but he’s lived in Dallas for nearly two decades.
“We didn't have anything like this when I was younger,” Martinez said. “So in all honesty, I was trying to be somebody that I needed when I was young.”
Graffiti is often done in the shadows and can be a high-risk art form with a lack of legal spaces to practice. Martinez says this space takes those risk factors away.
He says this space helps dispel the stigma around graffiti and those who practice it.
“You can come here and you can practice your craft…," Martinez said. "You've got so many problems going on, and the last thing you need is some charges from some spilled paint.”
Still, new development in the area has Martinez concerned about the future of the Fabrication Yard.
“We've had a lot of gentrification going on in the neighborhood," he said. "So it's time to get back talking to the city again about letting us find another spot... with an area that isn't getting fixed up or something that we can have longer than ten years."
Butch McGregor owns the Fabrication Yard property. He understands the meaning it holds for local artists.
"We're hoping that we can keep it around 10, 15 years," McGregor said. "I think it's awesome that the artists can come out and paint. If something does happen to it, we'll find a new spot and help them find a new spot."
McGregor has spearheaded the development of new studio spaces at the Fabrication Yard to give local artists a place to work.
Artist Josh Snodgrass is one of the newest tenants.
During the pandemic, he used the Fabrication Yard as a socially distant escape.
“ I can come out here... during COVID, not have to talk to anybody, not be close to anybody," Snodgrass said. "And I could do something outside, a little bit public facing."
Snodgrass and Ed Martinez both imagine a thriving future for the Fabrication Yard.
Martinez says graffiti will remain in Dallas, so why not give it a permanent home?
"I just try to help them understand that you're not taking graffiti art anywhere off the planet," Martinez said. "If anything, it's going to get bigger and better if they allow for it."
Got a tip? Email Solomon Wilson at swilson@kera.org. You can follow Solomon on Twitter @SolomonSeesIt.
KERA News is made possible through the generosity of our members. If you find this reporting valuable, consider making a tax-deductible gift today. Thank you.
|
https://www.keranews.org/arts-culture/2022-09-12/dallas-fabrication-yard-offers-a-haven-for-artists-but-could-new-development-change-that
| 2022-09-12T13:40:37Z
|
In a nod to JFK, Biden pushing ‘moonshot’ to fight cancer
WASHINGTON (AP) — President Joe Biden is set to channel John F. Kennedy on the 60th anniversary of JFK’s moonshot speech, highlighting Biden administration efforts aimed at “ending cancer as we know it.”
The president was traveling to Boston on Monday to draw attention to a new federally backed study that seeks to validate using blood tests to screen against multiple cancers — a potential game-changer in diagnostic testing to dramatically improve early detection of cancers. He also planned other announcements meant to better the lives of those suffering from cancer.
His speech at the John F. Kennedy Presidential Library and Museum comes as Biden seeks to rally the nation around developing treatments and therapeutics for the pervasive diseases that the Centers for Disease Control and Prevention rank as the second-highest killer of people in the U.S. after heart disease. Biden hopes to move the U.S. closer to the goal he set in February of cutting U.S. cancer fatalities by 50% over the next 25 years and to dramatically improve the lives of caregivers and those suffering from cancer.
Danielle Carnival, the White House cancer moonshot coordinator, told The Associated Press that the administration sees huge potential in the commencement of the blood diagnostic study on identifying and treating cancers.
“One of the most promising technologies has been the development of blood tests that offer the promise of detecting multiple cancers in a single blood test and really imagining the impact that could have on our ability to detect cancer early and in a more equitable way,” Carnival said. “We think the best way to get us to the place where those are realized is to really test out the technologies we have today and see what works and what really has an impact on extending lives.”
In 2022, the American Cancer Society estimates, 1.9 million new cancer cases will be diagnosed and 609,360 people will die of cancer diseases.
The issue is personal to Biden, who lost his adult son Beau in 2015 to brain cancer. After Beau’s death, Congress passed the 21st Century Cures Act, which dedicated $1.8 billion over seven years for cancer research and was signed into law in 2016 by President Barack Obama.
Obama designated Biden, then vice president, to run “mission control” on directing the cancer funds as a recognition of Biden’s grief as a parent and desire to do something about it. Biden wrote in his memoir “Promise Me, Dad” that he chose not to run for president in 2016 primarily because of Beau’s death.
Despite Biden’s attempts to hark back to Kennedy and his space program, the current initiative lacks that same level of budgetary support. The Apollo program garnered massive public investment — more than $20 billion, or more than $220 billion in 2022 dollars adjusted for inflation. Biden’s “moonshot” effort is far more modest and reliant on private sector investment.
Still, Biden has tried to maintain momentum for investments in public health research, including championing the Advanced Research Projects Agency for Health, modeled after similar research and development initiatives benefiting the Pentagon and intelligence community.
On Monday, Biden will announce Dr. Renee Wegrzyn as the inaugural director of ARPA-H, which has been given the task of studying treatments and potential cures for cancers, Alzheimer’s, diabetes and other diseases. He will also announce a new National Cancer Institute scholars’ program to provide resources to early-career scientists studying treatments and cures for cancer.
In Boston, Biden will also attend an event at Logan International Airport to highlight investments from the 2021 bipartisan infrastructure law as well as a fundraiser for the Democratic National Committee.
Experts agree it’s far too early to say whether these new blood tests for finding cancer in healthy people will have any effect on cancer deaths. There have been no studies to show they reduce the risk of dying from cancer. Still, they say setting an ambitious goal is important.
Carnival said the National Cancer Institute Study was designed so that any promising diagnostic results could be swiftly put into widespread practice while the longer-term study — expected to last up to a decade — progresses. She said the goal was to move closer to a future where cancers could be detected through routine bloodwork, potentially reducing the need for more invasive and burdensome procedures like colonoscopies, and therefore saving lives.
Scientists now understand that cancer is not a single disease, but hundreds of diseases that respond differently to different treatments. Some cancers have biomarkers that can be targeted by existing drugs that will slow a tumor’s growth. Many more targets await discovery.
“How do we learn what therapies are effective in which subtypes of disease? That to me is oceanic,” said Donald A. Berry, a biostatistician at the University of Texas M.D. Anderson Cancer Center. “The possibilities are enormous. The challenges are enormous.”
Despite the challenges, he’s optimistic about cutting the cancer death rate in half over the next 25 years.
“We can get to that 50% goal by slowing the disease sufficiently across the various cancers without curing anybody,” Berry said. “If I were to bet on whether we will achieve this 50% reduction, I would bet yes.”
Even without new breakthroughs, progress can be made by making care more equitable, said Dr. Crystal Denlinger, chief scientific officer for the National Comprehensive Cancer Network, a group of elite cancer centers.
And any effort to reduce the cancer death rate will need to focus on the biggest cancer killer, which is lung cancer. Mostly attributable to smoking, lung cancer now causes more cancer deaths than any other cancer. Of the 1,670 daily cancer deaths in the United States, more than 350 are from lung cancer.
Lung cancer screening is helping. The American Cancer Society says such screening helped drive down the cancer death rate 32% from its peak in 1991 to 2019, the most recent year for which numbers are available.
But only 5% of eligible patients are being screened for lung cancer.
“It’s tragic,” said Dr. Roy Herbst, a lung specialist at Yale Cancer Center.
“The moonshot is going to have to be a social fix as well as a scientific and medical fix,” Herbst said. “We’re going to have to find a way that screening becomes easier, that it’s fully covered, that we have more screening facilities.”
Biden planned to urge Americans who might have delayed cancer screenings during the pandemic to seek them out swiftly, reminding them that early detection can be key to avoiding adverse outcomes.
He was also set to highlight provisions in the Democrats’ healthcare and climate change bill that the administration believes will lower out of pocket drug prices for some widely used cancer treatments. He will also celebrate new guarantees for veterans exposed to toxic burn pits, that cover their potential cancer diagnoses.
Dr. Michael Hassett of Dana-Farber Cancer Institute in Boston, said Biden’s goal to reduce cancer deaths could met by following two parallel paths: one of discovery and the other making sure as many people as possible are reaping the advantages of existing therapies and preventive approaches.
“If we can address both aspects, both challenges, major advances are possible,” Hassett said.
In breast cancer, for example, many women who could benefit from a hormone-blocking pill either never start the therapy or stop taking it before the recommended five years, Hassett’s research has found.
“Those are big gaps,” Hassett said. “That’s a treatment that’s effective. But if many people aren’t taking that medication or if they’re taking it but stopping it before concluding the course of therapy, then the benefits that the medicine could offer aren’t realized.”
___
Johnson reported from Seattle.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/nod-jfk-biden-pushing-moonshot-fight-cancer/
| 2022-09-12T14:10:51Z
|
Police believe 3 children drowned by mother at NYC beach
NEW YORK (AP) — Three children died after being found on a New York City beach early Monday and police believe they may have been drowned by their mother.
The 7-year-old boy, a 4-year-old girl and a 3-month-old girl were found on Brooklyn’s Coney Island beach shortly after 4:30 a.m. and taken to a nearby hospital, Chief of Department Kenneth Corey said. All three were pronounced dead there.
The children’s 30-year-old mother had been picked up earlier about 2 miles (3.2 kilometers) away, Corey said. She was being questioned at the local stationhouse.
Police first got a call at about 1:40 a.m. from a concerned relative of the mother who “indicated she was concerned that her family member may have harmed her three small children,” Corey said at a news conference near where the children were found.
Officers went to the woman’s apartment building in the Coney Island neighborhood, where a man identified as the father of one of the children said he was similarly concerned.
Officers canvassed the area and found the woman about 90 minutes later, barefoot and soaking wet. She was still being questioned by detectives later Monday morning. “So far, she’s not said anything,” Corey said.
The search intensified and police located the three children on the beach. Efforts to revive them failed, Corey said.
Copyright 2022 The Associated Press. All rights reserved.
|
https://www.whsv.com/2022/09/12/police-believe-3-children-drowned-by-mother-nyc-beach/
| 2022-09-12T14:10:55Z
|
Several vehicles burn outside Miami stadium
Published: Sep. 12, 2022 at 9:21 AM EDT|Updated: 48 minutes ago
MIAMI (WPLG) - Sunday at around 1:28 p.m., more than 10 Miami-Dade Fire Rescue units responded to a fire at a remote parking lot outside the Hard Rock Stadium, officials said.
Fire crews arrived to find multiple vehicles on fire that were parked at the remote parking lot during the Miami Dolphins season-opening game against the New England Patriots.
Firefighters immediately worked to contain and place the fire under control.
There were no reported injuries.
Copyright 2022 CNN Newsource. All rights reserved.
|
https://www.whsv.com/2022/09/12/several-vehicles-burn-outside-miami-stadium/
| 2022-09-12T14:11:01Z
|
Process Improvements Standardize Longstanding AAA Practices, and Revise Rules to Generate Further Efficiencies and Reflect Advances in Technology
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- The American Arbitration Association-International Centre for Dispute Resolution® (AAA-ICDR®) announces that significant amendments have been made to the AAA Commercial Arbitration Rules and Mediation Procedures.
The updates to the arbitration rules, effective September 1, 2022, focus on process improvements in key areas, including technology, speed, economy, security, and privacy. The amended rules are the result of a two-year initiative by an internal AAA working group, with contributions from the AAA's case management and administrative groups, party surveys, and arbitrators, as well as the AAA-ICDR Council's Law and Practice and LLC Committees.
"The goals of our commercial arbitration rules—to ensure parties achieve a resolution to their disputes through an orderly, economical, and expeditious process—are the same as when these rules were first drafted 72 years ago," said Robert Matlin, Esq., Senior Vice President of the AAA's Commercial and Construction Divisions. "Our amended rules address the technology advancements which can make the arbitration process more streamlined and cost-effective—and standardize them, to continue to ensure the integrity, security, and confidentiality of our procedures."
The 2022 amendments to the AAA Commercial Arbitration Rules and Mediation Procedures ("the Rules") involve:
- Consolidation—The AAA has instituted its first-ever commercial rule to consolidate existing arbitrations or the joinder of additional parties.
- Confidentiality—The reinforcement of the longstanding requirements in the AAA Code of Ethics for Arbitrators, by including a commitment by AAA Staff and arbitrators to the confidentiality of arbitration in the Commercial Arbitration Rules.
- Conduct of Parties & Their Representatives—The AAA's expectations of civility and professionalism of all participants in arbitrations have been specifically incorporated into the Rules.
- Providing Arbitrators with the Authority to Interpret Awards—The AAA has drawn on the recently adopted ICDR article allowing the arbitrator to explain the award on a party's motion.
- Importance of Cybersecurity, Privacy & Data Protection—Reflecting the importance the AAA places on the safety and security of user and case information, the Rules recommend that the parties and the arbitrator discuss data protection during the preliminary hearing.
To read a more detailed explanation of the 2022 amendments to the AAA Commercial Arbitration Rules and Mediation Procedures, click here.
The not-for-profit American Arbitration Association® (AAA) is the leading provider of alternative dispute resolution (ADR) services for parties in commercial disputes, having administered more than seven million ADR cases since its founding in 1926. With 29 offices in the United States, in addition to Singapore, the AAA provides organizations of all sizes in virtually every industry with ADR services and products. For more information, visit www.adr.org.
The International Centre for Dispute Resolution® (ICDR®) is the international division of the American Arbitration Association (AAA) and the largest international provider of dispute resolution services. Established in 1996, the ICDR serves parties from over 100 countries with multilingual staff experienced in international dispute resolution proceedings, and a roster of over 725 arbitrators and mediators. For more information, visit www.icdr.org.
View original content to download multimedia:
SOURCE American Arbitration Association-International Centre for Dispute Resolution
|
https://www.whsv.com/prnewswire/2022/09/12/aaa-updates-commercial-arbitration-rules-amp-mediation-procedures-uphold-aaa-standards/
| 2022-09-12T14:11:02Z
|
HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors.
Arteriovenous malformations (AVMs) occur when capillaries, veins, and arteries don't develop properly and may lead to cutaneous discoloration, sensitivity, pain, and vascular bleeding. Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition.
Hypervascular tumors occur in both benign and malignant states and are characterized by blood supply from an abnormally large number of blood vessels. Microspheres embolization reduces or eliminates the blood flow to these tumors and is an effective interventional radiology therapy for treating this disease state.
Aravind Arepally, MD, FSIR, and Chief Medical Officer of ABK Biomedical said "The evolution of embolic therapies to treat these complex disease states has been notable in recent years. Now, with Easi-Vue embolic microspheres, interventional radiologists have a highly calibrated, see-and-do technology capable of visually targeted placement using conventional x-ray and fluoroscopy systems. This microspheres technology and proprietary controlled-concentration delivery system have the potential to improve patient outcomes."
"We are excited to achieve FDA 510(k) clearance for this new technology that has the potential to advance the field of embolic therapies", said Gary Donofrio, Chief Business Officer of ABK Biomedical. "This represents a major milestone for ABK as our team continues to execute our product development objectives. We will partner with key physicians to understand the range of clinical utilization and optimization of Easi-Vue therapy. Additionally, ABK continues to significantly advance the development program of our Eye90 microspheres® radio-embolic technology that's being investigated for the treatment of patients with unresectable Hepatic Cellular Carcinoma (HCC). Easi-Vue embolic microspheres share core technologies and design characteristics with Eye90 microspheres. Both devices continue to add to our knowledge base regarding the clinical experience of the first glass radiopaque embolic microspheres therapy."
ABK Biomedical is a clinical-stage development company focused on researching, developing, and commercializing medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. ABK Biomedical holds intellectual property in the areas of inorganic polymer microspheres and unique administration systems. The company possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing unique embolotherapy products. Eye90 microspheres are considered investigational products and are NOT approved for use in any regulatory jurisdiction outside of approved clinical trials.
View original content to download multimedia:
SOURCE ABK Biomedical Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/abk-biomedical-announces-fda-510k-clearance-easi-vue-embolic-microspheres-embolization-arteriovenous-malformations-hypervascular-tumors/
| 2022-09-12T14:11:03Z
|
The Lacy Chabert Collection reimagines loungewear and includes special 'Mommy & Me' matching garments
ST. PETERSBURG, Fla., Sept. 12, 2022 /PRNewswire/ -- HSN®, a leader in livestream shopping and video storytelling, today announced the exclusive launch of The Lacey Chabert Collection, the first-ever apparel line from actress, entrepreneur and mother Lacey Chabert. Inspired by precious moments shared with family, The Lacey Chabert Collection reimagines loungewear and includes special "Mommy & Me" matching garments. The collection is available exclusively on HSN.com. HSN is part of Qurate Retail, Inc. (NASDAQ: QRTEA, QRTEB, QRTEP).
Chabert collaborated with HSN to create this appealing cozy apparel line, which features soft colors and hand-selected prints and design elements, such as whimsical florals, hearts, stars, rose gold rivets, zippers and ties woven throughout.
"Here at HSN, we've been long-time fans of Lacey Chabert, so we jumped at the opportunity to work with her on this collection," said Bridget Love, GMM & VP Merchandising, HSN. "While Lacey draws inspiration from her many memorable roles on stage and screen, her new line mainly reflects her role as a mom. The Lacey Chabert Collection brings the love Lacey shares with her family to the forefront through imaginative patterns, luxe comfort and thoughtful designs which truly differentiate her collection from anything else in our portfolio."
In addition to "Mommy & Me" dresses, long sleeve pullovers and a hooded jacked, the new collection includes a lounge jumpsuit, weekender legging and Henley sleep set — with all pieces retailing for under $100 each. With chillier months upon us, Chabert will add family jammies to the collection in October and a fresh assortment of luxe separates and a cozy loungewear set in November.
While well known for her roles on "Party of Five," "Mean Girls," and the Hallmark Channel, Chabert is first and foremost a working mom. Chabert said her desire to create The Lacey Chabert Collection was sparked by the birth of her daughter, Julia: "This new venture expresses what I love most— the time I spend with my family. I hope my collection inspires others to celebrate the precious time they share with their loved ones, too."
Lacey will appear live on HSN and across their streaming platforms on Thursday, September 15 and Friday, September 16 to introduce viewers to The Lacey Chabert Collection. To learn more and shop The Lacey Chabert Collection, visit www.hsn.com .
HSN takes shoppers on a journey – embracing the new, exploring untrodden paths, and bringing shoppers a unique perspective that enriches their lives. HSN offers a curated assortment of exclusive products and top brand names in health and beauty, jewelry, home/lifestyle, fashion/accessories, and electronics and incorporates entertainment, personalities and industry experts to provide a unique shopping experience. HSN engages millions of customers across the U.S. via two TV channels, which are widely available on cable/satellite TV, free over-the-air TV, and digital livestreaming TV. The retailer also reaches millions of customers via the QVC+ and HSN+ streaming experience, a website and mobile app, and social pages. HSN was founded 45 years ago as the first shopping network and is based in St. Petersburg, Fla. To learn more, visit corporate.hsn.com, follow @HSN on Facebook, Instagram or Twitter, or follow HSN on Pinterest, YouTube or LinkedIn.
Qurate Retail, Inc. (NASDAQ: QRTEA, QRTEB, QRTEP) is a Fortune 500 company that includes QVC®, HSN, Zulily® and the Cornerstone brands (collectively, "Qurate Retail GroupSM"), as well as other minority interests and green energy investments. Qurate Retail Group is dedicated to providing a more human way to shop. Qurate Retail Group is the largest player in video commerce ("vCommerce"), which includes video-driven shopping across linear TV, ecommerce sites, digital streaming and social platforms. For more information, visit www.qurateretailgroup.com, follow @QurateRetailGrp on Facebook, Instagram or Twitter, or follow Qurate Retail Group on YouTube or LinkedIn.
View original content to download multimedia:
SOURCE HSN
|
https://www.whsv.com/prnewswire/2022/09/12/actress-entrepreneur-lacey-chabert-launches-first-ever-apparel-collection-exclusively-with-hsn/
| 2022-09-12T14:11:11Z
|
ATG's philanthropic program to reach over 30,000 meals donated to its local communities
SHREWSBURY, Mass., Sept. 12, 2022 /PRNewswire/ -- Advantage Truck Group (ATG) marks the 10-year anniversary of Haulin' 4 Hunger, the company's signature food donation program that helps provide meals to people facing hunger in communities near ATG locations throughout New England.
Founded in 2012 with a single donation of 200 holiday meals near ATG headquarters in Shrewsbury, Massachusetts, over the past decade ATG has expanded the program to food pantry organizations in more communities and increased its impact with quarterly donations of non-perishable food to help meet ongoing need.
In celebration of its commitment to its local communities, this year ATG is increasing donations to provide thousands of non-perishable foods each quarter to hunger-relief organizations near ATG locations and over 4,000 fresh meals this holiday season to food pantry organizations in Central Massachusetts.
Now in its tenth year, Haulin' 4 Hunger will reach over 30,000 meals donated to community food pantry organizations across three states.
"As we mark the 10-year anniversary of Haulin' 4 Hunger, our commitment to reducing food insecurity in our communities remains more important than ever. We are grateful for the continued support that our employees, customers and business partners have for this program," said Kevin G. Holmes, President and CEO of ATG.
These milestones are the result of efforts of ATG employees and its Haulin' 4 Hunger team, who dedicate countless hours to purchase, collect, sort, package and deliver food for those in need.
This quarter, ATG will hold events at each of its locations to celebrate Haulin' 4 Hunger and recognize the contributions and dedication of its employees.
At a time when food prices are rising alongside inflation, every donation is making a difference to local pantries and the people they serve. With support from employees and business partners, including Dennis K. Burke, G. Lopes Construction, SelecTrucks of New England, Worcester Railers Hockey Club and UniBank, Haulin' 4 Hunger is helping bring food to the people who need it most.
Learn more about Haulin' 4 Hunger and visit ATG on Twitter, Facebook and Instagram
ATG is the largest DTNA dealer in New England, offering truck sales, service and parts from locations in Raynham, Shrewsbury and Westfield, Massachusetts; Lancaster, Lebanon, Manchester and Seabrook, New Hampshire; and Westminster, Vermont.
View original content to download multimedia:
SOURCE Advantage Truck Group
|
https://www.whsv.com/prnewswire/2022/09/12/advantage-truck-group-celebrates-10-year-anniversary-haulin-4-hunger-strengthens-commitment-fighting-hunger-across-new-england/
| 2022-09-12T14:11:18Z
|
The donation will be instrumental in helping Nature Seekers protect the ancient, endangered leatherback turtles nesting in Trinidad
MATURA, Trinidad and Tobago and MONTREAL, Sept. 12, 2022 /PRNewswire/ - Age of Union Alliance, led by tech leader and environmental activist Dax Dasilva, is proud to announce a USD $1.5 million donation to Nature Seekers, a non-profit community-based organization in the village of Matura, on the east coast of Trinidad, with a focus on the conservation and protection of sea turtles. This will be the single largest private donation in Nature Seekers' history. Age of Union's support will be instrumental in the protection of endangered leatherback turtles whose nesting grounds on Matura Beach are in more danger than ever before due to climate change and pollution.
Matura Beach is one of the last remaining major turtle nesting sites in the world for leatherback turtles, which have existed for over 100 million years, dating back to the age of dinosaurs. These massive creatures, as long as 2.2 metres, are the largest sea turtle species in the world and also one of the most migratory, crossing the Atlantic Ocean. New GPS technology has allowed scientists to track their journeys, and many have migrated to Canada's Atlantic coasts in recent years where they feed on the abundant jellyfish every summer and fall.
The population of these turtles has declined drastically in the last century as a result of intense egg collection, poaching, fishery bycatch, habitat loss, climate change, and much more. They are listed as Vulnerable on International Union for Conservation of Nature's red list of Threatened Species. Nature Seekers, who have been working to conserve these turtles for over 30 years, were in desperate need of help after beach closures during the pandemic nearly eradicated their historical revenue sources.
- Patrol and protect the nesting site throughout the annual season to maintain or increase the survival rates of both adult and hatchling leatherback turtles. New drone technology will now extend their capabilities.
- Collect data during nesting season to better understand the physical health of the nesting population and monitor inter-nesting movement and migration of satellite-tagged turtles. This work is done in partnership with Dr. Michael James of Fisheries and Oceans Canada and the Canadian Sea Turtle Network.
- Collect data and assess the potential impacts of climate change on the turtle population at the Matura nesting site; create climate adaptation and/or mitigation plans.
- Design and deploy artificial hatcheries to promote the survival of at-risk nests and allow for the collection of new data sets.
- Increase community engagement and provide opportunities for sustainable livelihood activities that align with conservation goals, such as becoming a ranger to patrol the beach during nesting season.
This marks the ninth conservation project Age of Union has announced in less than one year following Dax Dasilva's initial pledge of $40 million. Today's announcement also aligns with Age of Union's global premiere of its short documentary film CAUGHT in Toronto on the evening of September 12. In partnership with Sea Shepherd, this film reveals the shocking consequences of industrial fishing and excess consumerism, depleting oceanic ecosystems, with a specific lens on dolphin bycatch off the coast of France.
"When I first met Suzan Baptiste, Managing Director at Nature Seekers, I was incredibly inspired by her determination and perseverance to help shift this coastal community in Trinidad from turtle poaching to turtle conservation. We hope with Age of Union's help, Nature Seekers will now be better equipped to protect these beautiful, endangered turtles who, through their incredible migration journeys, also have connections to Canada." - Dax Dasilva, Founder of Age of Union.
"We couldn't be more thankful for this generous gift from Age of Union. Leatherback turtles are recognized as a keystone species, and their demise could have global consequences on our oceans and their ecosystems. Now, with the help of Age of Union, these turtles have an amazing chance for survival." - Suzan Baptiste, Managing Director of Nature Seekers
"The Ministry of Agriculture, Land and Fisheries looks forward to continued conversations with both the High Commission of Canada and Mr. Dasilva to improve the sector and by extension Trinidad and Tobago." - Kazim Hosein, Honourable Minister of Agriculture, Land and Fisheries
"The Government and people of Trinidad and Tobago sincerely appreciate the support from Age of Union for their conservation initiatives in the country. We commit to working with Dax Dasilva and his team, exploring opportunities for broader collaboration in the environmental and technology sectors and beyond." - Senator Dr. Amery Browne, Minister of Foreign and CARICOM Affairs of Trinidad and Tobago
"Age of Union's conservation project for leatherback turtles is an excellent example of Canada Trinbagonian cooperation on environmental conservation." - Kumar Gupta, High Commissioner of Canada to Trinidad and Tobago
Age of Union is a non-profit environmental alliance that supports and makes visible a global community of changemakers working on the ground to protect the planet's threatened species and ecosystems. Launched in October 2021 by tech leader and environmental activist Dax Dasilva in Montreal, Canada with an initial $40 million pledge, Age of Union seeks to ignite a flame within every person through conservation efforts that solve critical environmental challenges around the world and inspire high-impact change by showing the positive impact that every individual can make.
For more information, please visit: AgeofUnion.com
On social media: Facebook, Instagram, YouTube, and Twitter
Nature Seekers is a non-profit community-based organization founded in 1990 and situated in the village of Matura, on the east coast of Trinidad in the south Caribbean. Its primary focus is the conservation and protection of the sea turtles that nest in the region, including the Leatherback turtle. Over a 30+ year period, Nature Seekers helped to shift this coastal community from turtle poaching to turtle conservation.
Press Contacts:
North America:
Victoria Baker
Victoriab@nkpr.net
+1-416-726-8002
Mishel Chavoulki
Mishel@nkpr.net
+1-416-559-7338
South America
Anna Lucie-Smith
anna@swfandco.com
+1-868-381-5050
View original content to download multimedia:
SOURCE Age of Union Alliance
|
https://www.whsv.com/prnewswire/2022/09/12/age-union-alliance-donates-15-million-nature-seekers-over-five-years/
| 2022-09-12T14:11:25Z
|
New frameworks, including NIST CSF, ISO/IEC 27002:2022, and GDPR, empower Compliance teams to leverage data and automation to expand security and privacy programs
TEL AVIV, Israel and PALO ALTO, Calif., Sept. 12, 2022 /PRNewswire/ -- Today, anecdotes, the first operating system (OS) for Compliance, announced they will be adding ten frameworks to their offering. The new release will empower users to further expand their security Compliance programs and gain greater visibility into their security and privacy posture.
As companies work towards building and strengthening trust with customers and partners, they look for ways to mature their Compliance posture. By adopting additional Compliance and privacy frameworks, they can improve their posture while clearly displaying that commitment to the world. Following the release of additional frameworks, Compliance leaders will be able to use the anecdotes Compliance OS's unique cross-mapping capabilities to expand their Compliance program. This will enable organizations to automatically apply their existing Compliance milestones to the new frameworks they wish to adopt.
"anecdotes is committed to empowering Compliance leaders", says Roi Amior, Co-Founder and CPO at anecdotes. "The data collected from our 100+ integrations, coupled with a growing list of frameworks, allows our users to expand their robust Security Compliance programs and provide great value to the organization."
Among the new frameworks announced are three privacy frameworks and regulations, including GDPR (SCF EGCC and CSA Code of Conduct for GDPR Compliance) and ISO/IEC 27701:2019. "Since GDPR and other regulations have come into effect, meeting privacy requirements has become a crucial aspect of a company's ability to grow", continues Amior. "This is why it's no surprise that privacy has become an integral part of the Compliance leader's role in growing companies. We are proud to provide them with the tools they need to meet common privacy frameworks and regulations."
The complete list of new frameworks includes ISO/IEC 27701:2019, ISO/IEC 27002:2022, GDPR (via SCF EGCC and CSA Code of Conduct), CSA Star CCM v4, CIS v8, NIST CSF, NIST 800-171, and PCI Self Assessment (via SAQ A & SAQ A-EP).
About anecdotes
Everything Compliance, all in one place. anecdotes is the first operating system (OS) for every stage of a business's Compliance journey. It reshapes the way the cloud-powered world thinks about security Compliance, transforming it from a box-ticking exercise into a powerful driver of growth for scale-ups, publicly traded companies, and everything in between. With a variety of applications powered by verified data, Compliance leaders can turn manual, time-consuming, and siloed tasks into an automated, continuous, and strategic Compliance journey. That's why some of the world's fastest growing brands - Unity, Fiverr, SimilarWeb, TripActions, and more - use anecdotes.
anecdotes has headquarters in Palo Alto, California, with R&D offices in Tel Aviv, Israel. For more information, visit anecdotes.ai.
View original content:
SOURCE anecdotes
|
https://www.whsv.com/prnewswire/2022/09/12/anecdotes-adds-10-new-frameworks-its-robust-offering/
| 2022-09-12T14:11:31Z
|
Cancer diagnostics from digital cytology and advanced imaging to new molecular tests, help veterinarians combat leading cause of canine death
FOUNTAIN VALLEY, Calif., Sept. 12, 2022 /PRNewswire/ -- Antech Diagnostics is advancing its leadership in canine cancer diagnostics to support early detection and personalized care pathways for dogs with cancer. Reflecting an ongoing commitment to molecular diagnostics, Antech's cancer diagnostic portfolio now includes Vidium Animal Health's SearchLight DNA® and OncoK9® from PetDx®. These new tests reflect Antech's commitment to building veterinary medicine's most advanced and extensive portfolio of canine cancer diagnostics that span multiple, essential diagnostic modalities, including ultrasound, digital cytology, and molecular medicine.
The American Veterinary Medical Association (AVMA) reports that nearly 50% of dogs will develop cancer in advanced age. Molecular diagnostics play a uniquely valuable role supporting detection and treatment of cancer in dogs. These advanced diagnostic tests' ability to analyze the DNA of tumor cells delivers specific information about which mutations are causing cancer to grow and spread and are adept at helping veterinarians identify cancer often when it's most treatable. Molecular diagnostics also help veterinarians understand the cancer's origin and behavior, which can guide the optimal approach to treatment. Their addition to Antech's cancer diagnostic portfolio allows a new level of personalized, precision therapy, which can support overall improved care and potentially better outcomes for dogs.
"A cancer diagnosis can be devastating for a pet owner," said Dr. Sue Ettinger, DVM, DACVIM (Oncology). "Accurate diagnosis and care can be expensive and complex. Reading the genomic material of a tumor, molecular diagnostics give us an unprecedented level of transparency into the nature of the cancer, allowing us to diagnose it earlier and to craft a highly personalized treatment plan."
Antech offers veterinary medicine's most comprehensive canine cancer diagnostic portfolio, beginning with Sound, which has a long history of providing best-in-class digital X-ray, ultrasound, laser therapy, mobile CT, imaging support, and PACS. As leaders in cancer pathology, Antech's Digital Cytology Scanner connects veterinarians at the point of care with a diverse, highly accomplished team of board-certified pathologists, significantly accelerating the speed at which veterinarians can deliver effective treatment to pets. Antech's use of molecular diagnostics began with CADET® BRAF, the first liquid biopsy for detection of the most common canine bladder and prostate cancer, canine transitional cell carcinoma (TCC), also called urothelial carcinoma (UC). Veterinarians have relied on Antech for this advanced DNA-based test since 2019, using it as a simple, non-invasive way to detect the presence of a single mutation present in 85% of confirmed cases of TCC/UC.
"Cancer has been and continues to be a frustrating disease for pet owners and veterinarians to diagnose and treat," said Cathleen Meeks, MS, DVM, DACVIM, Vice President of Medical Operations at Antech. "Antech is dedicated to the continued advancement of our diagnostic capabilities in oncology to help provide innovative ways in which we diagnose this disease compared to traditional methods. This will allow us to improve the quality of care by diagnosing these diseases sooner than in the past and avoid delays in initiating treatment."
Antech's expanded molecular diagnostic portfolio now includes:
SearchLight DNA™: a genomic test that analyzes the DNA of a dog's tumor cells, searching for mutations across 120 relevant cancer genes, to identify mutations that aid in the diagnosis and prognosis of cancer and helps guide treatment decisions.
OncoK9®: a blood-based "liquid biopsy" multi-cancer early detection (MCED) test that aids veterinarians in detecting 30 different cancer types, including 8 of the most common cancers in dogs. OncoK9® has been clinically validated through the CANDiD (CANcer Detection in Dogs) Study using samples prospectively collected from over 1,000 client-owned dogs across more than 40 clinical sites.
"Cancer has claimed the lives of too many beloved dogs, too soon, and for too long," said Lonnie Shoff, President of Antech. "I believe we're at the precipice of a new era in canine cancer care; one that offers new hope for veterinarians and pet owners alike. That's why we're extending our portfolio of canine cancer diagnostics. From molecular diagnostics to pathology expertise to being veterinary medicine's most trusted provider of digital X-ray, ultrasound, laser therapy, mobile CT, imaging support, and PACS, we'll continue to deliver the most advanced diagnostic tools for veterinarians to effectively combat this terrible disease. Offering the latest molecular diagnostics for cancer detection and personalized treatment is simply the right thing to do. We'll continue to leave no stone unturned as we strive to help veterinary teams attack this leading cause of canine death."
Antech is now an authorized reseller of Vidium Animal Health's SearchLight DNA™ and the OncoK9® test from PetDx®, which are available from Antech immediately in both the U.S. and Canada. Learn more about Antech's portfolio of cancer diagnostics at https://www.antechdiagnostics.com/lab-diagnostics/molecular-diagnostics-canine-cancer/
At the heart of Antech is our love for pets and our desire to see them live longer, healthier lives. Through superior diagnostic testing delivered with a flexible, can-do spirit, we endeavor to treat every sample as if it belongs to our own pet. Our innovative diagnostics, accessible through North America's largest reference laboratory network, span world-class imaging equipment, and services, advanced molecular and predictive diagnostic testing, and core diagnostics with gold-standard accuracy. 24x7 access to the most accomplished team of board-certified pathologists, medical consultants across 14 specialty areas, and industry-leading education round out our support for today's high-performance practices. Antech is helping to drive the future of veterinary care as part of Mars Petcare, the world's largest family-owned company focusing on pet health. Visit us at antechdiagnostics.com. Follow us on Instagram, Twitter, LinkedIn, and Facebook.
View original content to download multimedia:
SOURCE Antech Diagnostics
|
https://www.whsv.com/prnewswire/2022/09/12/antech-expands-molecular-diagnostic-offerings-veterinary-medicines-most-comprehensive-diagnostics-portfolio-canine-cancer/
| 2022-09-12T14:11:38Z
|
– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –
– Data highlighted in late-breaking presentation at the European Society for Medical Oncology (ESMO) Congress 2022 –
TOKYO and BOTHELL, Wash. and RAHWAY, N.J., Sept. 12, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), Seagen Inc. (Nasdaq:SGEN) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the phase 1b/2 EV-103 clinical trial (also known as KEYNOTE-869) Cohort K investigating PADCEV® (enfortumab vedotin-ejfv) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and PADCEV alone as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible to receive cisplatin-based chemotherapy. The findings were presented today at the European Society for Medical Oncology (ESMO) Congress as part of a late-breaking abstract presentation (Abstract #LBA73).
In patients treated with enfortumab vedotin and pembrolizumab (n=76), results demonstrated a 64.5% confirmed objective response rate (ORR) (95% CI: 52.7 to 75.1) per RECIST v1.1 by blinded independent central review (BICR), the primary endpoint of Cohort K, with 10.5% of patients experiencing a complete response and 53.9% of patients experiencing a partial response. The median duration of response (DOR) per BICR was not reached (95% CI: 10.25 months to NR). All-grade treatment-related adverse events (TRAEs) of special interest for enfortumab vedotin in combination with pembrolizumab were skin reactions (67.1%), peripheral neuropathy (60.5%), ocular disorders (dry eye, blurred vision, and corneal disorders) (26.3%), hyperglycemia (14.5%), and infusion-related reactions (3.9%). Pembrolizumab adverse events of special interest were consistent with previously observed safety data from monotherapy with the exception of severe skin reactions. Overall, the results were generally consistent with previously reported efficacy and safety results of the EV-103/KEYNOTE-869 dose-escalation cohort and expansion Cohort A.1
Please see Important Safety Information at the end of this press release for both drugs, including BOXED WARNING for enfortumab vedotin and immune-mediated adverse reactions for pembrolizumab.
Cohort K also included a monotherapy arm in which patients were treated with enfortumab vedotin alone (n=73), though this study was not designed to support a formal comparison between the two arms. Results showed a 45.2% confirmed ORR (95% CI: 33.5 to 57.3) per RECIST v1.1 by BICR, with 4.1% of patients experiencing a complete response and 41.1% of patients experiencing a partial response. The median DOR was 13.2 months (95% CI: 6.14 to 15.97) per RECIST v1.1 by BICR. All-grade TRAEs of special interest for enfortumab vedotin were peripheral neuropathy (54.8%), skin reactions (45.2%), ocular disorders (dry eye, blurred vision, and corneal disorders) (28.8%), hyperglycemia (11.0%), and infusion-related reactions (5.5%).
Additional secondary endpoints in the EV-103 Cohort K trial included progression-free survival (PFS) and overall survival (OS). Among patients treated with enfortumab vedotin and pembrolizumab, median PFS was not reached (95% CI: 8.31 months to NR). Median OS was 22.3 months (95% CI: 19.09 to NR). Among patients treated with enfortumab vedotin, median PFS was 8.0 months (95% CI: 6.05 to 10.35) and median OS was 21.7 months (95% CI: 15.21 to NR).
TRAEs of any grade that occurred in more than 20% of patients treated with enfortumab vedotin alone or in combination with pembrolizumab were fatigue, peripheral sensory neuropathy, alopecia, rash maculo-papular, pruritus, dysgeusia, weight decreased, diarrhea, decreased appetite, nausea, and dry eye.
"Results from EV-103/KEYNOTE-869 Cohort K support the ongoing investigation of enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who are in need of treatment options, and this combination may be an important therapeutic option for these patients," said Jonathan E. Rosenberg, M.D., Chief, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology, and Enno W. Ercklentz Chair, Memorial Sloan Kettering Cancer Center and EV-103/KEYNOTE-869 Cohort K primary investigator. Dr. Rosenberg has consulting relationships with Astellas, Seagen and Merck.
"We're encouraged by these positive findings from the combination of enfortumab vedotin and pembrolizumab in people with advanced urothelial cancer who historically have had limited treatment options in the first-line setting, and we intend to discuss these results with regulatory authorities," said Ahsan Arozullah, M.D., M.P.H., Senior Vice President and Head of Development Therapeutic Areas, Astellas.
"Nearly sixty-five percent of patients who were treated with enfortumab vedotin and pembrolizumab responded to the combination, with almost eleven percent showing no detectable cancer following treatment. These study results represent an encouraging finding for people with advanced urothelial cancer who are not eligible for cisplatin treatment," said Marjorie Green, Senior Vice President and Head of Late Stage Development, Seagen.
"We're pleased that this combination provided a meaningful benefit to this group of advanced bladder cancer patients in this study, and we will continue to investigate enfortumab vedotin plus pembrolizumab through our collaboration," said Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer, Merck Research Laboratories.
In February 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for enfortumab vedotin in combination with pembrolizumab for patients with unresectable la/mUC who are ineligible to receive cisplatin-based chemotherapy in the first-line setting. The designation is based on results from the dose-escalation cohort and expansion Cohort A of the phase 1b/2 trial, EV-103/KEYNOTE-869 (NCT03288545), evaluating patients with la/mUC who are ineligible to receive cisplatin-based chemotherapy treated in the first-line setting with enfortumab vedotin in combination with pembrolizumab.
Astellas, Seagen and Merck are further investigating enfortumab vedotin plus pembrolizumab in Phase 3 studies, including EV-302/KEYNOTE-A39 (NCT04223856), which is intended to confirm these results for the investigational treatment combination in previously untreated la/mUC and in muscle-invasive bladder cancer in EV-304/KEYNOTE-B15 (NCT04700124) and EV-303/KEYNOTE-905 (NCT03924895).
About Bladder and Urothelial Cancer
It is estimated that approximately 83,730 people in the U.S. were diagnosed with bladder cancer in 2021.2 Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra.3 Globally, approximately 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.4
About the EV-103/KEYNOTE-869 Trial (Cohort K)
The EV-103 trial (NCT03288545) is an ongoing, multi-cohort, open-label, multicenter phase 1b/2 trial of enfortumab vedotin alone or in combination with pembrolizumab and/or chemotherapy in first- or second-line settings in patients with locally advanced or metastatic urothelial cancer (la/mUC) and in patients with muscle-invasive bladder cancer.
Cohort K of the EV-103/KEYNOTE-869 trial is a randomized 1:1 cohort investigating enfortumab vedotin alone (n=73) or in combination with pembrolizumab (n=76) in adult patients with unresectable la/mUC who are ineligible for cisplatin-based chemotherapy and have received no prior treatment for la/mUC. The enfortumab vedotin monotherapy study arm is intended to characterize the activity of enfortumab vedotin alone in this patient population. The key outcome measure of EV-103/KEYNOTE-869 Cohort K is objective response rate (ORR) per blinded independent central review (BICR) using RECIST 1.1. Secondary endpoints include ORR per investigator assessment; duration of response (DOR), disease control rate (DCR) and progression-free survival (PFS) per BICR and investigator assessment; overall survival (OS); and assessment of safety.
About PADCEV
PADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer.5 Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).6
PADCEV (enfortumab vedotin-ejfv) U.S. Indication & Important Safety Information
BOXED WARNING: SERIOUS SKIN REACTIONS
- PADCEV can cause severe and fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which occurred predominantly during the first cycle of treatment, but may occur later.
- Closely monitor patients for skin reactions.
- Immediately withhold PADCEV and consider referral for specialized care for suspected SJS or TEN or severe skin reactions.
- Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions.
Indication
PADCEV® is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who:
- have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or
- are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.6
Important Safety Information
Warnings and Precautions
Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN, occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later. Skin reactions occurred in 55% of the 680 patients treated with PADCEV in clinical trials. Twenty-three percent (23%) of patients had maculo-papular rash and 33% had pruritus. Grade 3-4 skin reactions occurred in 13% of patients, including maculo-papular rash, rash erythematous, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), dermatitis bullous, dermatitis exfoliative, and palmar-plantar erythrodysesthesia. In clinical trials, the median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 6.4). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=59), 24% of patients restarting at the same dose and 16% of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in 2.6% of patients. Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. Withhold PADCEV and refer for specialized care for suspected SJS or TEN or for severe (Grade 3) skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN, or for Grade 4 or recurrent Grade 3 skin reactions.
Hyperglycemia and diabetic ketoacidosis (DKA), including fatal events, occurred in patients with and without pre-existing diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C ≥8% were excluded from clinical trials. In clinical trials, 14% of the 680 patients treated with PADCEV developed hyperglycemia; 7% of patients developed Grade 3-4 hyperglycemia. The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. Five percent (5%) of patients required initiation of insulin therapy for treatment of hyperglycemia. The median time to onset of hyperglycemia was 0.6 months (range: 0.1 to 20.3). Hyperglycemia led to discontinuation of PADCEV in 0.6% of patients. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.
Pneumonitis Severe, life-threatening or fatal pneumonitis occurred in patients treated with PADCEV. In clinical trials, 3.1% of the 680 patients treated with PADCEV had pneumonitis of any grade and 0.7% had Grade 3-4. In clinical trials, the median time to onset of pneumonitis was 2.9 months (range: 0.6 to 6). Monitor patients for signs and symptoms indicative of pneumonitis, such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV for patients who develop persistent or recurrent Grade 2 pneumonitis and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis.
Peripheral neuropathy (PN) occurred in 52% of the 680 patients treated with PADCEV in clinical trials, including 39% with sensory neuropathy, 7% with muscular weakness and 6% with motor neuropathy; 4% experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without pre-existing PN. The median time to onset of Grade ≥2 PN was 4.6 months (range: 0.1 to 15.8 months). Neuropathy led to treatment discontinuation in 5% of patients. Monitor patients for symptoms of new or worsening peripheral neuropathy and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade ≥3 PN.
Ocular disorders were reported in 40% of the 384 patients treated with PADCEV in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in 34% of patients, and blurred vision occurred in 13% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.6 months (range: 0 to 19.1 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders.
Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 680 patients, 1.6% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions.
Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose.
Adverse Reactions
Most Common Adverse Reactions, Including Laboratory Abnormalities (≥20%)
Rash, aspartate aminotransferase (AST) increased, glucose increased, creatinine increased, fatigue, PN, lymphocytes decreased, alopecia, decreased appetite, hemoglobin decreased, diarrhea, sodium decreased, nausea, pruritus, phosphate decreased, dysgeusia, alanine aminotransferase (ALT) increased, anemia, albumin decreased, neutrophils decreased, urate increased, lipase increased, platelets decreased, weight decreased and dry skin.
EV-301 Study: 296 patients previously treated with a PD-1/L1 inhibitor and platinum-based chemotherapy.
Serious adverse reactions occurred in 47% of patients treated with PADCEV; the most common (≥2%) were urinary tract infection, acute kidney injury (7% each) and pneumonia (5%). Fatal adverse reactions occurred in 3% of patients, including multiorgan dysfunction (1.0%), hepatic dysfunction, septic shock, hyperglycemia, pneumonitis and pelvic abscess (0.3% each). Adverse reactions leading to discontinuation occurred in 17% of patients; the most common (≥2%) were PN (5%) and rash (4%). Adverse reactions leading to dose interruption occurred in 61% of patients; the most common (≥4%) were PN (23%), rash (11%) and fatigue (9%). Adverse reactions leading to dose reduction occurred in 34% of patients; the most common (≥2%) were PN (10%), rash (8%), decreased appetite and fatigue (3% each). Clinically relevant adverse reactions (<15%) include vomiting (14%), AST increased (12%), hyperglycemia (10%), ALT increased (9%), pneumonitis (3%) and infusion site extravasation (0.7%).
EV-201, Cohort 2 Study: 89 patients previously treated with a PD-1/L1 inhibitor and not eligible for platinum-based chemotherapy.
Serious adverse reactions occurred in 39% of patients treated with PADCEV; the most common (≥3%) were pneumonia, sepsis and diarrhea (5% each). Fatal adverse reactions occurred in 8% of patients, including acute kidney injury (2.2%), metabolic acidosis, sepsis, multiorgan dysfunction, pneumonia and pneumonitis (1.1% each). Adverse reactions leading to discontinuation occurred in 20% of patients; the most common (≥2%) was PN (7%). Adverse reactions leading to dose interruption occurred in 60% of patients; the most common (≥3%) were PN (19%), rash (9%), fatigue (8%), diarrhea (5%), AST increased and hyperglycemia (3% each). Adverse reactions leading to dose reduction occurred in 49% of patients; the most common (≥3%) were PN (19%), rash (11%) and fatigue (7%). Clinically relevant adverse reactions (<15%) include vomiting (13%), AST increased (12%), lipase increased (11%), ALT increased (10%), pneumonitis (4%) and infusion site extravasation (1%).
Drug Interactions
Effects of other drugs on PADCEV (Dual P-gp and Strong CYP3A4 Inhibitors)
Concomitant use with a dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.
Specific Populations
Lactation Advise lactating women not to breastfeed during treatment with PADCEV and for at least 3 weeks after the last dose.
Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment.
For more information, please see the full Prescribing Information including BOXED WARNING for PADCEV here.
About KEYTRUDA® (pembrolizumab) injection, 100 mg
KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Merck has the industry's largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S.
Urothelial Carcinoma
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC):
- who are not eligible for any platinum-containing chemotherapy, or
- who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Non-muscle Invasive Bladder Cancer
KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
See additional selected KEYTRUDA indications in the U.S. after the Selected Important Safety Information.
Selected Important Safety Information for KEYTRUDA
Severe and Fatal Immune-Mediated Adverse Reactions
KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the PD-1 or the PD-L1, blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of anti–PD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. For patients with TNBC treated with KEYTRUDA in the neoadjuvant setting, monitor blood cortisol at baseline, prior to surgery, and as clinically indicated. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.
Immune-Mediated Pneumonitis
KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.
Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients. Of the patients who developed pneumonitis, 42% interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.
Immune-Mediated Colitis
KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (1.1%), and Grade 2 (0.4%) reactions. Systemic corticosteroids were required in 69% (33/48); additional immunosuppressant therapy was required in 4.2% of patients. Colitis led to permanent discontinuation of KEYTRUDA in 0.5% (15) and withholding in 0.5% (13) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Colitis resolved in 85% of the 48 patients.
Hepatotoxicity and Immune-Mediated Hepatitis
KEYTRUDA as a Single Agent
KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.4%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 68% (13/19) of patients; additional immunosuppressant therapy was required in 11% of patients. Hepatitis led to permanent discontinuation of KEYTRUDA in 0.2% (6) and withholding in 0.3% (9) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Hepatitis resolved in 79% of the 19 patients.
KEYTRUDA With Axitinib
KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT ≥3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT ≥3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT ≥3 ULN subsequently recovered from the event.
Immune-Mediated Endocrinopathies
Adrenal Insufficiency
KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.3%) reactions. Systemic corticosteroids were required in 77% (17/22) of patients; of these, the majority remained on systemic corticosteroids. Adrenal insufficiency led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.3% (8) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Hypophysitis
KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.3%), and Grade 2 (0.2%) reactions. Systemic corticosteroids were required in 94% (16/17) of patients; of these, the majority remained on systemic corticosteroids. Hypophysitis led to permanent discontinuation of KEYTRUDA in 0.1% (4) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Thyroid Disorders
KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in <0.1% (1) of patients.
Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in <0.1% (2) and withholding in 0.3% (7) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. Hypothyroidism occurred in 8% (237/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (6.2%). It led to permanent discontinuation of KEYTRUDA in <0.1% (1) and withholding in 0.5% (14) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement. The majority of patients with hypothyroidism required long-term thyroid hormone replacement. The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC, occurring in 16% of patients receiving KEYTRUDA as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. The incidence of new or worsening hypothyroidism was higher in 389 adult patients with cHL (17%) receiving KEYTRUDA as a single agent, including Grade 1 (6.2%) and Grade 2 (10.8%) hypothyroidism.
Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis
Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in <0.1% (1) and withholding of KEYTRUDA in <0.1% (1) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement.
Immune-Mediated Nephritis With Renal Dysfunction
KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (<0.1%), Grade 3 (0.1%), and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 89% (8/9) of patients. Nephritis led to permanent discontinuation of KEYTRUDA in 0.1% (3) and withholding in 0.1% (3) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, none had recurrence. Nephritis resolved in 56% of the 9 patients.
Immune-Mediated Dermatologic Adverse Reactions
KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti–PD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.
Other Immune-Mediated Adverse Reactions
The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received KEYTRUDA or were reported with the use of other anti–PD-1/PD-L1 treatments. Severe or fatal cases have been reported for some of these adverse reactions. Cardiac/Vascular: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine: Hypoparathyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.
Infusion-Related Reactions
KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.
Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after anti–PD-1/PD-L1 treatments. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between anti–PD-1/PD-L1 treatment and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using anti–PD-1/PD-L1 treatments prior to or after an allogeneic HSCT.
Increased Mortality in Patients With Multiple Myeloma
In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an anti–PD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.
Embryofetal Toxicity
Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.
Adverse Reactions
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (≥20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).
In KEYNOTE-054, when KEYTRUDA was administered as a single agent to patients with stage III melanoma, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (≥1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (≥20%) with KEYTRUDA was diarrhea (28%). In KEYNOTE-716, when KEYTRUDA was administered as a single agent to patients with stage IIB or IIC melanoma, adverse reactions occurring in patients with stage IIB or IIC melanoma were similar to those occurring in 1011 patients with stage III melanoma from KEYNOTE-054.
In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (≥20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).
In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.
In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (≥20%) was fatigue (25%).
In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (≥20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).
In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (≥20%) were fatigue (33%), constipation (20%), and rash (20%).
In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (≥20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).
In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (≥20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.
In KEYNOTE-204, KEYTRUDA was discontinued due to adverse reactions in 14% of 148 patients with cHL. Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA; those ≥1% were pneumonitis, pneumonia, pyrexia, myocarditis, acute kidney injury, febrile neutropenia, and sepsis. Three patients died from causes other than disease progression: 2 from complications after allogeneic HSCT and 1 from unknown cause. The most common adverse reactions (≥20%) were upper respiratory tract infection (41%), musculoskeletal pain (32%), diarrhea (22%), and pyrexia, fatigue, rash, and cough (20% each).
In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those ≥1% were pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression: 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (≥20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).
In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (≥20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).
In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or mUC. Serious adverse reactions occurred in 42% of patients; those ≥2% were urinary tract infection, hematuria, acute kidney injury, pneumonia, and urosepsis. The most common adverse reactions (≥20%) were fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%), constipation (21%), rash (21%), and diarrhea (20%).
In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8% of 266 patients with locally advanced or mUC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated patients; those ≥2% were urinary tract infection, pneumonia, anemia, and pneumonitis. The most common adverse reactions (≥20%) in patients who received KEYTRUDA were fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased appetite (21%), nausea (21%), and rash (20%).
In KEYNOTE-057, KEYTRUDA was discontinued due to adverse reactions in 11% of 148 patients with high-risk NMIBC. The most common adverse reaction resulting in permanent discontinuation of KEYTRUDA was pneumonitis (1.4%). Serious adverse reactions occurred in 28% of patients; those ≥2% were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%). The most common adverse reactions (≥20%) were fatigue (29%), diarrhea (24%), and rash (24%).
Adverse reactions occurring in patients with MSI-H or dMMR CRC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-811, when KEYTRUDA was administered in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 6% of 217 patients with locally advanced unresectable or metastatic HER2+ gastric or GEJ adenocarcinoma. The most common adverse reaction resulting in permanent discontinuation was pneumonitis (1.4%). In the KEYTRUDA arm versus placebo, there was a difference of ≥5% incidence between patients treated with KEYTRUDA versus standard of care for diarrhea (53% vs 44%) and nausea (49% vs 44%).
The most common adverse reactions (reported in ≥20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, weight loss, abdominal pain, arthralgia, myalgia, and insomnia.
In KEYNOTE-590, when KEYTRUDA was administered with cisplatin and fluorouracil to patients with metastatic or locally advanced esophageal or GEJ (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma who were not candidates for surgical resection or definitive chemoradiation, KEYTRUDA was discontinued due to adverse reactions in 15% of 370 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA (≥1%) were pneumonitis (1.6%), acute kidney injury (1.1%), and pneumonia (1.1%). The most common adverse reactions (≥20%) with KEYTRUDA in combination with chemotherapy were nausea (67%), fatigue (57%), decreased appetite (44%), constipation (40%), diarrhea (36%), vomiting (34%), stomatitis (27%), and weight loss (24%).
Adverse reactions occurring in patients with esophageal cancer who received KEYTRUDA as a monotherapy were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-line metastatic cervical cancer regardless of tumor PD-L1 expression who had not been treated with chemotherapy except when used concurrently as a radio-sensitizing agent, fatal adverse reactions occurred in 4.6% of patients, including 3 cases of hemorrhage, 2 cases each of sepsis and due to unknown causes, and 1 case each of acute myocardial infarction, autoimmune encephalitis, cardiac arrest, cerebrovascular accident, femur fracture with perioperative pulmonary embolus, intestinal perforation, and pelvic infection. Serious adverse reactions occurred in 50% of patients receiving KEYTRUDA in combination with chemotherapy with or without bevacizumab; those ≥3% were febrile neutropenia (6.8%), urinary tract infection (5.2%), anemia (4.6%), and acute kidney injury and sepsis (3.3% each).
KEYTRUDA was discontinued in 15% of patients due to adverse reactions. The most common adverse reaction resulting in permanent discontinuation (≥1%) was colitis (1%).
For patients treated with KEYTRUDA, chemotherapy, and bevacizumab (n=196), the most common adverse reactions (≥20%) were peripheral neuropathy (62%), alopecia (58%), anemia (55%), fatigue/asthenia (53%), nausea and neutropenia (41% each), diarrhea (39%), hypertension and thrombocytopenia (35% each), constipation and arthralgia (31% each), vomiting (30%), urinary tract infection (27%), rash (26%), leukopenia (24%), hypothyroidism (22%), and decreased appetite (21%).
For patients treated with KEYTRUDA in combination with chemotherapy with or without bevacizumab, the most common adverse reactions (≥20%) were peripheral neuropathy (58%), alopecia (56%), fatigue (47%), nausea (40%), diarrhea (36%), constipation (28%), arthralgia (27%), vomiting (26%), hypertension and urinary tract infection (24% each), and rash (22%).
In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with previously treated recurrent or metastatic cervical cancer. Serious adverse reactions occurred in 39% of patients receiving KEYTRUDA; the most frequent included anemia (7%), fistula, hemorrhage, and infections [except urinary tract infections] (4.1% each). The most common adverse reactions (≥20%) were fatigue (43%), musculoskeletal pain (27%), diarrhea (23%), pain and abdominal pain (22% each), and decreased appetite (21%).
Adverse reactions occurring in patients with HCC were generally similar to those in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of ascites (8% Grades 3-4) and immune-mediated hepatitis (2.9%). Laboratory abnormalities (Grades 3-4) that occurred at a higher incidence were elevated AST (20%), ALT (9%), and hyperbilirubinemia (10%).
Among the 50 patients with MCC enrolled in study KEYNOTE-017, adverse reactions occurring in patients with MCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy. Laboratory abnormalities (Grades 3-4) that occurred at a higher incidence were elevated AST (11%) and hyperglycemia (19%).
In KEYNOTE-426, when KEYTRUDA was administered in combination with axitinib, fatal adverse reactions occurred in 3.3% of 429 patients. Serious adverse reactions occurred in 40% of patients, the most frequent (≥1%) were hepatotoxicity (7%), diarrhea (4.2%), acute kidney injury (2.3%), dehydration (1%), and pneumonitis (1%). Permanent discontinuation due to an adverse reaction occurred in 31% of patients; KEYTRUDA only (13%), axitinib only (13%), and the combination (8%); the most common were hepatotoxicity (13%), diarrhea/colitis (1.9%), acute kidney injury (1.6%), and cerebrovascular accident (1.2%). The most common adverse reactions (≥20%) were diarrhea (56%), fatigue/asthenia (52%), hypertension (48%), hepatotoxicity (39%), hypothyroidism (35%), decreased appetite (30%), palmar-plantar erythrodysesthesia (28%), nausea (28%), stomatitis/mucosal inflammation (27%), dysphonia (25%), rash (25%), cough (21%), and constipation (21%).
In KEYNOTE-564, when KEYTRUDA was administered as a single agent for the adjuvant treatment of renal cell carcinoma, serious adverse reactions occurred in 20% of patients receiving KEYTRUDA; the serious adverse reactions (≥1%) were acute kidney injury, adrenal insufficiency, pneumonia, colitis, and diabetic ketoacidosis (1% each). Fatal adverse reactions occurred in 0.2% including 1 case of pneumonia. Discontinuation of KEYTRUDA due to adverse reactions occurred in 21% of 488 patients; the most common (≥1%) were increased ALT (1.6%), colitis (1%), and adrenal insufficiency (1%). The most common adverse reactions (≥20%) were musculoskeletal pain (41%), fatigue (40%), rash (30%), diarrhea (27%), pruritus (23%), and hypothyroidism (21%).
Adverse reactions occurring in patients with MSI-H or dMMR endometrial carcinoma who received KEYTRUDA as a single agent were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a single agent.
Adverse reactions occurring in patients with TMB-H cancer were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.
Adverse reactions occurring in patients with recurrent or metastatic cSCC or locally advanced cSCC were similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy.
In KEYNOTE-522, when KEYTRUDA was administered with neoadjuvant chemotherapy (carboplatin and paclitaxel followed by doxorubicin or epirubicin and cyclophosphamide) followed by surgery and continued adjuvant treatment with KEYTRUDA as a single agent (n=778) to patients with newly diagnosed, previously untreated, high-risk early-stage TNBC, fatal adverse reactions occurred in 0.9% of patients, including 1 each of adrenal crisis, autoimmune encephalitis, hepatitis, pneumonia, pneumonitis, pulmonary embolism, and sepsis in association with multiple organ dysfunction syndrome and myocardial infarction. Serious adverse reactions occurred in 44% of patients receiving KEYTRUDA; those ≥2% were febrile neutropenia (15%), pyrexia (3.7%), anemia (2.6%), and neutropenia (2.2%). KEYTRUDA was discontinued in 20% of patients due to adverse reactions. The most common reactions (≥1%) resulting in permanent discontinuation were increased ALT (2.7%), increased AST (1.5%), and rash (1%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA were fatigue (70%), nausea (67%), alopecia (61%), rash (52%), constipation (42%), diarrhea and peripheral neuropathy (41% each), stomatitis (34%), vomiting (31%), headache (30%), arthralgia (29%), pyrexia (28%), cough (26%), abdominal pain (24%), decreased appetite (23%), insomnia (21%), and myalgia (20%).
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596), fatal adverse reactions occurred in 2.5% of patients, including cardio-respiratory arrest (0.7%) and septic shock (0.3%). Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA in combination with chemotherapy; the serious reactions in ≥2% were pneumonia (2.9%), anemia (2.2%), and thrombocytopenia (2%). KEYTRUDA was discontinued in 11% of patients due to adverse reactions. The most common reactions resulting in permanent discontinuation (≥1%) were increased ALT (2.2%), increased AST (1.5%), and pneumonitis (1.2%). The most common adverse reactions (≥20%) in patients receiving KEYTRUDA in combination with chemotherapy were fatigue (48%), nausea (44%), alopecia (34%), diarrhea and constipation (28% each), vomiting and rash (26% each), cough (23%), decreased appetite (21%), and headache (20%).
Lactation
Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the final dose.
Pediatric Use
In KEYNOTE-051, 161 pediatric patients (62 pediatric patients aged 6 months to younger than 12 years and 99 pediatric patients aged 12 years to 17 years) were administered KEYTRUDA 2 mg/kg every 3 weeks. The median duration of exposure was 2.1 months (range: 1 day to 24 months).
Adverse reactions that occurred at a ≥10% higher rate in pediatric patients when compared to adults were pyrexia (33%), vomiting (30%), leukopenia (30%), upper respiratory tract infection (29%), neutropenia (26%), headache (25%), and Grade 3 anemia (17%).
Additional Indications for KEYTRUDA in the U.S.
Melanoma
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC, or III melanoma following complete resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
- stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
- metastatic.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
Head and Neck Squamous Cell Cancer
KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma
KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
Primary Mediastinal Large B-Cell Lymphoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.
Microsatellite Instability-High or Mismatch Repair Deficient Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.
Gastric Cancer
KEYTRUDA, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Esophageal Cancer
KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
- in combination with platinum- and fluoropyrimidine-based chemotherapy, or
- as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Cervical Cancer
KEYTRUDA, in combination with chemotherapy, with or without bevacizumab, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.
Hepatocellular Carcinoma
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merkel Cell Carcinoma
KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Renal Cell Carcinoma
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Endometrial Carcinoma
KEYTRUDA, as a single agent, is indicated for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Tumor Mutational Burden-High Cancer
KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.
Cutaneous Squamous Cell Carcinoma
KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.
Triple-Negative Breast Cancer
KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Please see Prescribing Information for KEYTRUDA (pembrolizumab) at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf and Medication Guide for KEYTRUDA at http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf.
About Astellas
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.
About Seagen
Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.
Merck's focus on cancer
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose, and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
About the Astellas, Seagen and Merck Collaboration
Astellas and Seagen entered a clinical collaboration agreement with Merck to evaluate the combination of Astellas' and Seagen's PADCEV® (enfortumab vedotin-ejfv) and Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated metastatic urothelial cancer. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Astellas Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development), which is included in this press release, is not intended to constitute an advertisement or medical advice.
Seagen Forward-Looking Statements
Certain statements made in this press release are forward-looking, such as those, among others, relating to the therapeutic potential of PADCEV alone or in combination, including its possible efficacy, safety and therapeutic uses; plans to discuss Cohort K results with regulatory authorities; and clinical development plans, including planned and ongoing clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the possibility that the data from the EV-103 trial may not be sufficient to support any regulatory approval; the risk of adverse events, including the potential for newly-emerging safety signals; adverse regulatory actions; delays, setbacks or failures in clinical development activities, the submission of regulatory applications and the regulatory review process for a variety of reasons, including the inherent difficulty and uncertainty of pharmaceutical product development; possible required modifications to clinical trials; the inability to provide information and institute safety mitigation measures as may be required by the FDA or other regulatory authorities from time to time; failure to properly conduct or manage clinical trials; and failure of clinical results to support continued development or regulatory approvals. More information about the risks and uncertainties faced by Seagen is contained under the caption "Risk Factors" included in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
1 C.J. Hoimes, J.E. Rosenberg et.al. EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Annals of Oncology 2019; 30 (Supplement 5): v356–v402.
2 American Cancer Society. Cancer Facts & Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf. Accessed September 10, 2022.
3 American Society of Clinical Oncology. Bladder Cancer: Introduction (9-20). https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed September 10, 2022.
4 International Agency for Research on Cancer. Cancer Tomorrow: Bladder. http://gco.iarc.fr/tomorrow. Accessed September 10, 2022.
5 Challita-Eid P, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res 2016;76(10):3003-13.
6 PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
View original content to download multimedia:
SOURCE Astellas Pharma Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/astellas-seagen-merck-announce-results-clinical-trial-investigating-padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-padcev-monotherapy-first-line-advanced-urothelial-cancer/
| 2022-09-12T14:11:44Z
|
At 409 U.S. Highway 177 North #2
BURGAW, N.C., Sept. 12, 2022 /PRNewswire/ -- BenchMark Physical Therapy opened an outpatient clinic today at 409 U.S. Highway 177 North #2.
The clinic is open 7 a.m. to 4 p.m. Monday, Wednesday and Friday and 9 a.m. to 6 p.m. Tuesday and Thursday. To make an appointment, call 910-970-8141 or visit benchmarkpt.com.
BenchMark has clinics throughout the Wilmington region and more than 50 in North Carolina.
BenchMark offers in-clinic and telehealth options for outpatient orthopedic physical therapy. Services include manual therapy, injury prevention, return to performance, total joint replacement, concussion management and vestibular rehabilitation.
Clinic director Dylan Mascarenas earned a bachelor's degree in athletic training from East Central University and a doctor of physical therapy degree from Chapman University.
Mascarenas is a certified athletic trainer and is certified as an orthopedic clinical specialist. He is a fellow in training with the Upstream Rehab Institute orthopedic manual therapy program and an advanced dry needling specialist. His special interests are TMJ treatment and athletic rehabilitation.
BenchMark, part of the Upstream Rehabilitation family of clinical care, offers access to care within 24 hours and works with all insurance types.
View original content to download multimedia:
SOURCE Upstream Rehabilitation
|
https://www.whsv.com/prnewswire/2022/09/12/benchmark-physical-therapy-opens-outpatient-clinic-burgaw-nc/
| 2022-09-12T14:11:51Z
|
At 810 Plaza Drive
ZEBULON, Ga., Sept. 12, 2022 /PRNewswire/ -- BenchMark Physical Therapy, which operates more than 160 outpatient clinics in Georgia, opened its newest site today at 810 Plaza Drive in McLeRoy Plaza.
The clinic operates 8 a.m. to noon Monday and Friday and 8 a.m. to 5 p.m. Wednesday.
To make an appointment, call 678-451-1280 or visit benchmarkpt.com.
BenchMark offers in-clinic and telehealth options for outpatient orthopedic physical therapy, including manual therapy, injury prevention, return to performance, total joint replacement, concussion management and vestibular rehabilitation programs.
Clinic director Kadie Coker earned a doctor of physical therapy degree from Alabama State University. Coker is certified in dry needling and LSVT BIG for treating patients with Parkinson's disease. She specializes in treating general orthopedic conditions, sports injuries, neurological conditions and post-operative conditions.
BenchMark, part of the Upstream Rehabilitation family of clinical care, offers access to care within 24 hours and works with all insurance types.
View original content to download multimedia:
SOURCE Upstream Rehabilitation
|
https://www.whsv.com/prnewswire/2022/09/12/benchmark-physical-therapy-opens-outpatient-clinic-zebulon-ga/
| 2022-09-12T14:11:58Z
|
Innovative cloud service offerings allow government agencies to implement the AI-driven solution to drive innovation, increase efficiencies, and reduce costs
HOUSTON, Sept. 12, 2022 /PRNewswire/ -- BMC, a global leader in software solutions for the Autonomous Digital Enterprise, today announced its BMC Helix service and operations management platform has achieved Federal Risk Authorization Management Program (FedRAMP) Moderate authorization for the BMC Helix v 21.3 in the Amazon Web Services (AWS) cloud. The BMC Helix solution in the AWS cloud allows federal agencies to confidently choose BMC for their seamless, secure cloud migrations as they face ever-changing and demanding missions.
The BMC Helix platform is designed for organizations looking to:
- Modernize the enterprise by accelerating the shift to the cloud, optimizing existing on-premises solutions, and enabling further innovation
- Find and solve problems faster, support high-velocity DevOps teams, and drive innovation with AI-powered service management and IT operations (AIOps) from the AWS cloud
In addition to previously authorized service management capabilities, governmental customers will now be able to capitalize on BMC's innovative, industry-leading operations management capabilities in the cloud with BMC Helix.
Highlights of the new BMC Helix solution include:
- Operations Management with AIOps—Predictive IT with artificial intelligence for IT operations (AIOps), service-centric monitoring, advanced event management, root cause isolation, and intelligent automation to improve performance for faster issue resolution with greater cost savings
- Continuous Optimization—Predictive analytics to manage IT resources in the cloud with support for Kubernetes and pods, microservices, and containers allowing for increased efficiencies across the organization
- Discovery—Discovery and dependency modeling that delivers instant visibility into hardware, software, and services across cloud, hybrid, and on-premises environments for greater compliance and assurance
- Service Management —The gold standard in service management (previously authorized—now updated to include v21.3) to support the ultimate service employee experience
- Digital Workplace—Provide employees with intuitive and intelligent, consumer-like experiences to help organizations step into the future of work
- Project Portfolio Management—A comprehensive graphical tool that seamlessly connects project and portfolio management with idea sourcing, idea management, and demand generation to spur innovation
"This authorization reflects the close coordination between BMC and our extensive customer base, providing the innovative software-as-a-service (SaaS) solutions they need to modernize their enterprise IT systems. Our partnership with AWS is a critical part of this capability. Together, we offer unimpeachable service and operations management SaaS solutions to our federal agencies," said David Sims, Area Vice President and General Manager of BMC Federal. "We are honored to provide our government customers this broader set of BMC Helix capabilities with FedRAMP Moderate authorization that accelerates their cloud initiatives and offers the highest levels of agility, scalability, and confidence to achieve program and mission success."
Additional Resources:
- Discover more about the BMC Helix platform at www.bmc.com/helix
- Curious about the organizational journey to becoming an Autonomous Digital Enterprise? Visit https://www.bmc.com/ade
- Learn how BMC helps public agencies modernize and accomplish the mission
About BMC
BMC works with 86% of the Forbes Global 50 and customers and partners around the world to create their future. With our history of innovation, industry-leading automation, operations, and service management solutions, combined with unmatched flexibility, we help organizations free up time and space to become an Autonomous Digital Enterprise that conquers the opportunities ahead.
BMC, BMC Software, the BMC logo, and other BMC marks are the exclusive properties of BMC Software, Inc. and are registered or may be registered with the U.S. Patent and Trademark Office or in other countries.
©Copyright 2022 BMC Software, Inc.
BMC—Run and Reinvent
www.bmc.com
Editorial contact:
Jannelle Allong-Diakabana
BMC
jannelle_allongdiakabana@bmc.com
View original content to download multimedia:
SOURCE BMC Software, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/bmc-delivers-modern-service-operations-management-with-bmc-helix-fedramp-certification/
| 2022-09-12T14:12:04Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Boost, the leading insurance infrastructure platform, today announced the appointment of Emy Donavan as Chief Underwriting Officer. Donavan joins Boost from Fin Capital where she was a venture partner leading the insurance segment across funds, working on investment thesis development, deal sourcing, and driving portfolio company operating value. Prior to Fin, Donavan established an impeccable track record as a senior underwriting executive over the past 20 years, including serving as the Global Head and CUO of Cyber, Tech, and Media at Allianz Global Corporate & Specialty (ACGS).
Donavan will oversee the company's program underwriting, product development, and portfolio management in collaboration with Boost's insurtech and embedded partners along with the development and execution of Boost's reinsurance and risk capital markets strategy.
"Emy is a highly accomplished senior insurance executive with a proven record of leading the development and execution of complex P&C programs while consistently delivering profitable underwriting returns," said Boost's CEO and Founder Alex Maffeo. "She is passionate about fostering innovation across the industry and challenges the status quo to find solutions where others accept the norm. Emy shares our excitement for the insurtech movement and I am thrilled to be working with her as we effect positive changes across the industry for the modern insurance customer."
Licensed to develop, file, and sell commercial and personal P&C insurance products in all 50 states in the U.S., Boost packages all the necessary compliance, capital, and technology infrastructure any company needs to offer digital insurance products to their end users and makes it accessible through a simple, turnkey API integration. Boost is powering many of the most innovative, high-growth insurtech programs in the industry today and is the leading platform for developing and launching highly configurable embedded insurance offerings as that market continues to boom.
"Boost's technology platform super-charges potential innovation in the insurance industry, both by lowering barriers for new entrants and improving speed to market for new products in both personal and commercial lines," said Donavan. "Boost's in-house team of insurance experts have built a suite of innovative products from the ground up, with programs designed to offer the most value - not just to the end buyer, but to stakeholders across the insurance value chain. Boost has unlocked a major barrier to innovation, designing a platform that allows for compliant deployment of new insurance programs in a complex U.S. regulatory environment.
"I look forward to helping the team continue to lead in this space and to working with our reinsurance partners to break new ground in modern insurance protection. Combined with increased flexibility enabled by Boost's tech platform, which supports both embedded and brokered distribution, we have a unique opportunity to make insurance more accessible and valuable to new customer segments, distributors and capital providers."
Prior to Fin, Donavan served as CUO for Resilience where she advised the executive team and board on the impact of specific strategies associated with product choice, positioning, and competitive considerations, and owned portfolio management and regulatory reporting strategy for all products. Prior to joining Resilience, she was CUO of Allianz's Global Corporate & Specialty's global cyber, technology and media professional liability operations. She is also a frequent speaker for PLUS, Advisen, APCIA, and other affiliation groups on Cyber & Professional Liability insurance topics, and is on the board of a number of insuretechs active in the US and global markets.
Boost Insurance empowers any company to engage with their customers and increase sales by offering insurance through their own digital experience. Licensed to develop and sell P&C insurance products in all 50 states, Boost provides insurance infrastructure-as-a-service that packages the necessary compliance, operational, capital, and technological components of an insurance program into a turnkey, white-labeled solution, accessible via a simple API integration. Businesses that choose Boost can reduce the cost and complexity of building and managing their insurance function, and quickly begin engaging their customers with valuable insurance products. For more information, please visit boostplatform.io.
View original content to download multimedia:
SOURCE Boost Insurance
|
https://www.whsv.com/prnewswire/2022/09/12/boost-insurance-appoints-emy-donavan-chief-underwriting-officer/
| 2022-09-12T14:12:12Z
|
VANCOUVER, BC, Sept. 12, 2022 /PRNewswire/ - Capella Minerals Ltd. (TSXV: CMIL) (OTCQB: CMILF) (FRA: N7D2) ("Capella" or the "Company") is pleased to announce that it has applied for an Exploration Reservation ("Perho") covering an area of 50 sq km over the Eräjärvi Lithium-Cesium-Tantalum ("LCT") pegmatite field in southern Finland. The Perho Reservation (VA2022:0056 and shown in green in Figure 1) covers the former Seppälä lithium mine and lies adjacent to the former Viitaniemi and Juurakko feldspar-quartz(-lithium) mines, which are reported by the Finnish geological survey ("GTK") to have ceased production in 1965 and 1935, respectively. Significantly, more than 70 pegmatite dykes, enriched in B, Be, Li, Nb, Sn and Ta, are reported from the area (Eilu 2012, Lahti 1981, Aviola 2004). Little modern systematic exploration for lithium deposits has been undertaken in the area.
The new Perho Reservation has been applied for by local subsidiary Cullen Finland Oy, which is currently owned 70:30 by Capella and ASX-listed Cullen Resources Ltd (ASX: CUL). Cullen Finland Oy is also owner of the Katajavaara-Aaeknus gold-copper project in the highly-prospective Central Lapland Greenstone Belt.
Figure 1. Perho reservation over the Eräjärvi LCT pegmatite field.
Eric Roth, Capella's President and CEO, commented: "The application for the Perho Reservation over the Eräjärvi lithium pegmatite field has the potential to provide Capella with further exposure to the metals required for Europe's green energy transition and energy storage. LCT pegmatites are important global sources of lithium, cesium, and tantalum as well as other by-products. In conjunction with our high-grade copper-cobalt assets in Norway, the Company is well placed to participate in the global electrification and decarbonization process. I look forward to keeping the market updated on progress at Perho".
The technical information in this news release relating to the Perho lithium project has been prepared in accordance with Canadian regulatory requirements set out in NI 43-101, and approved by Eric Roth, the Company's President & CEO, a Director, and a Qualified Person under NI 43-101. Mr. Roth holds a Ph.D. in Economic Geology from the University of Western Australia, is a Fellow of the Australian Institute of Mining and Metallurgy (AusIMM) and is a Fellow of the Society of Economic Geologists (SEG). Mr. Roth has 30 years of experience in international minerals exploration and mining project evaluation.
On Behalf of the Board of Capella Minerals Ltd.
"Eric Roth"
___________________________
Eric Roth, Ph.D., FAusIMM
President & CEO
Capella is engaged in the acquisition, exploration, and development of quality mineral resource properties in favourable jurisdictions with a focus on high-grade copper(-zinc-cobalt) and gold deposits. With respect to base and battery metals projects, the Company's current focus is on i) advancing its recently-acquired Hessjøgruva project and the adjacent Kongensgruve and Kjøli projects in the northern Røros copper mining district of central Norway, as well as ii) the discovery of further high-grade VMS-type deposits in a district-scale land position around the past-producing Løkken (Løkken Verk District) copper mine. The recent Perho reservation application over the Eräjärvi pegmatite field is ultimately expected to provide the Company with further exposure to battery metals, including lithium, cesium, and tantalum.
The Company's precious metals focus is on the discovery of high-grade gold deposits on the Katajavaara-Aakenus JV in Finland, its active Canadian Joint Ventures with Prospector Metals Corp (TSXV: PPP) at Savant (Ontario) and Yamana Gold Inc. at Domain (Manitoba), and its 100%-owned Southern Gold Line Project in Sweden. The Company also retains a residual interest (subject to an option to purchase agreement with Austral Gold Ltd) in the Sierra Blanca gold-silver divestiture in Santa Cruz, Argentina.
This news release contains forward-looking information within the meaning of applicable securities legislation. Forward-looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or are those, which, by their nature, refer to future events. Such statements include, without limitation, statements regarding the future results of operations, performance and achievements of Capella, including the timing, completion of and results from the exploration and drill programs described in this release. Although the Company believes that such statements are reasonable, it can give no assurances that such expectations will prove to be correct. All such forward-looking information is based on certain assumptions and analyses made by Capella in light of their experience and perception of historical trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. This information, however, is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Important factors that could cause actual results to differ from this forward-looking information include those described under the heading "Risks and Uncertainties" in Capella's most recently filed MD&A. Capella does not intend, and expressly disclaims any obligation to, update or revise the forward-looking information contained in this news release, except as required by law. Readers are cautioned not to place undue reliance on forward-looking information.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
References
Alviola, R. 2004, Oriveden Seppälä-Vittaniemi alueen pegmatiittitutkimus. Geologcal Survey of Finland, Report M19/2141/2004/1/85. 9p. 60 app. (In Finnish).
Eilu, P.(ed.) 2012. Geological Survey of Finland, Special Paper 53,224.
Lahti, S.I. 1981, On the granitic pegmatites of the Eräjärvi area in Orivesi, southern Finland. Geological Survey of Finland, Bulletin 314, 82p.
View original content to download multimedia:
SOURCE Capella Minerals Limited
|
https://www.whsv.com/prnewswire/2022/09/12/capella-applies-new-lithium-reservation-southern-finland-expand-battery-metal-portfolio/
| 2022-09-12T14:12:19Z
|
The acquisition signals the evolution of Celerium's business to powering active cyber defense from facilitating cyber threat sharing.
TYSONS CORNER, Va., Sept. 12, 2022 /PRNewswire/ -- Celerium Inc., a leader in innovative cyber defense solutions, today announced it has acquired Dark Cubed, the company providing automated network defense to small- and medium-sized businesses and U.S. Department of Defense contractors.
With this acquisition, Celerium is shifting its overall focus to powering active cyber defense from enabling cyber threat sharing. The Dark Cubed solution will work with Celerium's Cyber Defense Network suite of solutions to provide enhanced capability and functionality for Celerium's customers and the MSP partners working with Dark Cubed.
"Celerium's mission has always been to help companies fortify their overall cyber defense posture. The reality of today's climate – in which ransomware and other cyber threats continue to increase while organizations face a cyber skills gap and lack of resources – requires active defense. We look forward to enhancing Dark Cubed's active cyber defense solution and expanding its reach and adoption," said Aubrey Chernick, founder and chairman of Celerium.
Dark Cubed's product is an advanced, patented, and automated network defense solution. The company has focused on building a growing community of Managed Service Providers (MSPs) to deliver this solution to the SMB community, servicing a market segment that enterprise security vendors have been reluctant to address. At the high end of the market, U.S. Department of Defense contractors are using the Dark Cubed product hosted on AWS GovCloud.
"Our team has demonstrated that it is possible to deliver effective and affordable cybersecurity capabilities to the SMB using intelligent automation and partnering with exceptional MSPs," added Vince Crisler, founder and CEO of Dark Cubed, who will become Celerium's Chief Strategy Officer. "Joining forces with the team at Celerium will enable us to accelerate the development of that community and allow us to expand our reach and influence into additional markets that need active, effective automated cyber defense. This is a huge win for Dark Cubed, our MSP partners, and the cybersecurity industry -- and I look forward to what's next."
Over the next few months, Celerium will make additional product announcements, including planned enhancements of Dark Cubed's signature product and new active defense solutions.
Celerium® powers active cyber defense solutions to help companies in the fight against increasing cyberattacks. With a rich 16-year history of facilitating cyber threat sharing for critical industry sectors and government agencies, Celerium is an established leader in providing innovative cybersecurity solutions, with solution directions based on the evolving needs of the overall industry.
Celerium's CMMC Academy initiative, launched in early 2020, provides resources to help government contractors navigate the Department of Defense's cybersecurity compliance programs (CMMC and NIST 800-171).
Visit us online at www.Celerium.com and on Twitter at @CeleriumDefense.
Designed to stop just the types of threats targeting the SMB community, Dark Cubed is bringing genuine cyber security to the 99% of small businesses that can't afford - and don't need - products designed and priced for large enterprises. Designed from the ground up for the SMB community, we sell our solution exclusively through our growing network of MSP partners. The Dark Cubed set-it-and-forget-it solution delivers 100% automated threat detection and blocking, is deployed in minutes, is 100% SaaS, and requires no new hardware, no software to install, no agents, and no cyber security analysts to operate.
View original content to download multimedia:
SOURCE Celerium
|
https://www.whsv.com/prnewswire/2022/09/12/celerium-announces-acquisition-dark-cubed/
| 2022-09-12T14:12:25Z
|
CTO Nate Perry-Thistle to highlight ways healthcare leaders can utilize Google Cloud to enhance patient and provider journeys and boost engagement
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- CipherHealth, a leader in patient engagement technology and communications solutions, announced today that Nate Perry-Thistle, Chief Technology Officer, will participate in a roundtable discussion on how to enhance healthcare utilizing Google Cloud throughout the care continuum at the inaugural SADA IMPACT conference located at Sofi Stadium in Los Angeles, California on September 15, 2022.
Joining Perry-Thistle on the panel will be moderated by Michael Ames, Managing Director, Vertical Markets at SADA, and also feature Gregg Church, President at 4medica and Ian Shakil, Founder and Chief Strategy Officer at Augmedix. The session, "Healthcare impact: three unique technology companies making healthcare better for all of us," will address how healthcare companies can incorporate cloud-based technologies to improve patient and doctor experiences.
The panel will show how healthcare leaders can collect and digest massive amounts of data to support both patients and doctors at every stage of the journey. The panelists will explore specific use cases, from helping patients find the right clinicians to helping doctors make data-driven clinical decisions. At the heart of this discussion will be a focus on how leaders can improve the care experience and use technology to improve patient journeys, physician journeys, and data journeys. During the session, attendees will:
- Understand how leading healthcare innovators are utilizing cutting-edge technology to simplify healthcare journeys
- Discover best practices for incorporating Google Cloud in patient journeys to deliver optimal care and engagement
- Uncover ways to reduce spending and labor costs by implementing cloud-driven data solutions
The panel is scheduled for Thursday, September 15, from 1:55-2:35 PM PST. For more information and to register, click here.
About CipherHealth
CipherHealth is an award-winning digital patient engagement company committed to enhancing communication and coordination throughout the care continuum. Since 2009, CipherHealth has helped define the patient engagement category, delivering groundbreaking tools and superior services to help health systems deliver patient-centric, quality care that improves clinical outcomes, drives operational efficiency, and creates sustainable financial value through a full suite of communications solutions. CipherHealths's automated, scalable platform empowers healthcare organizations to drive meaningful conversations among patients, provider staff and caregivers, regardless of care setting, thereby achieving new standards for patient care and accelerating the digital transformation of the industry.
View original content to download multimedia:
SOURCE CipherHealth
|
https://www.whsv.com/prnewswire/2022/09/12/cipherhealth-cto-leader-present-future-cloud-based-healthtech-inaugural-sada-impact/
| 2022-09-12T14:12:32Z
|
SALT LAKE CITY, Sept. 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 24th Annual Global Investment Conference, being held virtually and in-person on September 12-14 in New York City, New York.
Dwight Egan, Company CEO, will be conducting a presentation discussing recent and expected Company progress along with its forthcoming Co-Dx PCR Home Diagnostic Platform. The presentation can be accessed by clicking here or through the Events and Webcasts section of the Co-Diagnostics website on September 13, 2022 at 8:30 AM Eastern Time, for institutional investors and industry professionals who have registered for the event.
The Company will also be participating in one-on-one meetings, which can be arranged with H.C. Wainwright representatives.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
View original content to download multimedia:
SOURCE Co-Diagnostics
|
https://www.whsv.com/prnewswire/2022/09/12/co-diagnostics-inc-participate-hc-wainwright-24th-annual-global-investment-conference-september-12-14-2022/
| 2022-09-12T14:12:39Z
|
Increased Expectations on Developers Puts the Onus on Enterprises to Arm Teams with Modern Technology That Empowers and Motivates Them
SANTA CLARA, Calif., Sept. 12, 2022 /PRNewswire/ -- Couchbase, Inc. (NASDAQ: BASE), provider of a leading modern database for enterprise applications, today announced findings from industry research examining the challenges faced by development teams amid the race to the cloud and to execute on digital transformation initiatives. The global survey of 650 senior IT decision makers found that development teams are under pressure and under-supported. The findings revealed that 88 percent of respondents are aware of challenges faced by development teams, with the top issues including that deadlines and agility requirements were difficult to meet (42 percent); that they were being asked to do too much in too little time (40 percent); or that they did not have the skills (24 percent) or technology (23 percent) they needed.
"Organizations need to understand that when they are undertaking digital transformation, what they are actually doing is putting developers front and center," said Ravi Mayuram, chief technology officer of Couchbase. "The modern business depends on the developer and development agility more than ever before. Development teams are not assisting the business, they are leading it to new frontiers through digital transformation. That's why they need to be given the right resources: be it cloud-based infrastructure, CI/CD friendly tooling and the right training. This is what will ensure success in these times of product-led transformation and growth."
Research from Couchbase found that despite development teams' extensive contributions to digital transformation and innovation initiatives, a lack of resources and communication with IT leaders is still frustrating them. This is preventing businesses from making the most of their potential, and moving with greater velocity.
Additional findings include:
- 86 percent of respondents report obstacles in supporting development teams: The key issues that these enterprises report include difficulty redeploying development teams rapidly to work on new projects when needed (32 percent); ensuring development teams always have the right technology (31 percent); and identifying and solving the problems their teams face (31 percent). Additionally, 40 percent of respondents did not know for certain whether their development teams were behind or ahead of schedule and 27 percent found it challenging to follow the development team's progress to ensure they are meeting their goal.
- Growth of development teams has stagnated, while digital investment is rising: Despite enterprises planning to increase digital transformation spend by 46 percent in 2022, developer teams only grew by an average of three percent in the last year. In order to bridge the gap, organizations will need to invest in growing their teams while making existing teams more efficient. This can explain why 32 percent of IT leaders are specifically investing in new technologies that make developers' jobs easier.
- There's opportunity to further empower developer teams: 30 percent of respondents say that the pandemic has taught them how to empower development teams, yet 24 percent find it difficult to gauge whether development teams are engaged in and enthusiastic about their work. The challenge now is understanding how to get developers excited about their work and demonstrating the results. For example, providing them with their desired technologies and allowing them to build with velocity the way they want to.
Without the right support, development teams aren't able to drive digital transformation as quickly as the business may need them to. 34 percent of respondents said pressure from developers to support agile development and innovation was a driver for digital transformation projects, showing developers' direct impact on the speed that an organization can move. Yet 19 percent said development teams' inability to meet goals set for them had prevented their organization from pursuing new digital transformation projects in the last 12 months.
IT leaders and developers share a similar goal: to build great applications. By increasing transparency and providing the right support and technologies, they can work together to make meaningful progress on digital transformation initiatives.
Couchbase Capella makes it faster, easier and more affordable for developers to build enterprise applications. Start a free trial today by clicking here and see how easy it is to be up and running with Couchbase in minutes.
- Read more about Couchbase's findings here.
- Read about the findings from Couchbase's Cloud Evolution Report here.
- Read about the findings from Couchbase's Digital Transformation Report here.
At Couchbase, we believe data is at the heart of the enterprise. We empower developers and architects to build, deploy, and run their most mission-critical applications. Couchbase delivers a high-performance, flexible, and scalable modern database that runs across the data center and any cloud. Many of the world's largest enterprises rely on Couchbase to power the core applications their businesses depend on. For more information, visit www.couchbase.com.
View original content to download multimedia:
SOURCE Couchbase
|
https://www.whsv.com/prnewswire/2022/09/12/couchbase-research-finds-that-88-developers-are-under-pressure-race-cloud-empowering-developers-is-critical-competitive-advantage/
| 2022-09-12T14:12:45Z
|
SAN MATEO, Calif., Sept. 12, 2022 /PRNewswire/ -- Coupa Software (NASDAQ: COUP), announced today that its management team will participate in the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 14, 2022.
The management team's live remarks, scheduled to begin at 9:15 am PT (12:15 pm ET), can be accessed from Coupa's investor relations website at http://investors.coupa.com. A replay of the live webcast will also be available on this website for at least 90 days following the event.
About Coupa Software
Coupa is the cloud-based Business Spend Management (BSM) platform that unifies processes across supply chain, procurement, and finance functions. Coupa empowers organizations around the world to maximize value and operationalize purpose through their business spend. To learn more about Coupa, visit www.coupa.com or follow us on LinkedIn or Twitter.
View original content to download multimedia:
SOURCE Coupa Software
|
https://www.whsv.com/prnewswire/2022/09/12/coupa-software-participate-goldman-sachs-communacopia-technology-conference/
| 2022-09-12T14:12:52Z
|
Sweepstakes fosters innovation and learning for students
THIEF RIVER FALLS, Minn., Sept. 12, 2022 /PRNewswire/ -- Digi-Key Electronics, which offers the world's largest selection of electronic components and automation products in stock for immediate shipment, has opened its highly-anticipated annual Back2School Prize Draw sweepstakes, which gives college students an opportunity to win prizes that empower them to use real-world engineering tools and resources.
There will be 11 prize giveaways total, and winners will be randomly selected. One grand prize winner will receive a LulzBot Mini 3D printer and filament; five second prize winners will receive the Picade X HAT Arcade Game kit, DK ruler and Innovation Handbook; and five third prize winners will receive a Pokit meter, DK ruler, 50 DK Solderful breadboards, Innovation Handbook, Machinechat license and Molex wire crimper. The content of the prize kits may vary depending on the applicant's region, but the prizes will be of equivalent value.
"We're excited to once again host our popular Back2School Prize Draw, providing students with components to not only apply to their classes but that also help to fuel their innovation," said YC Wang, global academic program director at Digi-Key. "Digi-Key is proud to offer the tools they need to flex their imaginations and engineering muscles while providing encouragement and support to advance their skills and cultivate their passion for engineering."
"Students are the next generation of innovators, and at Digi-Key, we're dedicated to empowering and supporting them," said David Sandys, director of technical marketing at Digi-Key. "We want to provide students with valuable tools, products and resources that encourage them to always continue learning and honing their skills to spark new ideas."
The sweepstakes is open to any student with a university or college email address, and entries may be made in students' local language. To learn more or enter the Back2School Prize Draw, visit Digi-Key's website here. Submissions are open from Sept. 12-Oct. 28, 2022, and winners will be announced shortly after the Oct. 28 deadline.
About Digi-Key Electronics
Digi-Key Electronics, headquartered in Thief River Falls, Minn., USA, is recognized as both the leader and continuous innovator in the high service distribution of electronic components and automation products worldwide. As the original pioneer in this space, Digi-Key provides more than 13.4 million components from over 2,300 quality name-brand manufacturers with an industry-leading breadth and depth of product in stock and available for immediate shipment. Beyond the products that drive technology innovation, Digi-Key also supports design engineers and procurement professionals with a wealth of digital solutions and tools to make their jobs more efficient. Additional information can be found at digikey.com and on Facebook, Twitter, YouTube, Instagram and LinkedIn.
Editorial Contact
Megan Derkey
Bellmont Partners
+1 612-255-1115
digikey@bellmontpartners.com
View original content to download multimedia:
SOURCE Digi-Key Electronics
|
https://www.whsv.com/prnewswire/2022/09/12/digi-key-electronics-announces-2022-back2school-prize-draw/
| 2022-09-12T14:12:59Z
|
MIDLAND, Mich., Sept. 12, 2022 /PRNewswire/ -- Howard Ungerleider, president and chief financial officer of Dow Inc. (NYSE: DOW), will participate in a fireside chat during the Credit Suisse 35th Annual Specialties & Basics Conference on Wednesday, September 14 at 2:00 p.m. ET.
Dow invites investors to join the live webcast through its website, where presentation materials will be made available the morning of the meeting. A replay and transcript will also be available on the website following the event, and all materials will remain available for approximately 12 months.
About Dow
Dow (NYSE: DOW) combines global breadth; asset integration and scale; focused innovation and materials science expertise; leading business positions; and environmental, social and governance (ESG) leadership to achieve profitable growth and deliver a sustainable future. The Company's ambition is to become the most innovative, customer centric, inclusive and sustainable materials science company in the world. Dow's portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated, science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility and consumer applications. Dow operates 104 manufacturing sites in 31 countries and employs approximately 35,700 people. Dow delivered sales of approximately $55 billion in 2021. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visit www.dow.com or follow @DowNewsroom on Twitter.
For further information, please contact:
Twitter: https://twitter.com/DowNewsroom
Facebook: https://www.facebook.com/dow/
LinkedIn: http://www.linkedin.com/company/dow-chemical
Instagram: http://instagram.com/dow_official
View original content to download multimedia:
SOURCE The Dow Chemical Company
|
https://www.whsv.com/prnewswire/2022/09/12/dow-participate-credit-suisse-35th-annual-specialties-amp-basics-conference/
| 2022-09-12T14:13:05Z
|
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Energy Exploration Technologies Inc.'s (EnergyX) announced it has added global sports and entertainment company Endeavor to its advisory roster, as the company looks to throw its support behind the global transition to a clean energy future. Keen on being involved in the United States' shift towards renewable energy and electric mobility, the business identified the lithium and battery sectors as critical areas of interest, and EnergyX as one of the leading American companies working on providing green jobs and sustainable technology within that industry.
With major world economies and global companies seeking to reduce their environmental footprint and impact, investments into low-carbon solutions are skyrocketing. For Endeavor, this means working with entities like EnergyX capable of bringing forth disruptive innovation in lithium, battery, and energy transition technology. The company joins advisors from NASA's Ames Research Center, Tesla Energy, CATL (the largest global battery producer), and General Electric Energy Storage.
Co-founded by CEO Ariel Emanuel in 1995, Endeavor is home to a number of industry leaders including entertainment agency WME; sports, fashion, events and media company IMG; and premier mixed martial arts organization UFC. The Endeavor network specializes in talent representation, sports operations & advisory, event & experiences management, media production & distribution, experiential marketing and brand licensing.
Founded in 2018 by CEO Teague Egan, EnergyX is a developing lithium and battery technologies to provide efficient, sustainable solutions to challenges facing global electric vehicle supply chains. From the raw lithium extraction process to refining, and the manufacturing of next generation batteries, EnergyX is innovating from lithium brine to battery. The company has filed over 50 patents to this end, and is developing its proprietary Lithium Ion Transport and Separation (LiTAS™) and Solid State Lithium Metal Battery (SoLiS™) technologies. Its LiTAS™ technology has been piloted in the Lithium Triangle in South America and increases lithium production from 30% in existing systems up to 94% recovery rate for that particular pilot project.
The news follows the announcement of a $450 million investment commitment from Global Emerging Markets (GEM) to boost commercialization efforts and solidify EnergyX as a market leader of direct lithium extraction and refinery technologies. EnergyX will look to Endeavor for valuable support, knowledge, relationships, and advice as the team looks to become a global force within the lithium industry.
"Bringing on Endeavor in this capacity is an honor for EnergyX and showcases our innovative and creative spirit," explains EnergyX CEO Teague Egan, "Ari's business achievements and relationships are unmatched and his vision truly spectacular. I'm thankful his company is engaged in the energy transition, and devoting time to a clean, sustainable future, which is a critically important issue for all of us."
For further information or to arrange interviews, please contact:
James Ellsmoor, Director of Communications, james@energyx.com
+1 510 426 7206
View original content:
SOURCE EnergyX
|
https://www.whsv.com/prnewswire/2022/09/12/energyx-taps-endeavor-advisory-services-it-expands-its-global-footprint/
| 2022-09-12T14:13:12Z
|
More to Explore with New Pretend-Play Toys from VTech®
CHICAGO, Sept. 12, 2022 /PRNewswire/ -- Today VTech® announced the availability of the Smart Chart Medical Kit™, Pop & Spin Mower™ and Toy of the Year Award Finalist Level Up Gaming Chair™, engaging new additions to its expansive infant, toddler, and preschool lines. The exciting new pretend-play toys keep kids engaged in good-for-you play that never runs out of fun!
"Gaming has become a large part of family entertainment time for parents and older children and we want to bring the littlest members of the family into the fun too with our new Level Up Gaming Chair," said Andy Keimach, President, VTech Electronics North America.
Little gamers will love the Level Up Gaming Chair, featuring a chair that swivels side to side, a game panel, joystick button and pretend headset. Parents will love that it features four interactive games and two levels of learning that introduce letters, phonics, words and meanings, as well as three play modes and a removable panel for on-the-go fun. Even the youngest doctors in the house can care for their family with the Smart Chart Medical Kit. They can dress up like a doctor then use the interactive tablet to explore medical instruments, the human body and common ailments. The Pop & Spin Mower helps improve motor skills while introducing gardening basics, lawn mower safety and colors to little ones with phrases, lights and music. Children can also sit and play by spinning the roller or pressing the light-up buttons to explore gardening themes and colors.
Highlights of the latest infant, toddler and preschool toys, available now at major retailers nationwide, include:
Level Up Gaming Chair™: Invite little gamers to get in on the action with the Level Up Gaming Chair™. Take newbies to the next level of learning with four activities that go from letters and phonics to words and meanings. Each activity includes two levels of learning to help kids progress as they are ready. Feel like a real gamer with a chair that swivels side to side, a game panel, joystick button and a pretend headset. Complete with 26 letter buttons, the removable panel includes ten piano keys and a light-up LED screen. Three play modes include Learning, Gaming and Music. Bring gaming and learning on the go with a portable panel that easily detaches from the tray. Use the tray and chair for snack time or story time. This versatile chair encourages kids to explore early learning concepts in an exciting setting. Game on! (Ages 1.5 – 4 years; MSRP: $49.99)
Smart Chart Medical Kit™: There's always a doctor in the house with the Smart Chart Medical Kit™! Kiddos can care for their family, friends, dolls and stuffed animals with this portable kit. Dress up like a doctor and grab your interactive healthcare tablet. Explore medical instruments, the human body and common ailments using the touch points on the tablet. Let's see how the patient is doing with the role-play check-up button! Walk through multiple patient scenarios and find the right tools to check your patient's symptoms, then see how to help them feel better. Use the play stethoscope to listen to their heart and lungs, then check for a fever with the thermometer. With the otoscope, have a look in your patient's eyes, ears, nose and throat. Help others while exploring wellness tips with the health tips button, like drinking plenty of water and getting enough rest. When the doctor's office is closed, pack up the 15 tools and accessories and place them all in the medical bag, ready for next time. (Ages 2 – 5 years; MSRP: $27.99)
Pop & Spin Mower™: Get motor skills growing with the Pop & Spin Mower™! This lean, green mowing machine introduces gardening basics, lawn mower safety and colors to little ones with phases, lights and music. Be careful to avoid hard objects when mowing! The yellow triangle button introduces lawn mower safety to help keep kids safe around the real thing. Pull the cord to start the engine and hear it rumble while watching the sparkly, pretend blade spin. Popping beads add to the role-play by mimicking grass clippings. Not quite ready to walk? Little gardeners can sit and play too! Spin the roller or press the light-up buttons to explore gardening themes and colors. Mower should not be exposed to water or moisture. (Ages 2 – 5 years; MSRP: $29.99)
For more information, visit www.vtechkids.com.
VTech is a world leader in age-appropriate and developmental stage-based electronic learning products for children. As a pioneer in the learning toy category, VTech develops high-quality, innovative educational products that enrich children's development and make learning fun. With a rich 45-year history, VTech has not only established itself as a learning authority but also consistently remains at the forefront of innovation with multiple award-winning products, including prestigious Toy of the Year (TOTY) Award winners. The company also has a broad range of award-winning infant, toddler and preschool products available in 28 different languages worldwide, with more than 100 new products introduced every year. In order to further strengthen VTech's position as a learning authority, new products are developed with critical insights from a dedicated team of in-house learning experts.
VTech Electronics North America, L.L.C. is based in Arlington Heights, Illinois. VTech Electronics Limited is headquartered in Hong Kong with distribution globally.
For more information about VTech's electronic learning products, visit www.VTechKids.com, www.facebook.com/VTechtoys on Facebook or follow @VTechToys on Twitter.
Media Contact:
Lauren Fagan
Coyne Public Relations
973-588-2000
lfagan@coynepr.com
View original content to download multimedia:
SOURCE VTech Electronics North America
|
https://www.whsv.com/prnewswire/2022/09/12/engaging-new-infant-toddler-preschool-toys-vtech-available-now/
| 2022-09-12T14:13:18Z
|
IR laser cleave technology enables nanometer-precision layer transfer through silicon, eliminating glass substrates for advanced packaging and enabling thin-layer 3D stacking
ST. FLORIAN, Austria, Sept. 12, 2022 /PRNewswire/ -- EV Group (EVG), a leading provider of wafer bonding and lithography equipment for the MEMS, nanotechnology and semiconductor markets, today introduced NanoCleave™, a revolutionary layer release technology for silicon that enables ultra-thin layer stacking for front-end processing, including advanced logic, memory and power device formation, as well as semiconductor advanced packaging. NanoCleave is a fully front-end-compatible layer release technology that features an infrared (IR) laser that can pass through silicon, which is transparent to the IR laser wavelength. Coupled with the use of specially formulated inorganic layers, this technology enables an IR laser-initiated release of any ultra-thin film or layer from silicon carriers with nanometer precision.
As a result, NanoCleave enables silicon wafer carriers in advanced packaging processes such as Fan-out Wafer-level Packaging (FoWLP) using mold and reconstituted wafers as well as interposers for 3D Stacked ICs (3D SIC). At the same time, its compatibility with high-temperature processes enables completely novel process flows for 3D IC and 3D sequential integration applications – enabling hybrid and fusion bonding even of ultra-thin layers on silicon carriers, thereby revolutionizing 3D and heterogeneous integration as well as material transfer in next-generation scaled transistor designs.
Company executives will be available to discuss this IR laser transfer technology breakthrough at SEMICON Taiwan, taking place at the Taipei Nangang Exhibition Center Hall 1 (TaiNEX 1) in Taipei, Taiwan, from September 14-16. Event attendees can visit EVG at Booth #L0316 (4th Floor) to learn more.
Silicon Carriers Benefit 3D Stacking and Back-end Processing
In 3D integration, carrier technologies for thin-wafer processing are key to enabling higher performance systems with increasing interconnection bandwidth. Glass carriers have become an established method for building up device layers through temporary bonding with organic adhesives, using an ultraviolet (UV) wavelength laser to dissolve the adhesives and release the device layers, which are subsequently permanently bonded onto the final product wafer. However, glass substrates are difficult to process with semiconductor fab equipment that have been designed primarily around silicon, and that require costly upgrades to enable glass wafer processing. In addition, organic adhesives are generally limited to processing temperatures below 300°C, which limits their use to back-end processing.
Enabling silicon carriers with inorganic release layers avoids these temperature and glass carrier compatibility issues. In addition, the nanometer precision of IR laser-initiated cleaving opens up the possibility of processing extremely thin device wafers without changing processes of record. Subsequent stacking of such thin device layers enables higher bandwidth interconnects and opens up new opportunities to design and segment dies for next-generation high-performance systems.
Next-generation Transistor Nodes Demand Novel Layer-transfer Processes
At the same time, transistor roadmaps for the sub-3-nm node are calling for new architectures and design innovations such as buried power rails, backside power delivery networks, complementary field-effect transistors (CFETs) and even 2D atomic channels, all of which will require layer transfer of extremely thin materials. Silicon carriers and inorganic release layers support process cleanliness, material compatibility and high processing temperature requirements for front-end manufacturing flows. However, until now, silicon carriers had to be completely removed using grinding, polishing and etching processes, which results in micron-range variations across the surface of the working device layer, making this method unsuitable for thin-layer stacking at advanced nodes.
EVG's new NanoCleave technology utilizes an IR laser and inorganic release materials to enable laser debonding on silicon with nanometer precision. This eliminates the need for glass substrates for advanced packaging, avoiding temperature and glass carrier compatibility issues, and enables the ability to transfer ultra-thin (single micron and below) layers via carriers in front-end processing without changing the processes of record. The nanometer-precision of EVG's new process supports advanced semiconductor device roadmaps calling for thinner device layers and packages, increased heterogeneous integration, and reduced processing costs through thin-layer transfer and the elimination of glass substrates.
"Semiconductor scaling has become increasingly complex and difficult to achieve due to tighter process tolerances," stated Paul Lindner, executive technology director at EV Group. "The industry needs new processes and integration approaches to enable higher integration density and device performance. Our NanoCleave layer release technology is a game-changer for semiconductor scaling through thin-layer and die stacking, with the potential to address the most pressing requirements of the industry. NanoCleave will help enable our customers to realize their advanced device and packaging roadmaps through a highly versatile and universal layer release technology that works with standard silicon wafers and wafer processes – enabling seamless integration in the fab and saving our customers both time and money."
Unique IR Laser Technology
Using EVG's NanoCleave technology, the backside of the silicon wafer is exposed with an IR laser, which utilizes a unique wavelength that silicon is transparent to. An inorganic release layer that is pre-built into the silicon stack through standard deposition processes absorbs the IR light, resulting in the cleaving of the silicon at a predetermined and precisely defined layer or area. The ability to use inorganic release layers enables more precise and thinner release layers to be used (in the range of a few nanometers versus a few microns for organic adhesives). In addition, the inorganic release layers are compatible with high-temperature processing (up to 1000°C), enabling layer transfer for many new front-end applications, such as epitaxy, deposition and annealing, where organic adhesives are incompatible.
Product Availability
Demonstrations of EVG's NanoCleave layer release technology are now available at the company's headquarters.
About EV Group (EVG)
EV Group (EVG) is a leading supplier of equipment and process solutions for the manufacture of semiconductors, microelectromechanical systems (MEMS), compound semiconductors, power devices and nanotechnology devices. Key products include wafer bonding, thin-wafer processing, lithography/nanoimprint lithography (NIL) and metrology equipment, as well as photoresist coaters, cleaners and inspection systems. Founded in 1980, EV Group services and supports an elaborate network of global customers and partners all over the world. More information about EVG is available at www.EVGroup.com.
View original content to download multimedia:
SOURCE EV Group
|
https://www.whsv.com/prnewswire/2022/09/12/ev-group-revolutionizes-3d-integration-advanced-packaging-transistor-scaling-with-nanocleave-layer-release-technology/
| 2022-09-12T14:13:25Z
|
Leader in video analytics and AI technology introduces a set of new product releases, feature enhancements, and integrations with leading video solutions providers.
ATLANTA, Sept. 12, 2022 /PRNewswire/ -- Evolon Technology, Inc., a developer of proprietary software technology that takes surveillance video and turns it into real-time actionable information, today announced the commercial availability of several new product releases, feature enhancements, and new partnerships at the GSX 2022 Expo which convenes today at the Georgia World Congress Center in Atlanta, Georgia.
- New Product Releases – New releases announced at GSX include Evolon Edge™ 4.5 and Evolon Enterprise™ 2.5, both debuting radically new user experiences that simplify video analytic installation and usability. Video analytic setup times are dramatically reduced using the streamlined interface. New feature enhancements also introduced today include Autolight™ and Day/Night Parameters for Evolon Edge, which dramatically enhance object detection in extreme low-light conditions. Custom integrations with the Immix® CMS management platforms were also introduced for Evolon Enterprise.
- Milestone® XProtect Integration – Evolon today announced general availability of its integration with Milestone XProtect. The solution delivers real-time object detection alerts by leveraging Evolon's metadata stream and XProtect's event management features. The integration enables fast and efficient forensic video searches to find events and objects of interest in recorded video. Evolon's patented object detection dramatically reduces the number of false alerts that are generated by video motion detection. Both Evolon Edge 4.5 and Evolon Enterprise 2.5 support the Milestone integration.
- Hanwha Techwin Partnership – Evolon today announced a technical partnership with Hanwha Techwin. Evolon will demonstrate its award-winning Edge perimeter detection running on Hanwha's Wisenet Open Platform for cameras. The Evolon solution adds analytics to Hanwha's X-series and P-series cameras as an application running directly on the cameras, requiring no additional hardware. As part of the partnership, Evolon Edge and Evolon Enterprise will be integrated with the Hanwha Wisenet Wave VMS to deliver real-time detection alerts and searchable metadata.
"As you can see, we've been busy," said Kevin Stadler, Evolon President and CEO. "In addition to providing more value to our customers in the form of new product enhancements, the work we announced today allows lower cost deployments with better situational intelligence. We see the work announced today as an important leap in the video analytic arena that marries the best technology with our award-winning analytic science. It's all part of our commitment to being the leader in the security video analytics space delivering improved value and situational intelligence."
Evolon Edge 4.5 and Evolon Enterprise 2.5 are available today. For information on pricing and availability, contact an Evolon representative at: sales@evolontech.com.
Evolon provides advanced, highly accurate perimeter surveillance software technology for critical infrastructure protection and central station monitoring, and its patented software & analytics transform video security cameras and security systems into smart devices by eliminating nuisance alerts. Evolon's award-winning edge-based video analytics and AI/deep learning solutions are fully scalable for commercial and government organizations that require real-time situational intelligence to enhance security effectiveness and to reduce the potential for loss due to criminal activity or business downtime. Evolon was founded by a talented team of former engineers and scientists from the U.S. Department of Energy's Los Alamos National Laboratory, with decades of national security experience in the design and deployment of advanced surveillance technologies. For more information, visit www.evolontech.com.
Evolon and the Evolon logo are registered trademarks of Evolon Technology, Inc. All Rights Reserved.
View original content to download multimedia:
SOURCE Evolon Technology, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/evolon-announces-latest-innovations-partnerships-gsx-2022/
| 2022-09-12T14:13:32Z
|
Consensus opinions report that lowering the doses of certain anti-seizure medications (ASMs) when beginning treatment with XCOPRI® (cenobamate tablets) CV may help manage possible side effects
PARAMUS, N.J., Sept. 12, 2022 /PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced the publication in the journal Neurology and Therapy. The epileptologist expert consensus opinions were created to improve treatment tolerability through dose adjustments of concomitant anti-seizure medications (ASMs) during the addition of cenobamate, approved in the United States under the brand name XCOPRI® for the treatment of partial-onset seizures in adults.
"Our goals of therapy for each patient with epilepsy are seizure freedom, little or no adverse effects from ASMs, and the fewest number of ASMs possible," said Michael C. Smith, M.D., Division Chief of Epilepsy and Clinical Neurophysiology at Rush Medical College. "With the introduction of new medications to a patient's treatment regimen, patients with epilepsy may experience an increase in adverse events (AEs); however, there is a large gap in understanding how to combat AEs in this scenario."
In this consensus study, a panel of seven epileptologists experienced in the use of ASMs, including cenobamate, were brought together to help address the gap in understanding how to manage AEs using a modified Delphi Method*. The consensus of experts, focused on the use of cenobamate, outline their experience with managing patients on multiple ASMs.
Their expert findings show that, when introducing cenobamate, lowering the dosage of other ASMS from the patient's treatment regimen may help manage side effects. A summary table of the expert opinions in the publication can be found here.
"When a new medication is added to a patient's antiseizure medication (ASM) regimen, it is important to consider the overall drug load that may increase the possibility for adverse reactions," said Pavel Klein, M.D., epileptologist and neurologist, Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD. "To help manage those potential adverse events, when adding the new medication, you may consider reducing the dose of existing ASMs."
*About the Delphi Method
In clinical research, the Delphi method is used to systematically generate consensus by gathering experts in the field to answer critical research questions that are not amenable to other types of research designs, such as experimental methods. 1 This method allows for information to be gathered to help inform the treatment decision-making process in a meaningful way.
About XCOPRI® (cenobamate tablets) CV
Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABAA) ion channel.
Cenobamate is approved in the United States for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI® (cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. The recommended initial dosage of cenobamate is 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg.
Cenobamate is also approved in the European Union and the United Kingdom for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with seizures that have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products and is marketed by Angelini Pharma under the brand name ONTOZRY®.
Additionally, cenobamate is in clinical development in Asia. Ono Pharmaceutical and Ignis Therapeutics have the rights to develop and commercialize cenobamate in Japan and in the Greater China region, respectively. SK Biopharmaceuticals has recently entered into an exclusive licensing agreement with Endo for cenobamate in Canada.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI® (cenobamate tablets) CV
DO NOT TAKE XCOPRI IF YOU:
- Are allergic to cenobamate or any of the other ingredients in XCOPRI.
- Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart.
XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING:
Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider.
QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.
Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood.
Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you.
Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider.
DISCONTINUATION:
Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).
DRUG INTERACTIONS:
XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
PREGNANCY AND LACTATION:
XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use.
Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org.
Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI.
COMMON SIDE EFFECTS:
The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired.
These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.
DRUG ABUSE:
XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law.
INDICATION:
XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age.
Please see additional patient information in the Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment.
Please see full Prescribing Information.
About Epilepsy
Epilepsy is the fourth most common neurological disorder. There are approximately 3.4 million people living with epilepsy in the United States, with 150,000 new cases each year in the country.2,3 Epilepsy is characterized by recurrent, unprovoked seizures. The seizures in epilepsy may be related to a brain injury or a family tendency, but often the cause is completely unknown. Having seizures and epilepsy can affect one's safety, relationships, work, driving, and much more.4,5 People with epilepsy are at risk for accidents and other health complications, including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).4,5 Despite the availability of many antiepileptic therapies, almost 40 percent of people with epilepsy are not able to achieve seizure freedom, meaning they have epilepsy that remains uncontrolled.6
About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.
SK Biopharmaceuticals and its U.S. subsidiary SK life science are pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin their expansion into oncology through research and development efforts. The companies have a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK life science's website at www.SKLifeScienceInc.com.
Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit http://hc.sk.co.kr/en/.
XCOPRI® and ONTOZRY® are registered trademarks of SK Biopharmaceuticals Co., Ltd.
Media Inquiries
SK Life Science, Inc.
media@sklsi.com
References
- Olsen, A., McLaughlin, J., How to use the Delphi method to aid in decision making and build consensus in pharmacy education. https://www.sciencedirect.com/topics/social-sciences/delphi-method#:~:text=The%20Delphi%20method%20is%20a%20unique%20methodology%20used%20to%20systematically,experimental%20or%20quasi%2Dexperimental%20methods. Published 2021
- Epilepsy Foundation. Who Gets Epilepsy? https://www.epilepsy.com/learn/about-epilepsy-basics/who-gets-epilepsy.Accessed July 2021.
- Epilepsy Foundation. Epilepsy Statistics. https://www.epilepsy.com/learn/about-epilepsy-basics/epilepsy-statistics. Accessed July 2021
- Epilepsy Foundation. Staying Safe. https://www.epilepsy.com/learn/seizure-first-aid-and-safety/staying-safe. Accessed July 2021.
- Epilepsy Foundation. Challenges with Epilepsy. https://www.epilepsy.com/learn/challenges-epilepsy. Accessed July 2021.
- Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. https://www.ncbi.nlm.nih.gov/pubmed/29279892. Published online December 26, 2017.
View original content to download multimedia:
SOURCE SK Life Science, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/expert-consensus-opinions-published-neurology-therapy-discuss-adjustment-anti-seizure-medication-dosing-optimal-care/
| 2022-09-12T14:13:38Z
|
—Portable Inspection Tools Now More Precise, Easier to Use & Improve Productivity by 20%—
LAKE MARY, Fla., Sept. 12, 2022 /PRNewswire/ -- FARO® Technologies, Inc. (NASDAQ: FARO), a global leader in 4D digital reality solutions, today announced the release of the new FARO® VantageS6 Max and VantageE6 Max Laser Tracker series. The new laser trackers offer comprehensive, large-volume 3D measurement up to 80 meters, significantly streamlining processes and reducing inspection cycle times while ensuring complete confidence in the results.
The new Vantage Max enables organizations to increase their throughput while maintaining high inspection accuracy with an attractive 3D metrology option that expands upon the proven track record of the FARO Vantage series. The trackers maximize 6 degrees of freedom (6DoF) measurement capabilities via the optional 6Probe, enabling precise measurement of hidden areas and small features.
The 6Probe is a 6DoF solution that meets the dynamic measurement, speed and accuracy requirements of the most challenging industrial applications. With kinematic self-identifying styli, users can change probing tips quickly and measure without any recalibration, plus measure hidden areas outside of the tracker's line of sight with wide acceptance angles.
Moreover, the new Vantage Max provides more accurate 6DoF probing that helps speed up inspections and reduce the number of tooling changes and device moves. Previously, users relied on a spherically mounted retroreflector (SMR) to measure high accuracy points. In order to take these measurements, the user had to select an appropriate target nest and have line of sight. Typical users of the new trackers can now save up to 60 minutes each workday.
"With the higher accuracy of the Vantage Max, users can probe more points beyond the line of sight, using an SMR only for alignment points and ultra-precision measurements," said Leo Martinez, FARO Product Marketing Manager. "This results in a significant productivity improvement of 20% compared to lower accuracy probes."
FARO serves the 3D Metrology, AEC (Architecture, Engineering & Construction), O&M (Operations & Maintenance), and Public Safety Analytics markets. For over 40 years, FARO has been a pioneer in #RealityCapture, bridging the digital and physical worlds through data-driven reliable accuracy, precision, and immediacy, providing industry-leading technology solutions that enable customers to measure their world and use that data to make smarter decisions faster. For more information, visit www.faro.com.
View original content to download multimedia:
SOURCE FARO
|
https://www.whsv.com/prnewswire/2022/09/12/faro-releases-all-new-vantage-max-high-accuracy-laser-tracker-series/
| 2022-09-12T14:13:45Z
|
HATFIELD, Pa., Sept. 12, 2022 /PRNewswire/ -- CurveBeam AI, Ltd announced its medical diagnostic software, OssView™, has received US Food and Drug Administration (FDA) Breakthrough Device Designation. OssView calculates a Structural Fragility Score (SFS), which determines bone microstructural deterioration, a clinical aid to assist a medical provider in determining bone fragility and fracture risk in over 70-year-old females.
OssView is investigational only and is not available for sale in the United States.
The goal of the FDA Breakthrough Devices Program is to provide patients and health care providers with timely access to medical devices that provide for more effective treatment or diagnosis of irreversibly debilitating diseases by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval or clearances.
Benefits associated with acceptance into the Breakthrough Devices Program include prioritized review of FDA 510(k) applications.
The current standard of care to determine fragility fracture risk in patients is bone mineral density (BMD) measurements obtained via dual energy X-Ray (DXA). In some cases, other fracture risk software tools are used to further identify fracture risk. These approaches to date have been limited in performance. When compared to these techniques, SFS has shown performance to support a Breakthrough Device Designation. Bone density defined-osteoporosis can miss up to 80%1 of fragility fractures – fractures that can be irreversibly debilitating and impact mortality.
"Most fractures occur in women with modest deficits in BMD called 'osteopenia'," said Ego Seeman, Professor of Medicine and Endocrinologist, Departments of Medicine and Endocrinology, Austin Health, University of Melbourne, Melbourne Australia. "The many women in the community with osteopenia who are at risk of a fracture are unlikely to be offered treatment because of the mistaken belief that finding BMD in the osteopenia range means the bone is not fragile."
BMD measures the amount of bone; it does not measure the breakdown of three-dimensional bone architecture.
"Even modest bone loss producing osteopenia concurrently destroys the architecture of bone which weakens the bone greatly," Seeman said. "An increase in holes in the outer shell of the bone (cortical porosity) reduces bone strength to the 7th power, loss of the inner honey-comb spongy (trabeculae) bone reduce strength to the 3rd power; disproportionate to the bone loss producing this destruction and disproportionate to the modest reduction in BMD found in osteopenia."
Medicare spent an estimated $57 billion in 2018 to provide care for patients who suffered osteoporotic fractures, according to the National Osteoporosis Foundation. SFS gives doctors an additional clinical tool to better aid in assessing fracture risk in non-osteoporotic patients to prevent fragility fractures.
"The challenge is to identify and pre-emptively treat those women at risk of a first or subsequent fracture among the many with osteopenia," said Seeman.
SFS is calculated from a high resolution peripheral quantitative computed tomography (HR-pQCT) scan of the wrist. CurveBeam AI intends to offer point-of-care, high resolution CT platforms to improve access to patients for medical providers dealing with patients who are non-osteoporotic.
SFS aids in the assessment of bone architecture breakdown quickly, easily, and safely. This test helps a doctor identify patients with osteopenia or normal bone density with fracture risk so treatment can be given to prevent fragility fractures.
"We are extremely pleased to be moving forward with the SFS diagnostic through the FDA Breakthrough Device Program," said Greg Brown, CEO of CurveBeam AI. "There is a clear need for an improved clinical aid like SFS to help clinicians more effectively assess bone health and prevent fractures. We are looking forward to progressing its clearance with the FDA."
CurveBeam AI specializes in cone beam CT imaging and complementary AI applications for orthopedics and bone health. CurveBeam AI's global operations headquarters for product development, Quality & Regulatory, manufacturing and operations including marketing, sales and customer care are in Hatfield PA, USA. CurveBeam AI's corporate office in Melbourne, VIC, Australia, covers AI research & development, AI Quality and regulatory corporate finance, and IP functions. CurveBeam AI, which has 51 employees, is an unlisted public company backed by several major professional investors and is targeting an Initial Public Offering in 2023.
1 Samelson E et al, Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study.Lancet .Published online November 28, 2018 http://dx.doi.org/10.1016/S2213-8587(18)30308-5
View original content:
SOURCE CURVEBEAM AI
|
https://www.whsv.com/prnewswire/2022/09/12/fda-grants-breakthrough-device-designation-curvebeam-ais-ossview-bone-fragility-software/
| 2022-09-12T14:13:51Z
|
PITTSBURGH, Sept. 12, 2022 /PRNewswire/ -- Federated Hermes Premier Municipal Income Fund (NYSE: FMN) has declared a dividend. The fund seeks to provide investors with current dividend income that is exempt from regular federal income tax. In addition, this fund features income exempt from the federal alternative minimum tax (AMT).
Investors can view additional portfolio information in the Products section of FederatedInvestors.com.
Federated Hermes, Inc. (NYSE: FHI) is a global leader in active, responsible investment management, with $631.9 billion in assets under management, as of June 30, 2022. We deliver investment solutions that help investors target a broad range of outcomes and provide equity, fixed-income, alternative/private markets, multi-asset and liquidity management strategies to more than 11,000 institutions and intermediaries worldwide. Our clients include corporations, government entities, insurance companies, foundations and endowments, banks and broker/dealers. Headquartered in Pittsburgh, Federated Hermes has nearly 2,000 employees in London, New York and offices worldwide. For more information, visit FederatedHermes.com.
View original content:
SOURCE Federated Hermes, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/federated-hermes-premier-municipal-income-fund-declares-dividend/
| 2022-09-12T14:13:58Z
|
LEIPZIG, Germany, Sept. 12, 2022 /PRNewswire/ -- HHL Leipzig Graduate School of Management (HHL) has achieved 19th place worldwide and third place in Germany in the annual ranking of the Financial Times. This makes HHL's Master in Management program one of the best in the world. According to the ranking published today, HHL graduates earn higher salaries than graduates of all other German business schools three years after graduation. In a European comparison, their salaries are in second place, and they rank in third place worldwide. The employment rate three months after graduation is 100 percent.
Prof. Dr. Stephan Stubner, HHL Rector comments,
"Being ranked among the world's top 20 business schools confirms our goal of providing a first-class education and proves the high quality that our students bring to their workplace."
As the first business school in the German-speaking world, HHL was founded by entrepreneurs in 1898 as the Commercial College of Leipzig. Since then, HHL has always been a pioneer in the world of academia. It was the first German business school to receive an international AACSB accreditation as a seal of approval and one of the first to establish a Chair of Business Ethics. With the first university-level part-time master's program, HHL is helping to reconcile work and family life. HHL's goal is to train efficient and responsible managers with an entrepreneurial mindset.
On October 8, the school will celebrate its reestablishment 30 years ago, grounded in the change of the political system that was occurring in Germany at the time. Press representatives are cordially invited! The Prime Minister of Saxony and the Mayor of the City of Leipzig will deliver addresses to mark the occasion.
Contact : E.Echterhoff@hhl.de; Tel: +49 341 98 51 614
View original content:
SOURCE HHL Leipzig Graduate School of Management
|
https://www.whsv.com/prnewswire/2022/09/12/financial-times-leipzig-has-one-20-best-business-schools-world/
| 2022-09-12T14:14:05Z
|
Meet the most exciting emerging culinary talent in the U.S. today—11 chefs and a restaurant in Nashville whose food is highly personal, unapologetic, and extremely fun.
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Dotdash Meredith's FOOD & WINE announces today its highly anticipated list of America's Best New Chefs of 2022, spotlighting the 11 most talented up-and-coming chefs reinventing restaurant culture with vibrant and innovative new concepts that are deeply personal, reflecting their social and cultural influences. This year, FOOD & WINE introduces a new accolade, naming Locust of Nashville its Restaurant of the Year. An in-depth story on Locust and its chef, Trevor Moran, and profiles of the 2022 Best New Chefs, along with their favorite spots to eat and drink in the cities they call home, are featured now online here: Best New Chefs and Restaurant of the Year, as well as in the October issue of FOOD & WINE, on newsstands September 23.
"We welcome the 2022 class of Best New Chefs to a prestigious community of more than 354 chefs and leaders, including luminaries like Daniel Boulud, Nancy Silverton, Kwame Onwuachi, and David Chang," said FOOD & WINE Editor in Chief Hunter Lewis. "The 34th class of FOOD & WINE Best New Chefs is modernizing the hospitality industry, and, now more than ever, we're honoring up-and-coming chefs who are as passionate about cultivating more respectful kitchen cultures as they are about their talent at the stove. Through their artistry and talent, these amazing chefs are reframing the dining experience."
FOOD & WINE BEST NEW CHEFS IN AMERICA 2022
Warda Bouguettaya, Warda Pâtisserie, Detroit
Damarr Brown, Virtue, Chicago
Ana Castro, Lengua Madre, New Orleans
Calvin Eng, Bonnie's, Brooklyn
Tim Flores & Genie Kwon, Kasama, Chicago
Melissa Miranda, Musang, Seattle
Justin Pichetrungsi, Anajak Thai, Los Angeles
Emily Riddell, Machine Shop Boulangerie, Philadelphia
Rob Rubba, Oyster Oyster, Washington, D.C.
Caroline Schiff, Gage & Tollner, Brooklyn
FOOD & WINE chooses the Best New Chefs after a monthslong selection process. Chefs who have been in charge of a kitchen or pastry program for five years or less are eligible. The process begins with F&W editors soliciting and vetting nominations from food writers, cookbook authors, Best New Chef alums, and other trusted experts around the country. Then, Restaurant Editor Khushbu Shah travels the country. This year, she visited 24 cities in three months, dining out in dozens of restaurants in search of the most promising and dynamic chefs right now. For more information about the selection and vetting process, please visit here.
Shah wrote in the Best New Chefs feature story: "We've all heard the stories: the endless stream of pivoting, closing, restructuring, reopening, and reacting to labor shortages, supply chain disruptions, and perpetually shifting local laws, all in the midst of an ongoing pandemic. We talk a lot about how resilient restaurant people are. But this year, above all, it seemed to me that restaurants began to find a new kind of freedom in the midst of all the turmoil and trouble: when they stopped playing by everyone else's rules and started writing their own … This year's class of Food & Wine Best New Chefs embodies this movement, delivering flavor, joy, and wonder on their own terms."
Shah, who also selected Locust as the Restaurant of the Year, says: "Locust is fully, uncompromisingly, and unapologetically itself—which is exactly what makes it so playful and brilliant."
FOOD & WINE celebrates the 2022 Best New Chefs this evening at CITY WINERY in New York City, featuring FOOD & WINE alumni Best New Chefs CHRIS SHEPHERD, SOUTHERN SMOKE FOUNDATION [2013 BNC]; ANGEL BARRETO, CHEF/PARTNER, ANJU [2021 BNC]; and PAOLA VELEZ, COFOUNDER, BAKERS AGAINST RACISM [2021 BNC]. To support the new class, FOOD & WINE will kick off the celebration with the Best New Chef Mentorship Program, which empowers new BNCs to grow personally and professionally in their careers.
Sponsors for the 2022 FOOD & WINE Best New Chefs event are Hestan Culinary, Santa Margherita, Santa Teresa 1796, and S.Pellegrino®. YETI sponsors the Best New Chef Mentorship Program.
FOOD & WINE is the ultimate authority on the best of what's new in food, drink, travel, design, and entertaining. FOOD & WINE has an extensive social media following on Facebook, Twitter, Instagram, Pinterest, and YouTube. FOOD & WINE includes a magazine in print and digital; a website, foodandwine.com; a books division; plus newsletters, events, and more. At FOOD & WINE, we inspire and empower our wine- and food-obsessed community to eat, drink, entertain, and travel better—every day and everywhere. FOOD & WINE is part of the Dotdash Meredith publishing family.
View original content to download multimedia:
SOURCE Dotdash Meredith
|
https://www.whsv.com/prnewswire/2022/09/12/food-amp-wine-announces-2022-best-new-chefs-america-its-restaurant-year/
| 2022-09-12T14:14:11Z
|
RICHARDSON, Texas, Sept. 12, 2022 /PRNewswire/ -- Fossil Group, Inc. (NASDAQ: FOSL) (the "Company" or "Fossil"), a global design, marketing, distribution, and innovation company, today announced that Lisa Marie Pillette has joined the Company as Senior Vice President and Chief Marketing Officer.
Lisa brings extensive marketing and brand expertise to Fossil from Lacoste, Ralph Lauren, and Levi Strauss. She most recently served as Chief Marketing Officer for direct-to-consumer brand Casper. Her successful relaunch of the Casper brand earned her acclaim as a 2021 Brand Innovators "Top 100 Women in Brand Marketing" and 2021 CMO Award for "Creativity & Storytelling."
"Lisa has tremendous depth and breadth of marketing experience with iconic brands, an innovative lens on what marketing of the future looks like, and a compelling track record of delivering insight-led solutions," said Holly Briedis, Executive Vice President and Chief Digital Officer. "Pairing her distinctive expertise with our global digital capabilities allows us to think holistically about the consumer experience."
In her role, Lisa will lead the Company's global marketing and center of excellence capabilities, including marketing strategy and innovation, CRM, creative and content operations, and go-to-market readiness.
"I am excited to join a company with such great brand heritage. Since its inception, Fossil has had a strong focus on innovation and craftsmanship and to be given the opportunity to tell these stories and steward such meaningful brands is a marketer's dream," said Ms. Pillette.
In addition to her professional work, Lisa is an active mentor and advisor. She serves on the boards of TRIPTK, a brand transformation group owned by Havas, and Best Pets, and she is also a member and mentor for Chief, a membership network focused on female executives, and for the New York Chapter of Women 50/50 on Boards.
About Fossil Group, Inc.
Fossil Group, Inc. is a global design, marketing, distribution and innovation company specializing in lifestyle accessories. Under a diverse portfolio of owned and licensed brands, our offerings include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. We are committed to delivering the best in design and innovation across our owned brands, Fossil, Michele, Relic, Skagen and Zodiac, and licensed brands, Armani Exchange, Diesel, DKNY, Emporio Armani, Kate Spade New York, Michael Kors, PUMA and Tory Burch. We bring each brand story to life through an extensive distribution network across numerous geographies, categories and channels. Certain press releases and SEC filing information concerning the Company is also available at www.fossilgroup.com.
©2022 Fossil Group | All rights reserved
View original content to download multimedia:
SOURCE Fossil Group, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/fossil-group-inc-announces-appointment-lisa-marie-pillette-chief-marketing-officer/
| 2022-09-12T14:14:18Z
|
Transportation Industry Sees Greatest Increase in Scale of Higher Burnout Risk
PLEASANTON, Calif. and ORLANDO, Fla., Sept. 12, 2022 /PRNewswire/ -- Workday (NASDAQ:WDAY), a leader in enterprise cloud applications for finance and human resources, today published a new report – Addressing Burnout Risk in 2022 – powered by employee engagement solution Workday Peakon Employee Voice. The report finds that, of the 10 industries tracked year-over-year, frontline industries such as transportation, healthcare, and government demonstrated increases in the levels of higher burnout risk, with the transportation industry showing the steepest rise of 16% since 2021. In addition, of the 10 geographies tracked year-over-year, the UK has become the country with the highest proportion of organizations (41%) in the higher burnout risk category. Meanwhile, the proportion of U.S.-headquartered companies with higher burnout risk remained at 17%.
The report, launched at Workday Rising, the company's annual customer conference, measures how burnout risk has evolved since 2021 across different industries and geographies, based on an analysis of de-identified employee survey data from 1.5 million employees from more than 600 companies around the world. Burnout risk is assessed using employee survey scores relating to connectedness, energy levels, and fulfillment, and then categorized as higher, medium, or lower risk.
Burnout Risk by Industry
The study found that the majority of surveyed industries saw greater or sustained levels of higher burnout risk in 2022, compared to 2021. Industries that operated on the front lines of the pandemic, such as transportation, government, and healthcare, saw the steepest increases year-over-year, whereas manufacturing, professional and business services, and financial services saw reduced levels of higher burnout risk.
- Increasing Risk
- Holding Steady
- Decreasing Risk
Burnout Risk by Geography
The report found global variation among the 10 geographies tracked year-over-year, with six seeing either increased or sustained levels of higher burnout risk, and four showing improvements.
- Increasing Risk
- Holding Steady
- Decreasing Risk
The issue of employee burnout is increasingly prevalent, with a 2021 survey, conducted by the American Psychological Association, finding that three in five employees reported negative impacts of work-related stress. However, as the Workday report explores, there are key actions employers can take, powered by intelligent listening, to help mitigate the risk of employee burnout. These include:
- Cultivating a more compassionate culture by building transparency around the issue of wellbeing and strengthening workplace policies to support it.
- Enabling people leaders to solve problems by encouraging open dialogues on workload, workplace fulfillment, and the impact of their contributions.
- Giving employees a shared sense of purpose by clearly articulating the organization's strategy and how new ideas speak to that vision.
Comment On The News
"The increasing levels of higher burnout risk in frontline industries like government, healthcare, and transportation reflects an urgent need to address the energy, connectedness, and fulfillment levels of employees," said Phil Chambers, general manager, of Workday Peakon Employee Voice, Workday. "From the Great Resignation to the more recent wave of quiet quitting, it is vital that leaders understand employees' evolving needs and take positive action to help keep them engaged, motivated, and meet them in the moment."
For more information:
- Download the report, "Addressing Burnout Risk in 2022"
- Read the blog, "How Rising Rates of Burnout Risk Are Impacting Different Industries in 2022"
About Workday
Workday is a leading provider of enterprise cloud applications for finance and human resources, helping customers adapt and thrive in a changing world. Workday applications for financial management, human resources, planning, spend management, and analytics have been adopted by thousands of organizations around the world and across industries – from medium-sized businesses to more than 50% of the Fortune 500. For more information about Workday, visit workday.com.
© 2022 Workday, Inc. All rights reserved. Workday and the Workday logo are registered trademarks of Workday, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.
Forward Looking Statements:
This press release contains forward-looking statements including, among other things, statements regarding Workday's plans, beliefs, and expectations. These forward-looking statements are based only on currently available information and our current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties, assumptions, and changes in circumstances that are difficult to predict and many of which are outside of our control. If the risks materialize, assumptions prove incorrect, or we experience unexpected changes in circumstances, actual results could differ materially from the results implied by these forward-looking statements, and therefore you should not rely on any forward-looking statements. Risks include, but are not limited to, risks described in our filings with the Securities and Exchange Commission ("SEC"), including our Form 10-Q for the fiscal quarter ended July 31, 2022, and our future reports that we may file with the SEC from time to time, which could cause actual results to vary from expectations. Workday assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.
Any unreleased services, features, or functions referenced in this document, our website, or other press releases or public statements that are not currently available are subject to change at Workday's discretion and may not be delivered as planned or at all. Customers who purchase Workday services should make their purchase decisions based upon services, features, and functions that are currently available.
View original content to download multimedia:
SOURCE Workday Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/frontline-industries-certain-geographies-show-increased-levels-employee-burnout-risk-workday-report-finds/
| 2022-09-12T14:14:25Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Future FinTech Group Inc. (NASDAQ: FTFT) ("hereinafter referred to as "Future FinTech", "FTFT" or "the Company"), a blockchain application technology developer and fintech service provider, announced that Future FinTech Labs ("FTFT Labs"), a wholly subsidiary of the Company, has teamed up with Currency Cloud Inc. ("Currencycloud"), a subsidiary of Visa and a global payment platform that is registered with FinCen and is licensed for money transmission in various states in the US, to launch the remittance app Tempo to offer US-based immigrants and others a streamlined, secure and cost-effective way to send money from the US to North America (Canada and Mexico), Europe (Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, Portugal, Spain, Sweden and the United Kingdom), Australia, India and the Philippines.
By working with Currencycloud and other service providers, FTFT Labs can provide its customers with a multicurrency digital wallet that makes sending money to the aforementioned countries easier and more cost-effective than many other remittance services who charge high fees per transfer. Most importantly for FTFT Labs, the Tempo app is a remittance service that its users can trust, with features that make moving money seamless and with in-app customer support at their fingertips. Tempo's conversion tool means users can remit payment to foreign accounts following currency conversion and hold foreign currencies for users' convenience; Tempo's Funds Feature allows users to easily add funds to the digital wallet.
By continuously adding new features to the app, FTFT Labs aims to bring the most innovative, easy-to-use remittance services to the fingertips of an often overlooked market: US immigrants. To learn more about the Tempo app, please visit http://ftfttempo.com.
Mr. Sean Liu, CEO of FTFT Labs, said of the launch, "Tempo represents an easy, fast and secure way to transfer money cross-border. Working with Currencycloud and using the breadth of its services, it allows us to offer our customers a seamless product from start to finish. We are confident we are making remittance a seamless process for our end users."
Lewis Nurcombe, Vice President Sales, Currencycloud commented, "Migrants in the US should be able to send money cross-border without friction and without prohibitive costs. A fintech company like Future FinTech Labs understands the needs of working people wanting to send money to family and friends, and as such is successfully re-imagining how money flows for this huge market."
The Tempo app is available for download from the Apple App Store and Google Play.
About Future FinTech Group Inc.
Future FinTech Group Inc. is a blockchain application technology developer and fintech service provider incorporated in Florida. The Company's operations include a blockchain-based online shopping mall platform, Chain Cloud Mall ("CCM"), supply chain financing services, assets management, and cryptocurrency market data services. The Company is also engaged in the development of blockchain based e-Commerce technology and cryptocurrency mining, cryptocurrency investment management as well as financial service technology businesses. For more information, please visit http:/www.ftft.com/.
About Currencycloud
Banks, Fintechs and businesses everywhere can make bigger, better, bolder leaps with Currencycloud, a Visa solution. Currencycloud gives businesses the capability to move money across borders, and transact globally in multiple currencies, fast. Experts at what they do, their technology makes it easy for clients to embrace digital wallets, and to embed finance into the core of their business - no matter what industry they're in.
Since 2012, Currencycloud has processed more than $100bn to over 180 countries, working with banks, financial institutions and Fintechs around the world, including Starling Bank, Revolut, Penta and Lunar. Based in London with offices in New York, Amsterdam, Cardiff, and Singapore, Currencycloud works with partners including Visa, Dwolla, GPS and Mambu to deliver simple, clear cross-border infrastructure solutions for clients. They are regulated in the UK, Canada, US, the EU and Australia.
Safe Harbor Statement
Certain of the statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause the actual results, performance, capital, ownership or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions of the future.
All written or oral forward-looking statements attributable to the Company are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2021 and other reports and filings of the Company with SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements otherwise are made.
View original content to download multimedia:
SOURCE Future FinTech Group Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/ftfts-future-fintech-labs-partners-with-currencycloud-launch-low-cost-remittance-app-tempo/
| 2022-09-12T14:14:32Z
|
New initiative will alleviate pressures of a tight labor market by bringing resources directly to job seekers through in-person and virtual events across the U.S.
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Goodwill Industries International announces its partnership with Indeed, a leading global hiring platform, as they launch their Ready to Work program, a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 12 to October 8, 2022. Through Ready to Work, Indeed aims to connect 50,000 job seekers with employers looking to hire talent right now, supporting the company's goal of helping 100 million people get jobs globally by 2030, including 30 million facing barriers.
Ready to Work brings Indeed's full suite of resources directly to job seekers with virtual and in-person support, tools and tips to build the skills they need on their journey to better work. In addition to helping secure interviews for job seekers, the series of events will provide thousands of people with resources and guidance for a successful job search. This includes assistance with hiring, training and coaching to help make the job search simpler and faster.
"Job seekers and career advancers win when Indeed and Goodwill work together with employers," said Wendi Copeland, Chief Partnerships Officer of Goodwill Industries International. "Through the Ready to Work Program, we can connect local talent to some of the 11 million available jobs in the U.S. We are committed to helping everyone access the opportunity to thrive."
The Ready to Work program brings together a coalition of businesses, nonprofits and civic partners dedicated to providing talent with the resources they need for a successful job search. Indeed, along with Glassdoor, Lyft, Goodwill, Dunkin, Rework America, Care.com, and NBA teams, Detroit Pistons and Chicago Bulls, will roll out a series of activations throughout the weeks' programming in Chicago, Detroit, Washington D.C., Los Angeles, and Dallas-Fort Worth. More information on the Ready to Work coalition of brand partners and their commitments can be found here.
"The last couple of years have brought new challenges and exacerbated existing ones for so many job seekers. This program is important because not only is it impacting entire communities, but deserving individuals who have the desire and the potential to do great work," said Abbey Carlton, Indeed VP of Social Impact. "The support from our partners will allow the Ready to Work initiative to reach as many job seekers as possible through both in-person and virtual events that will connect thousands of people with companies who need great talent now."
This program will provide thousands of job seekers with the support and guidance they need for a successful job search and work towards Indeed's goal of helping 100 million people get hired. Job seekers can visit indeed.com/readytowork for more details on the program and events in their area.
ABOUT GOODWILL INDUSTRIES INTERNATIONAL
Goodwill Industries International is a network of 155 community-based, autonomous organizations in the U.S. and Canada with a presence in 12 other countries. Goodwill industries International is a 501(c)(3) nonprofit that provides people with opportunities and support to empower themselves and thrive through training, development and employment. Local Goodwill organizations provide career navigation, skills training, job placement and other community-based services funded in part by selling donated clothing and household items in nearly 3,300 stores and at ShopGoodwill.com®.
About Indeed
More people find jobs on Indeed than anywhere else. Indeed is the #1 job site in the world and allows jobseekers to search millions of jobs on the web or mobile in over 60 countries and 28 languages. More than 250 million people each month search for jobs, post resumes, and research companies on Indeed. For more information, visit indeed.com.
View original content to download multimedia:
SOURCE Goodwill Industries International
|
https://www.whsv.com/prnewswire/2022/09/12/goodwill-indeed-announce-ready-work-program-connect-50000-job-seekers-with-employers-looking-hire-now/
| 2022-09-12T14:14:40Z
|
MOUNTAIN VIEW, Calif. and RESTON, Va., Sept. 12, 2022 /PRNewswire/ -- Google LLC today announced the completion of its acquisition of Mandiant, Inc. (NASDAQ: MNDT), a recognized leader in dynamic cyber defense, threat intelligence and incident response services. Mandiant will join Google Cloud and retain the Mandiant brand.
Google and Mandiant share a long commitment to industry-leading security. Over the past two decades, Google has innovated to build some of the most secure computing systems in the world. Google Cloud customers and partners benefit from these pioneering security capabilities including world-class threat intelligence, zero trust architecture, and planet-scale analytics for security operations. Mandiant, which is known for delivering unparalleled frontline expertise and industry-leading threat intelligence, is a proven first responder to the world's largest cybersecurity incidents. Mandiant's services, delivered by their team of security and intelligence individuals spread across 22 countries, are widely recognized for helping top enterprises and organizations prepare for and react to cybersecurity incidents.
With this acquisition, Google Cloud and Mandiant will deliver an end-to-end security operations suite with even greater capabilities to support customers across their cloud and on-premise environments.
"The completion of this acquisition will enable us to deliver a comprehensive and best-in-class cybersecurity solution," said Thomas Kurian, CEO of Google Cloud. "We believe this acquisition creates incredible value for our customers and the security industry at large. Together, Google Cloud and Mandiant will help reinvent how organizations protect themselves, as well as detect and respond to threats."
Organizations today are facing cybersecurity challenges that have accelerated in frequency, severity and diversity, creating a global security imperative. Enterprises need to be able to detect and respond to malicious actors quickly, with actionable threat intelligence to continually protect their organizations against new attacks.
"Mandiant is driven by a mission to make every organization secure from cyber threats and confident in their readiness," said Kevin Mandia, CEO, Mandiant. "Combining our 18 years of threat intelligence and incident response experience with Google Cloud's security expertise presents an incredible opportunity to deliver with the speed and scale that the security industry needs."
Hear from others on the impact of this acquisition:
- "The power of stronger partnerships across the cybersecurity ecosystem is critical to driving value for clients and protecting industries around the globe. The combination of Google Cloud and Mandiant and their commitment to multi-cloud will further support increased collaboration, driving innovation across the cybersecurity industry and augmenting threat research capabilities. We look forward to working with them on this mission." - Paolo Dal Cin, Global Lead, Accenture Security
- "Google's acquisition of Mandiant, a leader in threat intelligence, security advisory, consulting and incident response services will allow Google Cloud to deliver an end-to-end security operations suite with even greater capabilities and services to support customers in their security transformation across cloud and on-premise environments." - Craig Robinson, Research VP, Security Services, IDC
- "Bringing together Mandiant and Google Cloud, two long-time cybersecurity leaders, will advance how companies identify and defend against threats. We look forward to the impact of this acquisition, both for the security industry and the protection of our customers." - Andy Schworer, Director, Cyber Defense Engineering, Uber
For more information, see the Google Cloud blog and Mandiant blog.
About Google
Google's mission is to organize the world's information and make it universally accessible and useful. Through products and platforms like Search, Maps, Gmail, Android, Google Play, Chrome and YouTube, Google plays a meaningful role in the daily lives of billions of people and has become one of the most widely-known companies in the world. Google is a subsidiary of Alphabet Inc.
About Google Cloud
Google Cloud accelerates every organization's ability to digitally transform its business. We deliver enterprise-grade solutions that leverage Google's cutting-edge technology – all on the cleanest cloud in the industry. Customers in more than 200 countries and territories turn to Google Cloud as their trusted partner to enable growth and solve their most critical business problems.
About Mandiant, Inc.
Since 2004, Mandiant has been a trusted partner to security-conscious organizations. Effective security is based on the right combination of expertise, intelligence, and adaptive technology, and the Mandiant Advantage SaaS platform scales decades of frontline experience and industry-leading threat intelligence to deliver a range of dynamic cyber defense solutions. Mandiant's approach helps organizations develop more effective and efficient cyber security programs and instills confidence in their readiness to defend against and respond to cyber threats.
Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including but not limited to the ability of Google to successfully integrate Mandiant's operations, product lines and technology; the ability of Google to implement its plans, forecasts and other expectations with respect to Mandiant's business after the completion of the transaction and realize additional opportunities for growth and innovation; and the other risks and important factors contained and identified in Alphabet's filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from the forward-looking statements. The forward-looking statements included in this release are made only as of the date hereof. Google and Alphabet undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances.
View original content:
SOURCE Google Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/google-completes-acquisition-mandiant/
| 2022-09-12T14:14:49Z
|
NEW YORK, Sept. 12, 2022 /PRNewswire/ -- Igneo Infrastructure Partners, a global infrastructure investment manager with more than US$15 billion in assets, has entered into an agreement to acquire a 100 percent equity share of US Signal Company, LLC (US Signal), a leading data center and network solutions provider. The transaction is expected to close in the fourth quarter of this year subject to customary regulatory approvals.
Based in Grand Rapids, Mich., US Signal provides network, data center, connectivity, cloud hosting, colocation, data protection, and disaster recovery services to regional enterprise customers and large national telecommunications carriers. The company operates a 9,500 route mile fiber network and eight data centers across nine states in the upper Midwest. It has approximately 185 employees.
"Over the past two decades, US Signal has built an outstanding reputation for its client service and responsiveness, attracting customers in the healthcare, finance and telecommunications sectors that require a high degree of data security and reliability," said John Ma, partner and co-head of Igneo in North America. "We believe US Signal has substantial growth opportunities and is a great fit for our investment portfolio, which focuses on high-quality, mid-market, core infrastructure businesses and geographic and sector diversification."
US Signal represents Igneo's first investment in the US telecommunications sector and the fourth asset in North America. During the last three years, Igneo has invested more than US$1.5 billion of capital in Terra-Gen, Rialto Bioenergy Facility and Patriot Rail, which recently announced the acquisition of Pioneer Lines.
Richard Postma, chairman and CEO of US Signal, said, "Igneo is an experienced investor that is positioned to support and expand US Signal's data center presence and fiber network infrastructure to serve our regional enterprise customers. I am confident that the partnership with Igneo will enhance the US Signal experience for existing customers and allow the company to deliver this high standard of excellence to additional customers across our expanding footprint."
US Signal was advised by Bank Street and Dickinson Wright. Igneo was advised by KeyBanc Captial Markets and Mayer Brown.
About US Signal
US Signal, founded in 2001, is a leading IT solutions provider, offering connectivity, cloud hosting, colocation, data protection, and disaster recovery services – powered by its wholly owned and operated robust fiber network. US Signal also helps customers optimize their IT resources through the provision of managed and professional services. For more information, visit www.ussignal.com.
About Igneo Infrastructure Partners
Igneo Infrastructure Partners is an autonomous investment team in the First Sentier Investors Group. It invests in high-quality, mid-market infrastructure companies in the UK, Europe, North America, Australia and New Zealand. Operating since 1994, the team works closely with portfolio companies to create long-term sustainable value through innovation and proactive asset management. Igneo manages in excess of US$15 billion in assets as at June 30, 2022 on behalf of more than 120 institutional investors around the world. For more information, visit igneoip.com.
Media inquiries
Newton Park PR:
Margaret Kirch Cohen/Richard Chimberg
E: margaret@newtonparkpr.com
E: rich@newtonparkpr.com
T: +1 847-507-2229
T: +1 617-312-4281
Important information
This press release is intended for information only, aimed solely at the media and should not be further distributed to individual and/or corporate investors, and financial advisers and/or distributors. The information included within this document and any supplemental documentation provided should not be copied, reproduced or redistributed without the prior written consent of First Sentier Investors.
View original content:
SOURCE Igneo Infrastructure Partners
|
https://www.whsv.com/prnewswire/2022/09/12/igneo-infrastructure-partners-acquire-us-signal/
| 2022-09-12T14:14:58Z
|
IKEA Family loyalty members now have exclusive access to high-quality and affordable SunPower home solar system packages
CONSHOHOCKEN, Pa., Sept. 12, 2022 /PRNewswire/ -- To continue its ambition to make sustainable living more accessible and affordable, IKEA U.S. has teamed up with SunPower Corp. (NASDAQ: SPWR), a leading solar technology and energy services provider, to make home solar energy solutions easier to access in select California locations beginning today. Members of the IKEA Family customer loyalty program will be able to purchase home solar solutions, available through SunPower®, to generate and store their own renewable energy and live more sustainably.
"Our vision is to create a better everyday life for the many people, and we believe those lives are truly better when they are lived sustainably," said Javier Quiñones, CEO & Chief Sustainability Officer, IKEA U.S. "We are delighted to join the list of global IKEA markets that provide access to home solar and energy solutions, and we will continue to collaborate with our partners to showcase offerings that have a positive impact on people and our planet."
Customers can learn more about the home solar offering in IKEA California stores and online, and then work directly with SunPower to access solar energy packages developed specifically for IKEA Family loyalty members. The four packages include various combinations of solar, energy storage and electric vehicle (EV) charging. Each of the offerings include a SunPower Equinox® Solar System; access to the mySunPower® app to monitor energy production or manage storage use; and SunPower's Complete Confidence Warranty1 consisting of a 25-year limited warranty for panels, including coverage for power, product and labor, and a 10-year limited warranty for the monitoring device and storage system.
With SunPower, making the switch to renewable energy at home can be completed in five simple steps:
- Assessment: A SunPower Solar Advisor will assess the customer's electricity bills, energy goals, and roof configuration so they can design a custom solar package to meet their needs.
- Quote: SunPower will provide a proposed system design based on the customer's needs as well as financial products and incentives that may be available to them.
- Site Verification: A SunPower installation professional will visit the home to assess the roof and ensure the system is designed to optimize solar production. Updates will be made to the final proposal to reflect any changes needed.
- Installation: Once the proposal is signed, SunPower will work with the customer from installation to activation.
- Enjoy the Sun: Sit back and enjoy the benefits of having solar.
"To power more homes with clean, reliable and affordable energy, we need to make the process of switching to renewables convenient and easy," said Peter Faricy, SunPower CEO. "We're proud IKEA selected SunPower to bring the many benefits of solar to its customers, and we look forward to making their energy transition seamless. There has truly never been a better time to go solar."
Interested IKEA Family members in select California locations may visit IKEA-USA.com/solar where they will be prompted to sign into their IKEA Family account. They will then be redirected to the SunPower website and instructed to enter additional information to start the assessment process. Additionally, customers may visit any of the eight IKEA California stores (Emeryville, East Palo Alto, West Sacramento, Burbank, Carson, Covina, Costa Mesa and San Diego) to get more information through the home solar kiosk located in the IKEA Sustainability Shop.
In addition to the select California locations in the U.S., IKEA makes home solar and energy services accessible in Australia and 10 markets in Europe including Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Poland and Portugal. The company has a robust renewable energy portfolio2, including rooftop solar arrays on 90 percent of IKEA U.S. locations. Ingka Group, a strategic partner in the IKEA franchise system, has invested in two solar parks with 403-megawatt capacity in Utah and Texas and two wind farms producing 859 million kWh of energy in Illinois and Texas.
At IKEA, the vision is to create a better everyday life for the many people by offering well-designed, functional and affordable, high-quality home furnishing, produced with care for people and the environment. Ingka Group (Ingka Holding B.V. and its controlled entities) is one of 12 different groups of companies that own and operate IKEA retail under franchise agreements with Inter IKEA Systems B.V. Ingka Group has three business areas: IKEA Retail, Ingka Investments and Ingka Centres. Ingka Group is a strategic partner in the IKEA franchise system, operating 389 IKEA stores in 32 countries – including 51 retail locations in the U.S.
For more information on IKEA U.S., see IKEA-USA.com, @IKEAUSANews, @IKEAUSA or IKEAUSA on Facebook, YouTube, Instagram and Pinterest.
SunPower (NASDAQ: SPWR) is a leading solar, storage and energy services provider in North America. SunPower offers the only solar + storage solution designed and warranted by one company that gives customers control over electricity consumption and resiliency during power outages while providing cost savings to homeowners. For more information, visit www.sunpower.com.
SunPower Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding anticipated cost savings and business plans. These forward-looking statements are based on our current assumptions, expectations, and beliefs and involve substantial risks and uncertainties that may cause results to materially differ from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory changes and the availability of economic incentives promoting use of solar energy, fluctuations or declines in the performance of our solar panels and other products and solutions, and challenges managing our strategic relationships and partnerships, including our ability to successfully manage collaboration and supplier relationships. A detailed discussion of these factors and other risks that affect our business is included in filings we make with the Securities and Exchange Commission (SEC) from time to time, including our most recent reports on Form 10-K and Form 10-Q, particularly under the heading "Risk Factors." Copies of these filings are available online from the SEC or on the SEC Filings section of our Investor Relations website at investors.sunpowercorp.com. All forward-looking statements in this press release are based on information currently available to us, and we assume no obligation to update these forward-looking statements in light of new information or future events.
1 For more information about SunPower's warranty, visit https://us.sunpower.com/home-solar-system-warranty.
2 Find more details about renewable energy investments in the IKEA Sustainability Report FY21.
View original content to download multimedia:
SOURCE IKEA
|
https://www.whsv.com/prnewswire/2022/09/12/ikea-us-sunpower-launch-home-solar-offering-california/
| 2022-09-12T14:15:04Z
|
The panel will generate ideas and inspiration to build the foundational elements needed to make genomic health equitable, informed, and accountable
SAN DIEGO, Sept. 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will convene a panel of leading visionaries, titled "Architecting Health's Radically New Infrastructure," as part of its inaugural Illumina Genomics Forum being held in San Diego from September 28 through October 1. This main-stage session, taking place on Friday, September 30, will feature renowned experts addressing the cornerstone challenges and opportunities facing the health industry, including genomics literacy, equity, public health, and pathogen preparedness.
Moderated by Joao Bosco Oliveira, head of Genomics at Albert Einstein Hospital, the panel will include:
- Abasi Ene-Obong, Founder and CEO, 54Gene
- Stacey Gabriel, Chief Genomics Officer, Broad Institute
- Scott Gottlieb, Former FDA Commissioner
- Chris Wigley, CEO, Genomics England
"We are deeply humbled and absolutely thrilled to have these global leaders from across the genomics and health care ecosystem participating in our inaugural Illumina Genomics Forum," said Kathryne Reeves, chief marketing officer of Illumina. "Their collective vision for making genomic health a more inclusive, accessible standard of care is an inspiration to us all, and I look forward to the insights, perspectives, and transformative ideas they will share at the forum."
Illumina previously announced that former US President Barack Obama will headline the forum in a fireside chat on the evening of Wednesday, September 28. Twelve years after the passage of the Affordable Care Act, Obama will discuss the continued need for equity, accessibility, and smarter health care to improve the human condition. Then, on September 30, Bill Gates, co-chair of the Bill & Melinda Gates Foundation, will deliver a keynote address on the remarkable potential of genomics to change the trajectory of global health.
Other IGF key themes include:
- How genomic technology is driving more informed, proactive, and personalized patient diagnosis and treatment in clinics
- Ways in which whole-genome sequencing is revolutionizing patient care
- The role of genomics in supporting health care's quadruple aim to improve population health, reduce costs, enhance the patient experience, and improve provider satisfaction
Illumina Genomics Forum will take place in San Diego from September 28 through October 1. For more information and to register for the conference, go to illuminagenomicsforum.com.
lllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Matt Bianco
619-490-6414
PR@illumina.com
View original content to download multimedia:
SOURCE Illumina, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/illumina-genomics-forum-convene-leading-visionaries-explore-architecting-healths-radically-new-infrastructure/
| 2022-09-12T14:15:11Z
|
Thirty creatives from across the U.S. were celebrated and awarded to pursue aspirational goals in food, fashion, art, music and dance industries
EL PASO, Texas, Sept. 12, 2022 /PRNewswire/ -- Jarritos, the authentic and flavorful Mexican soda brand, today announced the five grand prize winners each to receive $10,000 and an additional top 25 finalists to each receive $1,000 for their participation in the JarriTODOS Artist Grant Contest. The contest challenged competitors to showcase their art and creative work in visual art, dance, fashion, food and music for the chance to win a grant to help them pursue their artistic goals.
"I'm absolutely blown away by all of the talent and effort placed into these innovative food concepts and the finalists' passion for cooking," said celebrity chef and Jarritos Food Judge, Pati Jinich. "It's inspiring to see the next generation of chefs, bakers and food enthusiasts come from diverse backgrounds and experience."
A panel of arts and entertainment professionals selected a top-scoring winner and five semifinalists per category. Judges included Courtney Plummer, Contemporary Art Dealer, Karla Martinez de Salas, editor of Vogue Mexico/Latin America, JoJo Gomez, professional dancer/choreographer, Pati Jinich, celebrity chef and host of La Frontera, and Javier Farfan, music, entertainment, and cultural marketing consultant.
"The Jarritodos Artist Grant Contest was created to help amplify the artists and creatives whose work impacts our communities on a daily basis," said Eric Delamare, marketing director for Jarritos. "We are honored to be a small part of supporting diverse artists who don't always have access, networks or funding to pursue their dreams and ambitions."
The five grand prize winners to receive $10,000 artist grants are as follows:
- ART: Calvin Clausell from Los Angeles, California
- DANCE: Lenai A Wilkerson from Cincinnati, Ohio
- FASHION: Nicole Bisono from New York City, New York
- FOOD: Mason Sanchez & Raffi Frensley from Bowling Green, Kentucky
- MUSIC: Andres Mejia from Baltimore, Maryland
The top 25 finalists to receive $1,000 artist grants are as follows:
- Keturah Benson from Atlanta, Georgia
- Eustace Mamba from Philadelphia, Pennsylvania
- Ruben Esquivel II from Austin, Texas
- Christian Pardo Cardenas & Raul Cardenas from El Paso, Texas
- Larissa Akhmetova from Denver, Colorado
- Rob Rich from Panorama City, California
- Julian Ray Carmolinga from Berwyn Illinois
- Derek Sisouphone from Los Angeles, California
- Thom Kitt from Burbank, California
- Naomi Rivera from Bakersfield, California
- Anabella Bergero from Miami, Florida
- Fanny Mena from Los Angeles, California
- Derrick C Perkins II from Dallas, Texas
- Adan Avila from Houston, Texas
- Nico Perez from Austin, Texas
- Gina Lawrence Grandjean from Las Cruces, New Mexico
- Juan J. Sanjuan III from Huntington Park, California
- Pablo Rodriguez from Crafton Hills, California
- Johnny Chanthavong from Boston, Massachusetts
- Tessa Flack from Los Angeles, California
- David Elias Delgado from El Paso, Texas
- Beatrice Roberts and Jared Burkhalter from Deland, Florida
- Isai Morales from Dayton, Ohio
- Bran Movay from Dallas, Texas
- Jonathan Romo from El Paso, Texas
From July 11 - August 10, the JarriTODOS Artist Grant Contest opened for video submissions from artists and creatives across the U.S. who were interested in showcasing their artistic talents for the chance to move forward in the contest. Eligible entries advanced to fan voting August 12 - August 20. Due to irregularities and potential fraudulent activity in the fan voting process, all eligible submissions moved forward for an internal process review in which the top 25 submissions per each visual art, dance, fashion, food and music category were moved forward in judge deliberation from August 23 - September 2.
Created in 1950, Jarritos are delicious fruit-flavored sodas from Mexico. Sold in iconic glass bottles throughout the U.S., the brand offers 13 unique flavors, all made with natural flavors and real sugar. Jarritos flavors are mandarin, tamarind, pineapple, fruit-punch, lime, grapefruit, strawberry, mango, guava, hibiscus, passion fruit, cola and watermelon. Each unique flavor represents a delicious slice of the brand's Mexican heritage. Jarritos is now distributed in 41 countries around the world. Find out more at www.Jarritos.com.
Press Release Contact:
Brianna Hernandez
brianna@apccollective.co
View original content to download multimedia:
SOURCE Jarritos
|
https://www.whsv.com/prnewswire/2022/09/12/jarritos-mexican-soda-announces-grand-prize-winners-top-finalists-jarritodos-75000-artist-grant-contest/
| 2022-09-12T14:15:18Z
|
GREELEY, Colo., Sept. 12, 2022 /PRNewswire/ -- JBS USA Food Company announced today that it has commenced a cash tender offer (the "Tender Offer") for any and all of the outstanding U.S.$350,000,000 aggregate principal amount of 6.500% Senior Notes due 2029 issued by JBS USA Lux S.A., JBS USA Food Company and JBS USA Finance, Inc. (the "Notes"). The Tender Offer is being made pursuant to an Offer to Purchase, dated September 12, 2022 (as may be amended or supplemented from time to time, the "Offer to Purchase") and the related Notice of Guaranteed Delivery (as it may be amended or supplemented from time to time, the "Notice of Guaranteed Delivery" and together with the Offer to Purchase, the "Offer Documents"), which set forth a more comprehensive description of the terms of the Tender Offer.
The Tender Offer is scheduled to expire at 5:00 p.m., New York City time, on September 20, 2022, unless extended by JBS USA Food Company (such time and date, as the same may be modified, the "Expiration Time"). Holders who (i) validly tender their Notes on or before the Expiration Time and do not validly withdraw on or before the Withdrawal Deadline (as defined below) or (ii) deliver a properly completed and duly executed Notice of Guaranteed Delivery and all of the other required documents on or before the Expiration Time and tender their Notes prior to the Guaranteed Delivery Date which is at 5:00 p.m., New York City time, on the second business day after the Expiration Time, and whose Notes are accepted for purchase by JBS USA Food Company, will receive the "Tender Offer Consideration" indicated in the table below. Accrued and unpaid interest on the Notes accepted for purchase (including those tendered through the guaranteed delivery procedure) from the most recent interest payment date of the Notes up to, but not including, the Settlement Date (as defined below) (the "Accrued Interest") will be paid in cash on the Settlement Date or the Guaranteed Delivery Settlement Date (as defined below), as applicable.
Certain information regarding the Notes and the terms of the Tender Offer is summarized in the table below.
JBS USA Food Company will purchase Notes that have been validly tendered by the Expiration Time and not validly withdrawn by the Withdrawal Deadline (other than Notes tendered in reliance upon the guaranteed delivery procedures) and that JBS USA Food Company chooses to accept for purchase, subject to all conditions to the Tender Offer having been satisfied or waived by JBS USA Food Company, expected to be within three business days following the Expiration Time, or as promptly as practicable thereafter (the "Settlement Date"). With respect to any Notes accepted for purchase pursuant to the guaranteed delivery procedures, the holders thereof will receive payment of the Tender Offer Consideration for such accepted Notes (to the extent that such Notes are not delivered prior to the Expiration Time) on the settlement date expected to be the third business days after the Expiration Time, or as promptly as practicable thereafter (the "Guaranteed Delivery Settlement Date"). Holders will be permitted to withdraw validly tendered Notes (i) at or prior to the earlier of (x) the Expiration Time and (y) in the event that the Tender Offer is extended, the tenth business day after commencement of the Tender Offer, and (ii) after the 60th business day after commencement of the Tender Offer if for any reason the Tender Offer has not been consummated within 60 business days after commencement, but not thereafter (such date in clause (i) or (ii), the "Withdrawal Deadline"). JBS USA Food Company has the right, in its sole discretion, to extend, amend or terminate the Tender Offer at any time, subject to applicable law.
JBS USA Food Company's obligation to accept for purchase, and to pay for, Notes validly tendered and not validly withdrawn pursuant to the Tender Offer is conditioned upon the satisfaction or, when applicable, waiver of certain conditions, which are more fully described in the Offer to Purchase, including, among others, a financing condition as described in the Offer to Purchase. In addition, subject to applicable law, JBS USA Food Company reserves the right, in its sole discretion, to (i) extend, terminate or withdraw the Tender Offer at any time or (ii) otherwise amend the Tender Offer in any respect at any time and from time to time. JBS USA Food Company further reserves the right, in its sole discretion, not to accept any tenders of Notes. JBS USA Food Company is making the Tender Offer only in those jurisdictions where it is legal to do so.
Barclays Capital Inc., BMO Capital Markets Corp., Mizuho Securities USA LLC, RBC Capital Markets, LLC and Truist Securities, Inc. are acting as dealer managers for the Tender Offer and can be contacted at their respective telephone numbers set forth on the back cover page of Offer to Purchase with questions regarding the Tender Offer.
The Offer Documents are available electronically at www.dfking.com/jbs-tenderoffer. Copies of the Offer Documents are also available to holders of Notes from D.F. King & Co., Inc., the information agent and the tender agent for the Tender Offer. Requests for copies of the Offer Documents should be directed to D.F. King at +1 (800) 967-7574 (toll free), +1 (212) 269-5550 (collect) or jbs@dfking.com.
None of the Offer Documents nor any related documents have been filed with the U.S. Securities and Exchange Commission, nor have any such documents been filed with or reviewed by any federal or state securities commission or regulatory authority of any country. No authority has passed upon the accuracy or adequacy of the Offer Documents or any related documents, and it is unlawful and may be a criminal offense to make any representation to the contrary.
The Tender Offer is being made solely on the terms and conditions set forth in the Offer Documents. Under no circumstances shall this press release constitute an offer to buy or the solicitation of an offer to sell the Notes or any other securities of JBS S.A. or any of its subsidiaries, including JBS USA Food Company. The Tender Offer is not being made to, nor will JBS USA Food Company accept tenders of Notes from, holders in any jurisdiction in which the Tender Offer or the acceptance thereof would not be in compliance with the securities of blue sky laws of such jurisdiction. No recommendation is made as to whether holders should tender their Notes. Holders should carefully read the Offer Documents because they contain important information, including the various terms and conditions of the Tender Offer.
Important Notice Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about the perspectives and expectations of JBS S.A. or any of its subsidiaries, including JBS USA Food Company, are forward-looking statements. The words "expect," "believe," "estimate," "intend," "plan" and similar expressions, when related to JBS S.A. and its subsidiaries and affiliates, indicate forward-looking statements. These statements reflect the current view of management and are subject to various risks and uncertainties. These statements are based on various assumptions and factors, including general economic, market, industry and operational factors. Any changes to these assumptions or factors may lead to practical results different from current expectations. Forward-looking statements relate only to the date they were made and none of JBS S.A. or any of its subsidiaries undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made.
About JBS USA Lux S.A.
JBS USA Lux S.A. is one of the world's largest producers of beef, pork, chicken and packaged food products. In terms of daily production capacity, JBS USA Lux S.A. is among the leading beef producers and the second-largest pork and chicken producer in the United States. In Australia, JBS USA Lux S.A. is the leading producer of beef, lamb and packaged foods. JBS USA Lux S.A. prepares, packages and delivers fresh, value-added and branded beef, pork, chicken, and lamb products to customers in more than 150 countries on six continents. JBS USA Lux S.A. is an indirect, wholly-owned subsidiary of JBS S.A., the largest protein company and the largest food company in the world in terms of net revenue.
CONTACT:
Diego Pirani
Treasurer JBS.USA@jbssa.com
+1 (970) 506-8117
View original content:
SOURCE JBS USA Food Company
|
https://www.whsv.com/prnewswire/2022/09/12/jbs-usa-food-company-announces-cash-tender-offer/
| 2022-09-12T14:15:24Z
|
IDC Financial Insights ranks top enterprises worldwide serving the financial services industry. This marks the eighth consecutive year Kasasa has earned recognition.
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Kasasa, an award-winning financial technology and marketing provider that partners exclusively with community banks and credit unions, announced it was ranked #87 on the 2022 IDC FinTech Rankings. The elite list features enterprise companies from around the globe serving multiple industries. This is the eighth time Kasasa has appeared on the prestigious list. To view the list in its entirety, please visit http://www.idc-fi.com.
"Kasasa provides cutting-edge technology and innovative products to community financial institutions so they can focus on their area of expertise – connecting personally with their account holders to offer customized financial guidance and support," said Gabe Krajicek, CEO of Kasasa. "Kasasa ultimately encourages people to support their local economies by banking locally with a partner that has their best interest at heart. We are honored to be named to the IDC FinTech Rankings for eight consecutive years and are excited to continue helping community financial institutions nationwide."
The Fortune 500-style ranking categorizes and evaluates the top global providers of financial technology based on calendar year revenues from financial institutions for hardware, software and/or services. These providers supply the technological backbone of the financial services industry, an industry in which IDC forecasts worldwide spending on IT across the globe to be $590 billion (USD) by 2025.
To thrive in a digital economy, financial services organizations must embrace innovative and integrate innovative technology effectively to enhance the customer experience and achieve operational excellence. Kasasa and the vendors featured on the IDC FinTech Rankings, represent those providers committed to helping financial institutions successfully execute their digital transformation initiatives for the betterment of their customers around the world. IDC Financial Insights publishes a comprehensive report about the year's findings that is available to view or download from http://www.idc-fi.com.
Kasasa serves over 700 community financial institutions nationwide, representing over 3 million consumer bank accounts across 3,400+ branches in all 50 states. Kasasa provides marketing, technology, and financial products people love and offers them exclusively at community banks and credit unions to keep money in the local economy. Since 2003, Kasasa financial institutions have given back $2.7 billion in rewards to Kasasa account holders.
For more information about the rankings, visit http://www.idc-fi.com and follow us on Twitter @IDC and look for #IDCFinTechRankings.
About Kasasa
Based in Austin, Texas, Kasasa® promotes community banks and credit unions and inspires people to bank locally, so they can be proud of their money and do more good. An award-winning fintech and marketing services company, Kasasa provides reward checking accounts people love, the first-ever loan with Take-Backs™, relationship-powered referral programs, and ongoing expert consulting services to community financial institutions. For more information, visit www.kasasa.com, Instagram, Facebook, or LinkedIn.
View original content to download multimedia:
SOURCE Kasasa
|
https://www.whsv.com/prnewswire/2022/09/12/kasasa-named-prestigious-idc-fintech-rankings-by-idc-financial-insights/
| 2022-09-12T14:15:32Z
|
The trusted primer and paint brands partner with MotorTrend® Group to give away a combined value of $115,000 in professional materials to one lucky winner of the KILZ® Ultimate Pro Van Contest
SANTA ANA, Calif., Sept. 12, 2022 /PRNewswire/ -- KILZ® & BEHR PRO® are teaming up to bring back their KILZ® Ultimate Pro Van Contest in partnership with MotorTrend® Group. For the second year in a row, KILZ and BEHR PRO will be giving away a brand new, fully equipped van with a professional painters' package, including all of the tools a professional needs and more, valued at more than $115,000.
The KILZ Pro Van Contest was born from the brand's commitment to the professional painter community and continues to provide the industry with an opportunity to win a quality setup made for success. In addition to being outfitted with KILZ and BEHR PRO products, the van will feature items from 3M®, Werner® and Graco® Inc. to bring the prize to the next level.
"It's important to us to set up professionals for success, and we want to continue to provide access to dependable products they can rely on for their jobs," says Jodi Allen, Global Chief Marketing Officer, Behr Paint Company. "The KILZ Ultimate Pro Van Contest is a great way to celebrate and give this community a once-in-a-lifetime opportunity to truly drive their business forward."
The prize, valued at $115,000, includes:
- A Customized 2021 Cargo Van featuring vinyl flooring, mechanical ladder system, custom galley and sink with water system, rack system, infotainment system (including speakers), cameras, exterior lighting, refrigerator, sound system
- KILZ Brand – Five Primer varieties (KILZ® Original, KILZ 2® All-Purpose, KILZ 3® Premium, KILZ® Restoration and KILZ® Mold + Mildew primers)
- BEHR PREMIUM PLUS® and BEHR PRO® Interior and Exterior Paints
- 3M – Painters' Tape and supplies
- Werner – Werner® Ladders, Weather Guard® bins, mats, and hook holders
- Graco – Airless sprayers and accessories
"We are so pumped to bring this contest back for pros on the road! We are bringing version 2.0 of the ultimate workspace for paint professionals, customized specifically for them. Full of thoughtful touches and functional features, this van will not only be chockful of supplies to get the job done, it will have all of the extras that will make the job enjoyable while bringing in a sense of pride," said Sean P. Holman, Content Director for MotorTrend Group.
To enter the contest, pros can share a video of their professional skills or a project photo showcasing the quality of their work. Visit http://www.kilz.com/provan to learn more. Entries will be accepted starting on September 12, 2022 at 9 a.m. PT, through November 12, 2022 at 11:59 a.m. ET, and the winner will be announced in the weeks following the end of the submission period. No purchase necessary.
About KILZ® Products
Since 1974, the KILZ® brand has served professional painters and do-it-yourselfers with a trusted line of professional grade, hardworking coatings products, including the #1 selling primer in the industry. With a durable, long-lasting finish, the quality of KILZ products has been trusted for generations, creating a legacy of quality and performance. Also included in this award-winning product lineup is the Magnolia Home by Joanna Gaines® Paint collection. For more information, and to find a nearby KILZ brand retailer in the United States or Canada, visit KILZ.com. The KILZ brand is owned by Santa Ana, Calif.-based Behr Paint Company, a subsidiary of Masco Corporation (NYSE: MAS).
About Behr Paint Company
Founded in 1947, Behr Paint Company is one of the largest manufacturers of paints, primers, decorative finishes, stains, surface preparation and application products for do-it-yourselfers and professionals in the United States, Canada and Mexico. The Santa Ana, Calif.-based company and maker of the BEHR®, KILZ®, WHIZZ® and E&J® brands is dedicated to meeting the project needs of DIYers, professionals, architects and designers with an unwavering commitment to quality, innovation and value. For more information, visit Behr.com. Professional contractors can visit BEHRPRO.com to learn about BEHR products and BEHR PRO® services. Behr Paint Company is a subsidiary of Masco Corporation (NYSE: MAS).
Media Contact:
M BOOTH
KILZ@mbooth.com
View original content to download multimedia:
SOURCE KILZ
|
https://www.whsv.com/prnewswire/2022/09/12/kilz-amp-behr-pro-offer-professional-painters-an-opportunity-win-custom-van-stocked-with-all-tools-any-job/
| 2022-09-12T14:15:38Z
|
Program toasts the achievements of Latinas revolutionizing the tech industry and uplifting their communities in honor of Hispanic Heritage Month
SAN FRANCISCO, Sept. 12, 2022 /PRNewswire/ -- Latinas in Tech, a non-profit organization with the aim to connect, support, and empower Hispanic women working in technology, is entering the metaverse in partnership with Korbel® California Champagne to present Luminarias, a virtual art exhibition spotlighting 30 Latina changemakers in the STEM industries. Ranging from corporate executives to digital creators, the honorees will be represented as individual NFT portraits and featured in a fully-immersive VR gallery. For more information, visit here.
Designed by award-winning illustrator and digital artist Lucia Diaz, each Luminarias portrait may be purchased as a charity NFT, with all proceeds donated to Latinas in Tech. Bidding will begin at 0.030 Ethereum (ETH) or $50 USD on OpenSea. Launching September 15 and open throughout Hispanic Heritage Month, the metaverse exhibition will be accessible via VR headset, computer, tablet, or smartphone.
While women represent 28.8% of the U.S. tech workforce, Hispanic women only make up 2%, according to a recent study. This notable disparity, as well as the highly-publicized Latina wage gap, have prompted community and professional leaders to advocate for more Latinas building careers in STEM. Empowering and connecting Hispanic women since 2014, Latinas in Tech works hand in hand with top technology companies to create safe spaces for learning, mentorship, and recruitment.
"Luminarias shines a light on some of the extraordinary Hispanic women who are illuminating career paths for Latinas in STEM," said Rocío van Nierop, Co-Founder and CEO of Latinas in Tech." Latinas in Tech is incredibly proud to partner with Korbel to raise a toast to these pioneers and role models who are making tremendous contributions to their industries and our community as a whole."
The first class of Luminarias, presented by Latinas in Tech x Korbel, are:
- Beatriz Acevedo, CEO and Co-Founder at SUMA Wealth
- Julie Acosta, Senior Web Analytics Manager at AutoZone
- Cecilia Ambros, Director of Research, Data Sciences at Compass
- Deborah Berebichez, Lead Scientist in Microelectronics and Quantum Computing at VTT
- Luz Bratcher, Founder at Golden Repair
- Ana Bretschneider, Director of Sponsorship and Program Operations at Latinas in Tech
- Diana Centeno-Gomez, Chief, Smart Sensing and Electronics Systems Branch at NASA Glenn Research Center
- Melissa Cintrón-Muñoz, Events Producer at Meta
- Priscila Cordero, Principle Product Marketing Manager at Amazon Luna
- Cecilia Corral, Co-Founder and Vice President of Product at CareMessage
- Claudia Cruz, Director, Internships and Experiential Learning at University of Nevada, Reno
- Sarahi Espinoza Salamanca, CEO and Founder at DREAMers Roadmap
- Adriana Gil Miner, Chief Marketing Officer at Iterable
- Veronica Gilliard, Deputy Director of Platform Services at the California Department of Technology
- Michelle Heng, CEO and Co-Founder at Everlaunch
- Catalina Laverde, Engineering Manager at Spotify
- Michelle LeClerc, Creative Director at LeClerc
- Heather Martinez, Senior Counsel at Uber
- Mariana Matus, CEO and Co-founder at Biobot Analytics
- Cynthia Maxwell, Director of Engineering, Animation Studio Technology at Netflix
- Hady Mendez, Director of Equality at Slack
- Alejandra Meza, Head of Product Design at Huckleberry Labs
- Lynette Midy, Senior Director Of Engineering at SpotHero
- Elaine Montilla, Chief Technology Officer for US School Assessment at Pearson
- Shannon Morales, CEO and Founder at Tribaja
- Sandra Mosquera, Vice President and Product Manager at JP Morgan Chase
- Maria Rubio, UX Lead at Keybank
- Monica SanMiguel, Head of Business at Enova International
- Diana Toscas, Director of Engineering, Developer Experience at PayPal
- Daniela Veloz, Senior Software Engineer at Expedia
Hosted on the Spatial metaverse platform, the Luminarias exhibition was inspired by the career journeys of its honorees. Visitors are invited to navigate a short maze to access their ultimate destination: the Luminarias Gallery. A sprawling two-level venue, the custom-built space features the NFT collection on its ground floor and a sun-drenched gathering lounge on its rooftop. Visitors can enjoy the scenic view from the top, along with a closing remark from the Luminarias spanning the sky. To celebrate its grand opening, Latinas in Tech and Korbel will host an exclusive launch event at the gallery on September 15. Click here for more details.
"Luminarias is a celebration of legacy, excellence, and innovation," said Gary Heck, Korbel President and Owner. "For this year's Hispanic Heritage Month, we not only wanted to recognize the historic contributions of the community but also showcase how they are also helping to shape our future. Korbel is honored to partner with Latinas in Tech for our very first entry into the metaverse that's both culturally-led and purpose-driven."
"I'm thrilled to be part of such a timely and important conversation happening within the Hispanic community," said Lucia Diaz, who has previously collaborated with global luxury fashion and beauty brands. "For this NFT collection, my intention was to portray each of the Luminarias as relatable iconoclasts that were both inspirational and aspirational. I want guests coming out of this exhibition to feel like anything is possible, especially in the age of the Web3 and the metaverse."
About Latinas in Tech
Latinas in Tech is a non-profit with humble origins. What started as two friends in need of career support is now a global community of almost 20,000 Latinx women. Our group began in Silicon Valley in 2014 and has since then expanded to 20 additional cities with a local footprint around the world. Our mission is ambitious, just like our members: we seek to reshape the tech industry so that Latinx women are not only well-represented but also thriving in the technology ecosystem. For more information or to donate to our non-profit, please visit www.latinasintech.org.
About Korbel® California Champagne
Established in 1882 in Sonoma County's Russian River Valley, Korbel Champagne Cellars produces the United States' most popular méthode champenoise champagne. But the true measure of Korbel's success during its 140 years can be seen in the impact it's had on American consumers and its presence at various celebrations throughout the years. Owned and managed by the Heck family since 1954, Korbel currently makes eleven California champagnes and a limited amount of still wine. In a separate facility, Korbel also produces one of the country's most respected brandies.
For downloadable press information, click here.
Celebrate responsibly.
View original content to download multimedia:
SOURCE Latinas in Tech
|
https://www.whsv.com/prnewswire/2022/09/12/latinas-tech-partners-with-korbel-california-champagne-celebrate-influential-hispanic-women-stem-with-luminarias-nft-collection-metaverse-art-exhibition/
| 2022-09-12T14:15:45Z
|
DALLAS, Sept. 12, 2022 /PRNewswire/ -- Lennox International Inc. (NYSE: LII) today announced that CEO Alok Maskara and CFO Joe Reitmeier are scheduled to present at the Morgan Stanley 10th Annual Laguna Conference in Laguna Nigel, California, on Wednesday, September 14. Presentation materials and a live webcast beginning at 3:45 p.m. Pacific time that day can be accessed on the company's website at www.lennoxinternational.com.
About Lennox International
Lennox International Inc. is a global leader in energy-efficient climate-control solutions. Dedicated to sustainability and creating comfortable and healthier environments for our residential and commercial customers while reducing their carbon footprint, we lead the field in innovation with our cooling, heating, indoor air quality, and refrigeration systems. Lennox International stock is listed on the New York Stock Exchange and traded under the symbol LII. Additional information on Lennox International is available at www.lennoxinternational.com or by contacting Steve Harrison, Vice President, Investor Relations, at 972-497-6670.
View original content to download multimedia:
SOURCE Lennox International Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/lennox-international-present-morgan-stanley-10th-annual-laguna-conference-laguna-nigel/
| 2022-09-12T14:15:51Z
|
Expresses Disappointment in Zendesk's Lack of Engagement
Reiterates Confidence in Alternative Proposal and Intention to Vote AGAINST the Proposed Transaction
Affirms Intention to Secure Capital Needed to Execute on Superior Alternative Proposal with Constructive Engagement from Zendesk Board and Management
Highlights Strong Support for Alternative Proposal from Major Zendesk Shareholders
Full Text of the Letter, along with Details of Light Street's Alternative Proposal, Available at www.lightstreet.com/zen
PALO ALTO, Calif., Sept. 12, 2022 /PRNewswire/ -- Light Street Capital Management, LLC ("Light Street" or the "Firm"), which manages funds that own more than two percent of the outstanding shares of Zendesk, Inc. (NYSE: ZEN) ("Zendesk" or the "Company"), today delivered a letter to the Zendesk Board of Directors (the "Board") expressing extreme disappointment in the Board's failure to engage with Light Street or its shareholders regarding the alternative and superior path forward for the Company and its shareholders that was delivered to the Board on August 29 (the "Alternative Proposal").
In the letter, Light Street affirms its intention to vote AGAINST the Company's proposed transaction with affiliates of funds advised by Hellman & Friedman LLC and Permira Advisers LLC (the "Proposed Transaction"), and highlights strong indications of support from many of Zendesk's largest shareholders who believe the Alternative Proposal, under the right terms and with qualified partners, represents a superior path forward for Zendesk. Further, after discussions with a number of large, multi-billion-dollar asset managers that are premier enterprise software investors in both the public and private equity markets, Light Street affirms its confidence that committed financing would be available with constructive and collaborative engagement of the Zendesk Board and management.
In light of the superior nature of the Alternative Proposal and access to committed financing necessary to execute it, Light Street urges the Board to postpone the upcoming shareholder vote and constructively engage with Light Street and other investors in good faith to seriously consider both paths forward for the benefit of all Zendesk shareholders.
The full text of the letter delivered to the Zendesk Board, along with detail regarding Light Street's alternative proposal to Zendesk can be found at www.lightstreet.com/zen.
About Light Street Capital Management
Founded in 2010, Light Street Capital Management, LLC is an investment management firm based in Palo Alto, California. The firm invests globally in technology businesses across public and private markets.
Important Information
Light Street, together with the other participants named herein, intends to file a proxy statement with the Securities and Exchange Commission (the "SEC") to be used to urge stockholders of Zendesk, Inc. (the "Company") to vote on the Company's proxy card "AGAINST" the proposed merger of the Company with affiliates of funds advised by Hellman & Friedman LLC and Permira Advisers LLC, and other Company proposals, at the upcoming special meeting of stockholders of the Company.
LIGHT STREET STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ LIGHT STREET'S PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS AND ANY OTHER RELEVANT DOCUMENTS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.
STOCKHOLDERS OF THE COMPANY ARE ALSO ADVISED TO READ THE DEFINITIVE PROXY STATEMENT, DATED AUGUST 8, 2022, AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY THE COMPANY FROM ITS STOCKHOLDERS FOR USE AT THE COMPANY'S UPCOMING SPECIAL MEETING OF STOCKHOLDERS, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. A DEFINITIVE PROXY STATEMENT HAS BEEN MAILED TO STOCKHOLDERS OF THE COMPANY AND IS ALSO AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT WWW.SEC.GOV.
Participant Information
The participants in the proxy solicitation are anticipated to be Light Street, Light Street Mercury Master Fund, L.P., Light Street SPV7, L.P., Light Street Tungsten Master Fund, L.P., Light Street Halo, L.P. and Glen Kacher.
As of the date hereof, Light Street Mercury Master Fund, L.P. ("Mercury") directly owns 1,257,571 shares of common stock, par value $0.01 per share, of the Company ("Common Stock"), Light Street SPV7, L.P. ("SPV7") directly owns 1,260,549 shares of Common Stock, Light Street Tungsten Master Fund, L.P. ("Tungsten Master Fund") directly owns 174,400 shares of Common Stock, and Light Street Halo, L.P. ("Halo") directly owns 33,721 shares of Common Stock. Light Street, as the investment adviser and general partner of Mercury, SPV7, Tungsten Master Fund and Halo, exercises voting and investment power over the Common Stock held for the account of Mercury, SPV7, Tungsten Master Fund and Halo, and as such may be deemed to beneficially own the 2,726,241 shares of Common Stock owned in the aggregate by Mercury, SPV7, Tungsten Master Fund and Halo. Mr. Kacher, as the Chief Investment Officer of Light Street, may be deemed to beneficially own the 2,726,241 shares of Common Stock owned in the aggregate by Mercury, SPV7, Tungsten Master Fund and Halo.
Forward-looking Statements
Certain statements contained in this letter, and the documents referred to in this letter, are forward-looking statements including, but not limited to, statements that are predications of or indicate future events, trends, plans or objectives including the Light Street proposal set forth herein. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future performance or activities and are subject to many risks and uncertainties. Due to such risks and uncertainties, actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements, including the facts that the Light Street proposal set forth herein is non-binding and subject to due diligence and the execution of mutually acceptable definitive documents, may be rejected by the Company, and/or may be subject to certain closing conditions including stockholder approval and therefore such proposal may not be consummated. Forward-looking statements can be identified by the use of the future tense or other forward-looking words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "should," "may," "will," "objective," "projection," "forecast," "management believes," "continue," "strategy," "position" or the negative of those terms or other variations of them or by comparable terminology.
Important factors that could cause actual results to differ materially from the expectations set forth in this letter include, among other things, the factors identified under the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as amended, and under the section entitled "Forward-Looking Statements" in the Company's Definitive Proxy Statement, filed with the SEC on August 8, 2022. Such forward-looking statements should therefore be construed in light of such factors, and Light Street is under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Information Regarding Any Proposed Transaction
In furtherance of the Light Street proposal and subject to future developments, Light Street (and, if a negotiated transaction is agreed, the Company) may file one or more registration statements, proxy statements, tender offer statements or other documents with the SEC. This letter is not a substitute for any proxy statement, registration statement, tender offer statement, prospectus or other document Light Street and/or the Company may file with the SEC in connection with any proposed transaction.
INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ ANY SUCH PROXY STATEMENT(S), REGISTRATION STATEMENT, TENDER OFFER STATEMENT, PROSPECTUS AND/OR OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT A PROPOSED TRANSACTION. Any definitive proxy statement(s) or prospectus(es) (if and when available) will be mailed to stockholders of the Company. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by Light Street and/or the Company through the SEC's web site at www.sec.gov.
This letter is neither a solicitation of a proxy nor a substitute for any proxy statement or other filings that may be made with the SEC. Nonetheless, Light Street and/or its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of any proposed transaction. Additional information regarding the interests of such potential participants may be included in one or more registration statements, proxy statements, tender offer statements or other documents filed with the SEC if and when they become available. These documents (if and when available) may be obtained at no charge on the SEC's website at www.sec.gov.
Notice to Investors
Notwithstanding anything stated herein, Light Street reserves the right to sell shares of the Company in the future in connection with redemption requests by investors in its affiliated funds or in the event the Company's Board of Directors is not responding, in the opinion of Light Street, appropriately to the Light Street proposal and it is in such funds' interests to do so.
Media Contacts
ASC Advisors
Steve Bruce / Taylor Ingraham
sbruce@ascadvisors.com / tingraham@ascadvisors.com
{203} 992-1230
View original content:
SOURCE Light Street Capital Management
|
https://www.whsv.com/prnewswire/2022/09/12/light-street-capital-urges-zendesk-board-delay-vote-constructively-engage-good-faith-with-its-shareholders/
| 2022-09-12T14:15:57Z
|
SEOUL, South Korea, Sept. 12, 2022 /PRNewswire/ -- Magnachip Semiconductor Corporation (NYSE: MX) ("Magnachip" or the "Company") today announced that the Board of Directors has authorized an expansion of the Company's previously announced stock repurchase program from $75 million to $87.5 million of the Company's common stock. The Company has already repurchased shares worth $37.5 million under the program.
The remaining $50.0 million of the expanded $87.5 million program will be repurchased in the open market or through privately negotiated transactions. In connection with the repurchase program, the Company has established a stock trading plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
The timing of stock repurchases and the number of shares of common stock to be repurchased will depend upon prevailing market conditions and other factors.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to the safe harbor created thereby. Statements that are not historical or current facts, including statements about beliefs and expectations, are forward-looking statements. These forward-looking statements are often, but not always, made through the use of words or phrases such as "may," "will," "will be," "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "believe(s)," "intend," "predict," "potential," "future," "strategy," "opportunity" and similar words or phrases or the negatives of these words or phrases. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including, but not limited to: the impact of changes in macroeconomic and/or general economic conditions, including those caused by or related to inflation, potential recessions or other deteriorations, economic instability or civil unrest the COVID 19 pandemic or the emergence of various variants of the virus or other outbreaks of disease, and governmental lock-downs or other measures implemented in response thereto, and the Russia-Ukraine conflict; manufacturing capacity constraints or supply chain disruptions that may impact our ability to deliver our products or affect the price of components, which may lead to an increase in our costs, as well as impacting demand for our products from customers who are similarly affected by such capacity constraints or disruptions; the impact of competitive products and pricing; timely design acceptance by our customers; timely introduction of new products and technologies; ability to ramp new products into volume production; industry wide shifts in supply and demand for semiconductor products; industry and/or company overcapacity or supply constraints; effective and cost efficient utilization of manufacturing capacity; financial stability in foreign markets and the impact of foreign exchange rates; unanticipated costs and expenses or the inability to identify expenses which can be eliminated; compliance with U.S. and international trade and export laws and regulations by us, our customers and our distributors, including those related to the Russia-Ukraine conflict; change or ratification of local or international laws and regulations, including those related to environment, health and safety; public health issues, including the COVID-19 pandemic or the emergence of various variants of the virus; other business interruptions that could disrupt supply or delivery of, or demand for, Magnachip's products, including uncertainties regarding the impacts of the COVID-19 pandemic or the emergence of various variants of the virus that may result in factory closures, reduced workforces, scarcity of raw materials and goods produced in infected areas, as well as reduced consumer and business spending affecting demand for Magnachip's products due to government and private sector mandatory business closures, travel restrictions or the like to prevent the spread of disease; and other risks and uncertainties and the factors identified under "Risk Factors" in Part II, Item 1A of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and updated in subsequent reports filed by the Company with the U.S. Securities and Exchange Commission and/or make available on our website. These reports are available at www.magnachip.com or www.sec.gov. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update them in light of new information or future events.
About Magnachip Semiconductor
Magnachip is a designer and manufacturer of analog and mixed-signal semiconductor platform solutions for communications, IoT, consumer, computing, industrial and automotive applications. The Company provides a broad range of standard products to customers worldwide. Magnachip, with more than 40 years of operating history, owns a portfolio of approximately 1,100 registered patents and pending applications, and has extensive engineering, design and manufacturing process expertise. For more information, please visit www.magnachip.com. Information on or accessible through Magnachip's website is not a part of, and is not incorporated into, this release.
CONTACT:
Yujia Zhai
The Blueshirt Group
Tel. (860) 214-0809
Yujia@blueshirtgroup.com
View original content to download multimedia:
SOURCE Magnachip Semiconductor Corporation
|
https://www.whsv.com/prnewswire/2022/09/12/magnachip-announces-expanded-stock-repurchase-program/
| 2022-09-12T14:16:03Z
|
FN Media Group Presents USA News Group News Commentary
VANCOUVER, British Colombia , Sept. 12, 2022 /PRNewswire/ -- USA News Group –The airline industry is projecting an industry-wide return to profitability in 2023, and full recovery in 2024. Along the way, the world's top airline carriers have been revamping the in-flight experience, most noticeably by adding more meatless options to their menus. Among the airlines that have been adding options have been Alaska Air Group, Inc. (NYSE:ALK), Delta Air Lines, Inc. (NYSE:DAL), Onex Corporation (TSX:ONEX) (OTCPK:ONEXF) subsidiary WestJet, and most recently International Consolidated Airlines Group S.A. (OTCPK:ICAGY) subsidiary British Airways, which has begun offering a new high-protein snack mix from newly-public Pangea Natural Foods (CSE:PNGA) (OTCQB:PNGAF) based out of Vancouver, Canada.
"Food is one of the most tangible signals of what an airline thinks of its customers," said former airline executive Henry Harteveldt, founder of travel consulting firm Atmosphere Research Group.
Customers of International Consolidated Airlines Group S.A. (OTC:ICAGY) (OTC:BABWF) subsidiary British Airways, now will have a new snack option that goes beyond the cliched bag of peanuts or pretzels. British Airways did the same as Air Canada to bring in the new Munchie Mix from Pangea Natural Foods (CSE:PNGA) (OTC:PNGAF), that's packed with non-GMO superfoods including dried cranberries, yorgut chips, roasted cashews, almonds and pumpkins.
"We are excited to work with one of the world's leading airlines to introduce the Pangea Munchie Mix into British Airways' fleet of planes." said Pangea CEO Pratap Sandhu, "Whether a traveler is waiting in an airport lounge or on a long-haul global flight, the Munchie Mix is a high-protein, healthy mix that will solve a passenger's snack cravings."
Being added to the British Airways fleet, which is scheduled to fly over 120,000 flights over the winter season is another win for Pangea after it had already been added to Air Canada's scheduled passenger service that flies directly to 51 Canadian airports, 46 destinations in the United States and 67 airports in Europe, the Middle East, Asia, and Africa, and flying up to 438 daily flights between Canada and the United States alone. With British Airways, Pangea snacks will now be available within their fleet of over 230 airplanes, serving 13 domestic UK destinations, and 192 international destinations in 76 countries.
By the year of the projected industry recovery in 2024, the world's in-flight catering services market alone is expected to reach $21.5 billion.
Pangea manufactures the Munchie Mix, along with their Plant-Based Patties and Old Fashioned Ghee in-house at their Vancouver Lower Mainland facility, which has been approved by both the Canadian Food Inspection Agency and the U.S. Food and Drug Administration.
Prior to being added to a pair of major airlines, Pangea was busy establishing its other products, (Pangea Plant-Based Patties and Old Fashioned Ghee) via their online website and through over 250 retail outlets across Canada and the United States.
Air Canada's largest Canadian competitor WestJet was bought back in 2019 by the Onex Corporation (TSX:ONEX) (OTC:ONEXF), ahead of the hit the industry took after 2020. While the airline has done a lot lately to impress a new generation of fliers, including the announcement of gender-neutral uniforms, not everyone is impressed by their menus when they were introduced in 2020.
Apparently WestJet's menu was too vegan-friendly for some of its customers, as the newer menus provided health vegan options such as vegetable fritters, Waldorf and Greek sales, as well as Korean cauliflower—however meat-eating customers took to Twitter to vent what they perceived was a lack of animal products.
Despite the complaints, WestJet has held steady to appease all of its customers' tastes, by providing options to economy passengers such as a breakfast with vegetarian sausage and baked beans, as well as a vegetarian penne pasta, and a green Thai curry with chunks of chicken. For business cabin flights, the carrier also provides special meals such as an all-vegan meal, as well as Kosher, Muslim and Hindu meals, as well as a gluten intolerant meal.
Two of WestJet's airline partners are Alaska Air Group, Inc. (NYSE:ALK) and Delta Air Lines, Inc. (NYSE:DAL), both of which have significantly improved their meatless offerings.
Back in March, Delta introduced five new meatless meals to its inflight menu, and tapped into the expertise of Impossible Foods—which itself is expected to go public soon, either through a traditional IPO or a SPAC merger.
For context, Delta flies 200 million people a year, making the new dishes available on select flights that travel 900 miles or longer.
"Not only are plant-based meats like Impossible™ Burger delicious to eat, but they're also often better for the environment, using far less land and water to produce," said Kristen Manion Taylor, SVP – In-Flight Service for Delta. "These new options are one part of Delta's broader mission to promote a wellness-focused travel journey."
Along with Impossible Foods, the airline has also enlisted the help of Black Sheep Foods to provide plant-based "lamb" meatballs, while also providing its own cauliflower cakes, and a warm seasonal vegetable plate.
For Alaska Airlines, they celebrated the summer with a new in-flight vegan meal dubbed "Soy Meets World", which was a summer vegetable salad topped with fried tofu, developed in partnership with West Coast-based company, Evergreens.
"We're thrilled to offer our guests more healthy and nutritious choices when they fly with us," said Todd Traynor-Corey, Alaskan Airlines' Managing Director of Guest Products. "We built our menu thoughtfully to offer more plant-based, vegan and gluten-free options, which include a range of fresh, bright flavors inspired by the West Coast and ingredients that are authentically healthy by nature such as roasted broccoli, crisp romaine and baby lettuce greens, quinoa, fresh fruit and more."
As per the company's statement, Alaskan Airline boasts "the most comprehensive domestic food and beverage program in the industry—offering three meal options in First Class, including their Signature Fruit & Cheese on flights as short as 550 miles.
The trend of improved in-flight menus should likely continue, as improved food improves the carrier's image and its perceived care for its customers. As airlines continue to recuperate from the pandemic's financial impacts, likely they'll also seek to allure in high-paying customers in first- and business-class sections.
Because of "the incentive to win those premium class passengers, the incentive to spend more money [on food] is high," said Steve Walsh, partner at management consulting firm Oliver Wyman in its transportation and services practice in an interview with CNBC.
However, for those seeking fresher, natural foods, the game for airlines is challenging to secure them. Greens and salads are among the most difficult dishes to serve on board. So, look to the carriers to bring in more hot-meals involving grains, as well as improved snack options along the way.
For More Information, please visit: https://usanewsgroup.com/2022/09/01/skyrocketing-demand-for-clean-label-natural-foods-fuels-this-stocks-incredible-potential/
Article Source:
USA News Group
http://USAnewsgroup.com
info@usanewsgroup.com
DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Pangea Natural Foods Inc. advertising and digital media from Maynard Communication Limited. There may be 3rd parties who may have shares of Pangea Natural Foods Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ owns shares of Pangea Natural Foods Inc. which were purchased in the open market at least 72 hours after our initial coverage date of the company. MIQ reserves the right to buy and sell, and will buy and sell shares of Pangea Natural Foods Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ on/about Pangea Natural Foods Inc. has been reviewed and approved by the principals at Pangea Natural Foods Inc.; this is a paid advertisement, and while we do own shares of Pangea Natural Foods Inc. that were purchased in the open market, we plan on buying and selling more shares of Pangea Natural Foods Inc. in the open market. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
View original content:
SOURCE USA News Group
|
https://www.whsv.com/prnewswire/2022/09/12/major-airlines-listening-hungry-customers-bringing-their-meatless-a-game-in-flight-menus/
| 2022-09-12T14:16:10Z
|
LONDON, Sept. 12, 2022 /PRNewswire/ -- Mecobit Solar is a company serving globally with an emphasis on high-quality solar at an affordable price, we're dedicated to providing the best solar-powered systems. Based on system improvement and design, the Mecobit solar system users can use backup energy during a grid outage to help keep indispensable appliances running or power things like home appliances,dryer, pool pump or electric vehicle charger and even cryptocurrency mining rigs
Our Solar system products includes the following: Portable solar station, Solar Panel kits (complete), Solar Unit M4000.
With the improvement to our innovation comes our upgraded Solar System that powers our cryptocurrency miners and other existing miners. Some cryptocurrencies, including bitcoin, are created by a process called proof of work which requires computers to "mine" the currency by solving complex puzzles. Powering those computers involves large amounts of electricity.
Bitcoin is infamous for wasting enough electricity to add 40 million tons of carbon dioxide to the atmosphere a year—but now, a growing cadre of miners around the world are developing green, and lucrative, new strategies worth a fortune all their own.
As the share of solar-powered hash rate seems likely to grow, many see the potential for renewable energy use in Bitcoin mining as a virtuous cycle —Mecobit which provides the unique incentives in cryptocurrency mining, which propel operations to leverage the cheapest power possible, will encourage more operations worldwide to convert to renewable energy sources, like solar.
And as governments agree to reduce levels of carbon emissions and introduce additional incentives like investment tax credits, it's possible that the share of mining operations using solar power will increase even more.
Solar power may be considered green and renewable, but also that there are significant problems with solar, including the limits of sunlight hours.
Shipping costs
As a consequence of this, Mecobit will pay for both shipping and import tariffs, enabling customers to acquire everything they require to get started with no further costs beyond the cost of the device itself.
About Mecobit
Established in 2015 with the goal of developing and marketing the world's solar powered cryptocurrency miners, which can use either Ethash, SHA-256 or Scrypt technology depending on the miner's preference. The company asserts that it was the very first solar powered cryptocurrency mining enterprise in the world. "We wanted to revolutionise the industry with the solar panels by providing more power at a more affordable price than was previously thought to be possible"-B. Franci (Founder).
Mecobit is headquartered in Chiswick High Road,London, England, and has offices in several other cities across the world, including the United States. The company's website, www.mecobit.com provides additional information on the company and its products.
View original content to download multimedia:
SOURCE MECO LIMITED
|
https://www.whsv.com/prnewswire/2022/09/12/mecobit-begins-new-period-photo-voltaic-powered-cryptocurrency-mining/
| 2022-09-12T14:16:13Z
|
PyTorch Foundation to foster an ecosystem of vendor-neutral projects alongside founding members AMD, AWS, Google Cloud, Meta, Microsoft Azure, and NVIDIA
DUBLIN , Sept. 12, 2022 /PRNewswire/ -- The Linux Foundation, a global nonprofit organization enabling innovation through open source, today announced PyTorch is moving to the Linux Foundation from Meta where it will live under the newly-formed PyTorch Foundation. Since its release in 2016, over 2400 contributors and 18,0000 organizations have adopted the PyTorch machine learning framework for use in academic research and production environments. The Linux Foundation will work with project maintainers, its developer community, and initial founding members of PyTorch to support the ecosystem at its new home.
Projects like PyTorch—that have the potential to become a foundational platform for critical technology—benefit from a neutral home. As part of the Linux Foundation, PyTorch and its community will benefit from many programs and support infrastructure like training and certification programs, research, and local to global events. Working inside and alongside the Linux Foundation, PyTorch will have access to the LFX collaboration portal—enabling mentorships and helping the PyTorch community identify future leaders, find potential hires, and observe shared project dynamics.
"Growth around AI/ML and Deep Learning has been nothing short of extraordinary—and the community embrace of PyTorch has led to it becoming one of the five-fastest growing open source software projects in the world," said Jim Zemlin, executive director for the Linux Foundation. "Bringing PyTorch to the Linux Foundation where its global community will continue to thrive is a true honor. We are grateful to the team at Meta—where PyTorch was incubated and grown into a massive ecosystem—for trusting the Linux Foundation with this crucial effort."
"Some AI news: we're moving PyTorch, the open source AI framework led by Meta researchers, to become a project governed under the Linux Foundation. PyTorch has become one of the leading AI platforms with more than 150,000 projects on GitHub built on the framework. The new PyTorch Foundation board will include many of the AI leaders who've helped get the community where it is today, including Meta and our partners at AMD, AWS, Google Cloud, Microsoft Azure, and NVIDIA. I'm excited to keep building the PyTorch community and advancing AI research," said Mark Zuckerberg, Founder & CEO, Meta.
The Linux Foundation has named Dr. Ibrahim Haddad, its Vice President of Strategic Programs, as the Executive Director of the PyTorch Foundation. The PyTorch Foundation will support a strong member ecosystem with a diverse governing board including founding members: AMD, Amazon Web Services (AWS), Google Cloud, Meta, Microsoft Azure and NVIDIA. The project will promote continued advancement of the PyTorch ecosystem through its thriving maintainer and contributor communities. The PyTorch Foundation will ensure the transparency and governance required of such critical open source projects, while also continuing to support its unprecedented growth.
Member Quotes
AMD
"Open software is critical to advancing HPC, AI and ML research, and we're ready to bring our experience with open software platforms and innovation to the PyTorch Foundation," said Brad McCredie, corporate vice president, Data Center and Accelerated Processing, AMD. "AMD Instinct accelerators and ROCm software power important HPC and ML sites around the world, from exascale supercomputers at research labs to major cloud deployments showcasing the convergence of HPC and AI/ML. Together with other foundation members, we will support the acceleration of science and research that can make a dramatic impact on the world."
Amazon Web Services
"AWS is committed to democratizing data science and machine learning, and PyTorch is a foundational open source tool that furthers that goal," said Brian Granger, senior principal technologist at AWS. "The creation of the PyTorch Foundation is a significant step forward for the PyTorch community. Working alongside The Linux Foundation and other foundation members, we will continue to help build and grow PyTorch to deliver more value to our customers and the PyTorch community at large."
Google Cloud
"At Google Cloud we're committed to meeting our customers where they are in their digital transformation journey and that means ensuring they have the power of choice," said Andrew Moore, vice president and general manager of Google Cloud AI and industry solutions. "We're participating in the PyTorch Foundation to further demonstrate our commitment of choice in ML development. We look forward to working closely on its mission to drive adoption of AI tooling by building an ecosystem of open source projects with PyTorch along with our continued investment in JAX and Tensorflow."
Microsoft Azure
"We're honored to participate in the PyTorch Foundation and partner with industry leaders to make open source innovation with PyTorch accessible to everyone," Eric Boyd, CVP, AI Platform, Microsoft, said. "Over the years, Microsoft has invested heavily to create an optimized environment for our customers to create, train and deploy their PyTorch workloads on Azure. Microsoft products and services run on trust, and we're committed to continuing to deliver innovation that fosters a healthy open source ecosystem that developers love to use. We look forward to helping the global AI community evolve, expand and thrive by providing technical direction based on our latest AI technologies and research."
NVIDIA
"PyTorch was developed from the beginning as an open source framework with first-class support on NVIDIA Accelerated Computing," said Ian Buck, General Manager and Vice President of Accelerated Computing at NVIDIA. "NVIDIA is excited to be an originating member of the PyTorch Foundation to encourage community adoption and to ensure using PyTorch on the NVIDIA AI platform delivers excellent performance with the best experience possible."
Additional Resources:
- Visit pytorch.org to learn more about the project and the PyTorch Foundation
- Read Jim Zemlin's blog discussing the PyTorch transition
- Read Meta AI's blog about transitioning PyTorch to the Linux Foundation
- Read this blog from Soumith Chintala, PyTorch Lead Maintainer and AI Researcher at Meta, about the future of the project
- Join Soumith Chintala and Dr. Ibahim Haddad for a fireside chat on Thursday, September 15, at 3pm GMT / 11am ET / 8am PT
- Learn more about PyTorch training opportunities from the Linux Foundation
- Follow PyTorch on Facebook, LinkedIn, Spotify, Twitter, and YouTube
About the Linux Foundation
Founded in 2000, the Linux Foundation and its projects are supported by more than 3,000 members. The Linux Foundation is the world's leading home for collaboration on open source software, hardware, standards, and data. Linux Foundation projects are critical to the world's infrastructure including Linux, Kubernetes, Node.js, ONAP, Hyperledger, RISC-V, PyTorch, and more. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users, and solution providers to create sustainable models for open collaboration. For more information, please visit us at linuxfoundation.org.
The Linux Foundation has registered trademarks and uses trademarks. For a list of trademarks of The Linux Foundation, please see our trademark usage page: https://www.linuxfoundation.org/trademark-usage. Linux is a registered trademark of Linus Torvalds.
Media Contact
Dan Whiting
for the Linux Foundation
202-531-9091
dwhiting@linuxfoundation.org
View original content to download multimedia:
SOURCE The Linux Foundation
|
https://www.whsv.com/prnewswire/2022/09/12/meta-transitions-pytorch-linux-foundation-further-accelerating-aiml-open-source-collaboration/
| 2022-09-12T14:16:19Z
|
The announcement follows Sabah Mikha's appointment as CFO and signals a turning point in the brand's omnichannel growth
LOS ANGELES, Sept. 12, 2022 /PRNewswire/ -- MeUndies, the direct-to-consumer purveyor of softer-than-soft underwear and loungewear, announced today that Elizabeth Krause has joined as Chief Marketing Officer. Krause will lead teams across growth, retention, creative, and brand at a critical juncture for MeUndies as it diversifies its distribution channels and invests in building brand awareness.
"I am honored to work with such a high caliber of talent across an authentic, diverse and passionate team," said Krause. "I look forward to helping an already successful brand grow to the next level by sharing the MeUndies love with more people."
With over two decades of marketing experience at brands like Speedo, Volcom, and Oakley, the Northwestern University alum brings data-driven rigor to the world of brand innovation.
"Elizabeth is an expert at devising thoughtful growth strategies. As MeUndies expands into new markets and explores new channels, we couldn't be more excited to have her setting the tone and ensuring we're crushing our goals," said Jonathan Shokrian, MeUndies' Founder and CEO.
Krause's appointment comes mere months after Sabah Mikha, veteran of TechStyle Fashion Group and McKinsey & Company, joined MeUndies as Chief Financial Officer. Mikha has brought finance, accounting, analytics, and consumer insights together into a strategic center for the business.
"With the investments we're making in technology, operations, and wholesale, the path to doubling - and tripling - this business is clear," Mikha said. "I'm excited to partner with Elizabeth as she builds an agile marketing organization and unlocks all the growth opportunities ahead of MeUndies."
Krause and Mikha will both report to Shokrian, who expressed his enthusiasm for what's ahead: "MeUndies has been changing the game since day one. Now that our C-suite is fully staffed, we have the right team in place to bring what we're confident is the world's most comfortable underwear to even more customers worldwide."
About MeUndies
MeUndies is a Los Angeles-based underwear and loungewear company best known for its softer-than-soft basics. Founded in 2011, MeUndies disrupted the underwear industry when it launched the first online underwear subscription.
Today, MeUndies has sold more than 25 million pairs of underwear and has raised $50M in funding. The direct-to-consumer brand offers multiple purchasing options, including singles, packs and matching pairs as well as a monthly membership.
Media Contact:
brand@meundies.com
View original content to download multimedia:
SOURCE MeUndies, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/meundies-appoints-elizabeth-krause-chief-marketing-officer/
| 2022-09-12T14:16:26Z
|
Sir'Quora Carroll shines the light on September's Direct Support Professional (DSP) Week and an ever-growing crisis
COLUMBUS, Ohio, Sept. 12, 2022 /PRNewswire/ -- 1st Choice Family Services (1CFS), a direct support professional (DSP) and remote monitoring services agency serving those with developmental disabilities, is celebrating DSP Week, September 11-17 by announcing Sir'Quora Carroll, Miss Ohio USA 2022, as its latest brand ambassador.
An important aim behind the partnership with Carroll is to help get the word out about the need for direct support professionals, currently experiencing a crisis due to a low number of people in the field. Sir'Quora will help bring attention to the crisis and encourage others to join the 1CFS team as direct support professionals.
"My mom was a direct support professional and my brother chose the profession," says Carroll. "There are millions of people with disabilities who count on DSP support to help them become the best versions of themselves.The benefits of becoming a DSP are exceptional, both DSPs and clients experience great personal growth because of their bond. DSPs deserve praise during their special week for what they do!"
One of Sir'Quora's platforms as Miss Ohio USA involves standing up for youth and mental health and encouraging others to be the best version of themselves so aligning with 1st Choice is a natural match.
1CFS is actively seeking DSP job applicants to handle the large number of people with developmental disabilities who need assistance. "We know the crisis is real everywhere; without an adequate number of DSPs in the field, people with intellectual and developmental disabilities as well as their families are all impacted," says Aonist Coles, 1st Choice Family Services CEO. "DSPs help people with developmental disabilities become integrated and engaged in their communities, help them make informed decisions and complete tasks on their own. With Sir'Quora's help, we hope to raise awareness about the critical need for more DSPs. They help create a better quality of life for others, and that is the ultimate reward of choosing the profession."
1st Choice Family Services supports people with developmental disabilities by connecting them to expert direct support professionals who help them overcome challenges and live their best lives. 1st Choice Family Services is dedicated to providing uncompromising quality service that addresses each client's specialized needs. https://www.1stchoicefamilyservices.org/
Contact:
Kate McAndrews
1st Choice Family Services
Kate@1stCFS.org
614.560.5028 (phone/text)
View original content to download multimedia:
SOURCE 1st Choice Family Services
|
https://www.whsv.com/prnewswire/2022/09/12/miss-ohio-usa-joins-1st-choice-family-services-brand-ambassador/
| 2022-09-12T14:16:32Z
|
SINGAPORE, Sept. 12, 2022 /PRNewswire/ -- XT.COM, the world's first socially infused global trading platform, will soon list the NAI token in its Main Zone with USDT and BTC pairing. Trading of the token will be open to the users from 12th September 2022 at 07:00 (UTC). Users are welcome to trade NAI/USDT and NAI/BTC effortlessly.
The NAI token uses the BEP20 algorithm on the Binance Smart Chain (BSC) and is controlled by smart contracts. Natiol brings a revolutionary and futuristic approach that will add value to the cryptocurrency market and provide users with new experiences.
This partnership allows the XT community to buy and grow with NAI tokens by participating in Natiol's ecosystem such as Staking, P2E Game, E-Commerce, ... and a wide range of games including Primitive World and events in Legend World.
With that in mind, crypto enthusiasts and traders are encouraged to have the chance to be among the first to trade NAI and enjoy the newly improved exchange. As a promise, XT.COM will continue to welcome projects on cryptocurrency listings and achieve common development.
About Natiol Infinity
Natiol Infinity is a technology company established in Singapore in 2022. The company focuses on Blockchain technology-oriented development and product development and operation related to decentralized Blockchain technology.
Natiol Infinity is a technology organization, a worldwide company with software design orders from all continents. At the same time, it is also one of the first teams to deeply research Blockchain technology into practice. Natiol focuses on exploiting Blockchain platform for business management, human resource management and researching and applying blockchain technology to securities, Crypto, social networks, e-commerce, games... to improve transparency. Transparency, convenience, speed and user empowerment.
Website: https://natiol.io/index.html
Twitter: https://twitter.com/natiolinfinity
Facebook: https://www.facebook.com/natiol.io/
Telegram Channel: https://t.me/natiolinfinity
Whitepaper: https://doc.natiol.io
Youtube: https://www.youtube.com/channel/UCt8oSeoeDrPJ7wcNTBaauqA
About XT.COM
By consistently expanding its ecosystem, XT.COM is dedicated to providing users with the most secure, trusted, and hassle-free digital asset trading services. Our exchange is built from a desire to give everyone access to digital assets regardless of where you are.
Founded in 2018, XT.COM now serves more than 6 million registered users, over 500,000+ monthly active users, and 40+ million users in the ecosystem. Covering a rich variety of trading categories together with an NFT aggregated marketplace, our platform strives to cater to its large user base by providing a secure, trusted and intuitive trading experience.
As the world's first social-infused digital assets trading platform, XT.COM also supports social networking platform based transactions to make our crypto services more accessible to users all over the world. Furthermore, to ensure optimal data integrity and security, we see user security as our top priority at XT.COM.
Website: https://www.xt.com/
Telegram: https://t.me/XTsupport_EN
Twitter: https://twitter.com/XTexchange
View original content:
SOURCE XT.com
|
https://www.whsv.com/prnewswire/2022/09/12/nai-gets-listed-xtcom/
| 2022-09-12T14:16:39Z
|
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study
AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congress, taking place September 9-13 in Paris, France.
Signatera data was presented in 4 abstracts, including both oral and poster presentations. These include results from a real-world study on colorectal cancer (CRC) patients as well as an early readout from the BELLINI trial that highlights how circulating tumor DNA (ctDNA) dynamics can help inform neoadjuvant treatment decision-making in hormone receptor negative, HER2 negative (triple-negative) breast cancer (TNBC). The key highlights are below:
Abstract # 1828 | Late-Breaking Oral Presentation | Presenter: Marleen Kok
Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial
This study evaluates the potential clinical utility of ctDNA in assessing the response to neoadjuvant immunotherapy in patients with early stage (I-II) TNBC. Thirty patients were treated with two cycles of the immune checkpoint inhibitor (ICI) nivolumab, alone or in combination with ipilimumab, prior to the start of neoadjuvant chemotherapy. Response to ICIs was evaluated radiographically, as well as through the analysis of ctDNA dynamics. All of the patients who achieved partial response by imaging presented with 50-100% reduction in ctDNA levels compared to pretreatment, while increasing or stable ctDNA levels were observed in non-responders.
"The BELLINI trial supports MRD testing for early, reliable immunotherapy response monitoring in the neoadjuvant TNBC setting," said Dr. Minetta Liu, Natera's chief medical officer of oncology. "We are very encouraged by the data generated through our collaboration with Dr. Kok and colleagues, and we look forward to ongoing work to push the boundaries of chemotherapy de-escalation."
Abstract # 319MO | Mini Oral Presentation | Presenter: Stacey A. Cohen
Real world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer
In this retrospective analysis of a real-world cohort of 16,347 patients with early stage colorectal cancer, MRD status was assessed using the Signatera test after surgery and during surveillance. Complete clinical information was available for a subset of 417 patients, and showed that postoperative MRD-positive status was significantly associated with inferior recurrence-free survival. Patients who were MRD-negative showed no significant benefit from adjuvant chemotherapy, regardless of other risk factors such as stage, age or microsatellite instability status.
"The results from this large, real-world dataset reinforce those from the CIRCULATE-Japan study presented earlier this year, and provide further evidence for the potential value of MRD testing in the clinic," said the study's principal investigator, Dr. Stacey Cohen of the Fred Hutchinson Cancer Center. "Incorporating MRD testing into the standard of care for CRC may better identify the patients with a high risk of recurrence – enabling timely intervention, while sparing those who would not benefit from unnecessary treatment."
Abstract # 1649P | Poster Presentation | Presenter: Danica Vodopivec Kuri
A proof-of-concept study for detecting ctDNA in rare thyroid cancers
Abstract # 728O | Oral Presentation | Presenter: Omid Hamid
Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors
Signatera dynamics used to assess therapy response across multiple tumor types.
About Signatera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. The test is available for both clinical and research use, and has been granted three Breakthrough Device Designations by the FDA for multiple cancer types and indications. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual's tumor. This maximizes Signatera's accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Signatera is intended to detect and assess how much cancer is left in the body, to identify recurrence earlier and to help optimize treatment decisions.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers, or coverage and reimbursement determinations from third-party payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090
Media: Brian Symmons, SVP of Marketing and Corporate Affairs, Natera, Inc., pr@natera.com
View original content to download multimedia:
SOURCE Natera, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/natera-presents-new-colorectal-breast-cancer-data-esmo-2022-highlighting-signateras-ability-inform-treatment-decisions-adjuvant-neoadjuvant-settings/
| 2022-09-12T14:16:45Z
|
BOSTON, Sept. 12, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company, announced today a 1-for-30 reverse split of its Common Stock, par value $0.001 ("common stock"), effective at 5:00 pm Eastern time today. Beginning on September 13, 2022, the Company's common stock will trade on The Nasdaq Capital Market on a split adjusted basis.
At the Company's annual meeting of stockholders on June 9, 2022, the stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse split of the Company's outstanding common stock at a ratio in the range of 1-for-5 to 1-for-35 to be determined at the discretion of our Board of Directors, whereby each outstanding 5 to 35 shares would be combined, converted and changed into 1 share of Common Stock, to enable the Company to comply with the Nasdaq Stock Market's continued listing requirements.
Upon effectiveness, the reverse stock split will cause a reduction in the number of shares of common stock outstanding and issuable upon the conversion of the Company's outstanding stock options and warrants in proportion to the ratio of the reverse split, and will cause a proportionate increase in the conversion and exercise prices of such stock options and warrants. Any fraction of a share of Common Stock that would be created as a result of the Reverse Stock Split will be rounded down to the next whole share and the stockholder will receive cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company's Common Stock as reported on Nasdaq on the last trading day before the Reverse Stock Split becomes effective (on a split-adjusted basis).
The Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "NRBO". The new CUSIP number for the common stock following the reverse split is 64132R 206.
The number of authorized shares of the Company's common stock will remain at 100 million, while the number of outstanding shares will be reduced from approximately 26.7 million to approximately 0.9 million.
Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on May 18, 2022, a copy of which is also available on the Company's website under the Investor Relations page.
Investor Relations Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content:
SOURCE NeuroBo Pharmaceuticals, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/neurobo-pharmaceuticals-announces-reverse-stock-split/
| 2022-09-12T14:16:52Z
|
Firms face significant gap in return on their investment, as more than 90% fail to utilize their employees' analytics skills
IRVINE, Calif., Sept. 12, 2022 /PRNewswire/ -- Alteryx, Inc. (NYSE: AYX), the Analytics Automation company, issued findings from Alteryx-commissioned IDC research, "4 Ways to Unlock Transformative Business Outcomes from Analytic Investments," revealing that 73 percent of organizations expect analytics spend will outpace other software investments in the next 12-18 months. As organizations increase their spending on analytics, the global survey finds less than half of business decisions are based on analytics.
Further, even fewer are maximizing advanced analytics, as less than 30 percent of decisions are informed by artificial intelligence and machine learning for most organizations. To help businesses maximize their analytics investments, the global IDC survey uncovered the impacts of people, data, and analytics automation on return on investment (ROI).
Ninety-three percent of organizations are not fully using the analytics skills of their employees. This is in part due to only one out of five organizations reporting commensurate investment in upskilling for analytics and data literacy. IDC further uncovered:
- 9 out of 10 respondents say that less than half of their knowledge workers are active users of analytics software other than spreadsheets
- 63 percent of organizations are not using the full breadth of data types available
- 82 percent of organizations indicate data access policies are only moderately effective or worse
- Enterprise-wide analytics solutions have been deployed in less than half of the departments that need them
Key strategies to maximize analytics investments and drive transformative business outcomes
Many business processes in today's digital economy are still manually running on paper and outdated spreadsheets, creating a widening analytics gap. When respondents invested in a low-code/no-code analytics automation platform and followed specific strategies, IDC found organizations improved their financial, customer, and operational metrics. These strategies included:
- Deploying easy-to-use cloud-based or hybrid AI-infused analytics technology to support cross-functional use cases
- Breaking down data and analytics silos by emphasizing enterprise-wide analytics
- Developing a data culture that aligns technology spend with upskilling on data literacy
- Ensuring alignment on analytics initiatives between IT and line of business to eliminate shadow IT
"It's no surprise that so few organizations are ahead of the curve when it comes to analytic maturity considering they leave out a key component: people," said Dan Vesset, group vice president, Analytics and Information Management, IDC. "What we're seeing is that organizations that provide analytics tools that are easy to use and easy to access, while upskilling their talent, achieve more ROI from their respective analytics investment than organizations who do not."
One of the key organizations using Alteryx to enable a culture of analytics is United Kingdom-based financial services company Brookson. "Alteryx has transformed the careers of so many individuals at our company," said Brian Millrine, CIO and strategy director at Brookson. "I believe they have one of the most exciting roles in the organization delivering high-velocity digital transformation, and what they do is recognized as golden at all levels of our organization. Alteryx will be a fundamental solution for them to use going forward and they will become rockstars of business."
Take the Alteryx Democratization of Analytics Maturity Assessment and receive a complimentary report of your organization's performance with insights into how to maximize your analytics ROI.
The IDC Infobrief titled "4 Ways to Unlock Transformative Business Outcomes from Analytics Investments" is based on a comprehensive sample of 1,501 respondents across three regions of: North America; Europe, Middle East, and Africa; and Asia/Pacific. The full IDC Infobrief can be viewed and downloaded here.
Alteryx (NYSE: AYX) powers analytics for all by providing our leading Analytics Automation Platform. Alteryx delivers easy end-to-end automation of data engineering, analytics, reporting, machine learning, and data science processes, enabling enterprises everywhere to democratize data analytics across their organizations for a broad range of use cases. More than 8,000 customers globally rely on Alteryx to deliver high-impact business outcomes. To learn more, visit www.alteryx.com.
Alteryx is a registered trademark of Alteryx, Inc. All other product and brand names may be trademarks or registered trademarks of their respective owners.
View original content to download multimedia:
SOURCE Alteryx, Inc.
|
https://www.whsv.com/prnewswire/2022/09/12/new-research-shows-analytics-outpaces-other-software-spending-next-12-18-months/
| 2022-09-12T14:16:59Z
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.